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Influenza A viruses are important pathogens of humans, other mammals and birds. 
Swine are considered to be the ‘mixing vessel’ for influenza viruses because of their 
susceptibility to infection with not only swine influenza viruses but also human and 
avian influenza viruses. After infection of pigs with different influenza viruses, 
reassortment events between genomic RNA segments and point mutations can take 
place which can result in novel influenza virus strains capable of causing human 
pandemics. To combat infections, vaccination is available in many countries for 
humans, but not typically used in pigs. However, anti-influenza drugs have been used 
to treat livestock, and mutations conferring drug resistance occur in circulating 
strains. The mechanisms responsible for the emergence and spread of drug resistant 
mutations against amantadine and oseltamivir have been studied previously but often 
gave conflicting results. Therefore, this PhD thesis focused on resolving the 
mechanisms responsible for this rapid drug resistance spread.  
 
In chapter one I examine the extent of reassortment events in swine influenza A 
viruses by analysing within subtype reassortment and extrapolating the results for the 
between subtype reassortment. Reassortment is one of the mechanisms that can be 
responsible for mutations, conferring resistance to drugs, to spread between strains, 
and thus spread in the host population. The findings of this chapter show that the 
genomic segments most prone to reassortment code for a polymerase (PB1) and both 
glycoproteins, within all three subtypes studied. Since particular mutations in the 
matrix protein (MP) segment cause resistance to amantadine, my study focused on 
MP compared to other segments and revealed moderate level of reassortment. MP 
reassorts well with polymerases, both within and between subtype, while non-
structural (NS) is least likely to reassort.  
 
Chapter two of this thesis aimed at resolving the origin and spread of the most 
common drug resistance conferring mutation in swine influenza viruses which causes 
amantadine resistance. I show first that this mutation occurred in swine influenza 
viruses and was therefore not transmitted from the recently ancestral avian influenza 
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strains, and second that the prevalence of resistance in swine influenza viruses is due 
to functional linkage of mutations at other sites and not by direct drug pressure.  
 
In chapter three I examine the mechanisms responsible for the rapid rise and spread 
of oseltamivir resistance in human influenza H1N1 viruses which arose in the 
absence of drug use. The primary mutation lies in the neuraminidase glycoprotein but 
because of the close functional interaction I focus on changes in haemagglutinin that 
occurred in association with resistance. The results showed several mutations in 
haemagglutinin were associated with resistance suggesting selection acting on 
haemagglutinin in order to balance the activity of both glycoproteins.  
 
Overall these results show the importance of functional linkage between segments as 
a mechanism for the occurrence of drug resistance conferring mutations, and 
















Influenza A viruses are important pathogens of humans, other mammals and birds. 
The genetic material of these viruses is separated into eight molecules, called 
segments, and may change very rapidly. Swine are considered to be crucial for 
generating genetically novel influenza viruses because they are susceptible to 
infection with influenza viruses infecting swine, humans and birds. After pigs are 
infected with different influenza viruses at the same time, viral segments can be 
mixed into different combinations within swine generating novel influenza viruses. 
This process is called reassortment. These novel influenza A viruses are potentially 
capable infecting humans worldwide in a relatively short time causing severe illness. 
Two anti-influenza drugs have been widely used and resistance to these drugs has 
arisen: amantadine in both humans and livestock, and oseltamivir in humans. The 
mechanisms of the virus for the global spread of drug resistant influenza A viruses 
have been studied previously but often gave conflicting results. Therefore, this PhD 
thesis focused on resolving the mechanisms responsible for this rapid drug resistance 
spread.  
 
Firstly, I investigated how much reassortment occurred in pigs as it can be 
responsible for generating drug resistant viruses. In this chapter I show that some of 
the eight segments are very prone to reassortment and some are unlikely to reassort. 
The segments that reassort very frequently encode two proteins found on the surface 
of the virus and one protein essential for replication of viral genetic information 
during infection. The segments that reassort very infrequently encode four proteins, 
two of them are structural components of the virion, the other two proteins are 
nonstructural, regulatory proteins. 
 
Next the origin of genetic changes (mutations) rendering the swine influenza A 
viruses amantadine resistant was studied. Results of this chapter show that these 
mutations occurred in the swine host and not in the bird host before this virus was 
transmitted from birds to swine. The results also showed that the influenza A virus 
did not acquire the amantadine drug resistance multiple times. The mechanism for 
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acquiring amantadine drug-resistant mutations lies in the functional connection of 
advantageous mutations for the virus to the amantadine drug-resistant mutations.  
 
Finally, influenza A viruses of H1N1 subtype infecting humans were examined. 
These viruses acquired mutations that make this virus oseltamivir resistant. This drug 
binds to the neuraminidase, found on viral surface, and blocks its function. The 
function of another surface protein, called haemagglutinin, is balanced with the 
function of the neuraminidase. The results of this chapter show that several mutations 
in the haemagglutinin occurred around the time of oseltamivir drug-resistant 
mutation in the neuraminidase. So, mutations in the haemagglutinin are associated 
with the resistance mutation in the neuraminidase. 
 
Overall, these results show the importance of ‘functional linkage’ between different 
viral segments for the occurrence of mutations making the influenza A viruses drug 
resistant. Further, reassortment is an important mechanism for spreading these 
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1 Introduction to influenza viruses 
 
In this chapter, an overview of the influenza virus is provided. In particular, the focus 
is on human and porcine influenza viruses, their structure, replication, transmission 
and evolution. 
 
1.1 Background to influenza 
 
Influenza is an infectious disease of birds and mammals that is caused by influenza 
viruses. Influenza of humans spreads around the world in seasonal epidemics with 
three to five million cases of severe illness and between 250,000 to 500,000 deaths 
per year (WHO, 2009a). In pandemic years, loses of human lives can be in millions. 
New influenza strains of humans often appear when an existing influenza virus 
spreads from some animal species to humans, or when an existing human influenza 
strain obtains new genes from another influenza virus that commonly infects birds or 
pigs. Therefore, vaccination of humans and farmed poultry is available in developed 
countries (WHO, 2005; Villegas, 1998). Also, antiviral drugs have been used for 
decades (WHO, 2009b). However, influenza viruses evolve rapidly and vaccines 
against new influenza strains have to be produced on a yearly basis. In the last 
decade, we have also seen a rapid rise in drug resistant strains. Therefore, influenza 
viruses pose a threat to human health in either developed or developing countries. 
 
In this PhD, the focus is on studying the origin and mechanisms for the spread of 
drug resistant influenza strains in humans (oseltamivir resistance) and pigs 
(amantadine resistance). In both cases, drug resistance rose and spread globally in a 
very short time period and the reasons for that are not fully understood or they are 
contradictory. One of the mechanisms for this could be the reassortment occurring in 
swine therefore this PhD focused also on the study of the amount or the quantity of 
this genetic process in porcine host, which is also one of the areas of influenza study 
not fully elucidated. 
                                                                           1.2: Influenza A virus taxonomy and nomenclature 
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1.2 Influenza A virus taxonomy and nomenclature 
 
Influenza viruses belong to the Orthomyxoviridae virus family which includes six 
genera: Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus, Thogotovirus 
and Quaranjavirus (Fauquet et al., 2005; Bussetti et al., 2012). Influenza viruses are 
classified into types A, B and C on the basis of their ribonucleoprotein antigens. 
Influenza A viruses only are classified further into subtypes according to the 
combination of two surface glycoproteins; haemagglutinin and neuraminidase (WHO 
Expert Committee on Influenza, 1953; Anon, 1979). Haemagglutinin (HA) and 
neuraminidase (NA) are morphologically and immunologically distinct and are 
known to undergo antigenic variation. Therefore, all three antigens must be 
considered when describing influenza virus strains. A uniform code was proposed for 
designating influenza virus strains. Their name consists of a viral genus (type), the 
species from which the virus was isolated (omitted if human), isolate location, isolate 
number, the year of isolation, and only in the case of influenza A viruses, the 
subtypes of HA and NA. For example, the name A/England/1/1953 refers to the type 
A, which was isolated from a human host in England in 1953. Number 1 indicates 
the isolate number. Currently there are 18 different hemagglutinin and 11 different 
neuraminidase subtypes known (Fouchier et al., 2005; Webster et al., 1992; Tong et 
al., 2012; Tong et al., 2013). 
 
1.3 Genome structure 
 
The genome of influenza A viruses is approximately 13.5 kb long and segmented 
into eight negative sense single stranded RNA molecules which are numbered 1 to 8 
with segment 1 being the longest and segment 8 the shortest. Negative sense RNA is 
complementary to mRNA and must be copied to positive sense RNA by viral RNA 
polymerase prior to translation. The three largest segments code for RNA 
polymerase complex proteins PB2, PB1 and PA. In some strains of influenza A virus 
the segment 2 which codes for PB1 polymerase subunit also codes for the accessory 
protein PB1-F2, a small, 87-amino acid protein with pro-apoptotic activity, in a +1 
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alternate reading frame (Chen et al., 2001). Segment 4 carries a gene for HA and 
segment 5 a gene for nucleoprotein (NP). Segment 6 of influenza A virus encodes the 
NA protein and segment 7 codes for the M1 matrix protein. In the influenza A 
genome, the M2 ion channel is also expressed from segment 7 by RNA splicing 
(Lamb et al., 1981). From segment 8 influenza A expresses the interferon-antagonist 
NS1 protein (Dauber et al., 2004; Garcia-Sastre, 2001; Kochs et al., 2007) and, by 
mRNA splicing, the NEP/NS2 (Briedis and Lamb, 1982; Lamb et al., 1980), which is 
involved in viral RNP export from the host cell nucleus (Table 1.1). Other proteins 
have also been discovered but their functions remain unclear. These proteins are PA-
X (Jagger et al., 2012), PA-N155, PA-N182 (Muramoto et al., 2013) and PB1-N40 
(Wise et al., 2009). 
Table 1.1 












1 PB2 2,277 
PB2 polymerase 
subunit 
binds to a 5’ 
cap of host 
mRNAs 
 









removes 5’ cap 
from host 
mRNAs 
4 HA 1,698 haemagglutinin 
attachment and entrance 
into the host cell 
5 NP 1,494 nucleoprotein 
structural and regulatory 
role 
6 NA 1,407 neuraminidase 
removes sialic acid from 
receptors on cell surface, 
from HA and NA to 
facilitate virus release 
7 MP 979 
M1 matrix 
protein 
virus structure: forms a 






8 NS 835 
nonstructural 
NS1 protein 





export of vRNPs from 
the nucleus 
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RNA segments share a common structure (Figure 1.1). Both ends of each segment 
are untranslated regions (UTRs) and constitute promoter sequences which contain a 
universal conserved region (UCR) and a segment specific region (SSR). UCR is 13 
nucleotides long at 5’ end and 12 nucleotides at 3’ end (Desselberger et al., 1980; 
Robertson, 1979; Skehel and Hay, 1978). However, the fourth nucleotide at 3’ end is 
variable carrying either C (cytosine) or U (uracil). UCR regions are highly conserved 
across all influenza segments and due to partial complementarity these ends base pair 
to form a helical hairpin which binds proteins of RNA polymerase complex (Bouvier 
and Palese, 2008). UCRs are followed by segment specific regions (SSRs) which 
vary in length across segments (19 to 58 nucleotides). The rest of the segment is 
coding region (open reading frame – ORF). SSRs and coding regions are covered by 
positively charged NP due to arginine residues (Baudin et al., 1994; Compans et al., 
1972; Murti et al., 1988). Influenza virus segments also contain packaging signals 
which are crucial for the incorporation of the whole viral genome into newly 
synthesized virions. Packaging signals span the entire UTR and terminal parts of a 
coding region. Alltogether, this structure of viral RNA and proteins represents a 
ribonucleoprotein (RNP) (Hutchinson et al., 2010) (Figure 1.1). 
 
Figure 1.1 
Schematic diagram of the structure of one influenza genome segment. Untranslated 
regions (UTRs) at 5’ and 3’ segment ends constitute a promoter and are composed 
of a universal conserved region (UCR) (green box) and a segment specific region 
(SSR) (yellow box). Each segment contains packaging signals (red box). Open 
reading frame of a protein coding region (ORF) is presented as a grey box. Figure 
made by the author. 
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1.4 Virion structure 
 
When outside the host cell, the infectious particle of influenza is called a virion. The 
shape of influenza virions is usually spherical or elliptical with 80-120 nm in 
diameter or filamentous reaching more than 20 μm in length (Bourmakina and 
Garcia-Sastre, 2003). The surface of influenza virions is covered by a membrane 
which is host derived (Nayak et al., 2004) and contains two glycoproteins, HA and 
NA as well as M2 ion channel protein, protruding from the membrane (Figure 1.2). 
Each virion contains approximately 500 HA and 100 NA molecules. Beneath the 
lipid membrane is the M1 matrix protein that forms a coat for the encapsidation of 
the viral ribonucleoprotein complexes (Sha and Luo, 1997) which are the genetic 
material of the virus. Each ribonucleoprotein complex contains one RNA segment 
bound by PB2, PB1, PA and NP proteins. Virions also contain NEP/NS2 protein 
(Richardson and Akkina, 1991) (Figure 1.2). 
 
Figure 1.2 
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1.5 Characterization of the HA and NA antigens into subtypes 
 
The haemagglutinin and neuraminidase subtypes are characterized separately (Anon, 
1971). It is not advised to use sera containing antibodies to both antigens because 
antibodies to one antigen can sterically interfere with antibodies to another antigen. 
By using the haemagglutination - inhibition test, the haemagglutinin antigen subtype 
is recognized. The neuraminidase antigens are divided into subtypes according to the 
results of the neuraminidase - inhibition test. For both, haemagglutinin and 
neuraminidase, immunoprecipitation test can be used, which reveals antigenic 
variation within a given subtype (Anon, 1971). 
 
1.5.1 Characterization of the HA subtype 
 
The haemagglutination-inhibition assay uses reference antisera and is the standard 
method for subtyping HA of influenza viruses (Office International des Epizooties, 
2005; Swayne et al., 1998). The basis for this test is that influenza viruses will bind 
to the sialic acid on red blood cells. One influenza virion can attach to more than one 
red blood cell (erythrocyte) at a time, therefore cross-linking or clumping of 
erythrocytes occurs. Haemagglutination can be inhibited by antibodies directed 
against the HA protein, which are subtype specific and so antibodies against one 
subtype will not typically react with the HA of another subtype. Therefore, the 
haemagglutination-inhibition assay has been used as the primary and classical 
method of identifying the HA subtype of an unknown influenza virus. 
 
1.5.2 Characterization of the NA subtype 
 
The basis for this assay is the inhibition of viral neuraminidase enzymatic activity by 
specific antibodies. The neuraminidase-inhibition assay can be performed on cell 
culture fluid or amnioallantoic fluid with subtype-specific antisera for the 
determination of NA subtype. Using reference sera from viruses with the same HA 
                                                                                                                  1.6: Structures of HA 
24 
subtype as the test materials will improve specificity by allowing the NA subtype to 
be the only variable in the test (Van Deusen et al., 1983).  
 
1.6 Structures of HA 
 
There are three structures of haemagglutinin ectodomain known that have been 
determined by X-ray crystallography for 1968 Hong Kong influenza: (i) HA0, which 
is a single-chain precursor; (ii) the conformation found on virus and (iii) the fusion 
conformation (reviewed in Skehel and Wiley, 2000). These structures enabled the 
insight in the activity of haemagglutinin when binding to a receptor and membrane 
fusion during viral entry. 
 
1.6.1 Roles of different HA structures in influenza virus replication process 
Haemagglutinin is a type I membrane glycoprotein with a signal sequence that is 
removed post-translationally. It also encompasses a membrane anchor domain near 
the C-terminus and a short N-terminus cytoplasmic tail (reviewed in Steinhauer DA, 
1999). In the infected cell, haemagglutinin is synthesized as a precursor HA0 of 
approximately 75 kDa and homotrimerized noncovalently with the aid of chaperones 
in the endoplasmic reticulum and then transferred to the cell surface through the 
Golgi apparatus (Gething et al., 1986; Copeland et al., 1988; Hebert et al., 1995). 
Cleavage of HA0 into HA1 and HA2 subunits of human and most non-pathogenic 
avian strains occurs at a conserved arginine residue and is carried out by extracellular 
host proteases after the release of newly synthesized virions from the host cell. 
Cleavage of HA0 of highly pathogenic avian strains occurs at polybasic residues 
intracellularly by ubiquitous proteases (Steinhauer, 2010). HA1 and HA2 are linked 
by a single disulfide bond. This activates the membrane fusion potential of the 
haemagglutinin (Maeda and Ohnishi, 1980; Huang et al., 1980; White et al., 1981) 
and thus enables virus infectivity (Klenk et al., 1975; Lazarowicz et al., 1975). 
Cleavage of the precursor HA0 liberates the hydrophobic N-terminus of HA2 (the 
fusion peptide), which is inserted into target membranes during fusion. After 
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cleavage, the HA2 undergoes molecular rearrangements required for fusion, 
triggered by the acidic pH of endosomes (Bullough et al., 1994). The cleavage 
properties of HA0 and the distribution of infectivity-activating proteases in the host 
are major factors for virus tropism and the capacity for systemic spread. HA1 subunit 
contains oligosaccharide attachment sites, receptor binding site which determines 
host specificity of the virus, and antigenic sites which are prone to mutations causing 
structure changes against which neutralizing antibodies are produced (reviewed in 
Skehel and Wiley, 2000). 
 
1.7 HA cleavage site as a critical determinant of pathogenicity 
 
Factors contributing to the pathogenicity of influenza viruses have been extensively 
studied (reviewed in Steinhauer, 1999). Relevant factors for the influenza virus 
pathogenicity are tissue tropism and host range specificity, the availability of a 
functional receptor on the host cell and the presence of an appropriate gene 
constellation of the virus, which determines growth characteristics and the 
pathogenicity (Steinhauer, 1999). The human pandemics viruses (1957 and 1968), 
which were generated due to reassortment of avian and human influenza viruses, 
derived the surface antigens from an avian source (Kawaoka et al., 1989; Scholtissek 
et al., 1978b, Smith et al., 2009b). For naturally occurring avian influenza A viruses, 
the most important determinant of pathogenicity is the cleavage site structure of the 
HA precursor. It is present at the HA1 – HA2 junction and contains basic residues in 
pathogenic strains (Bosch et al., 1981; Porter et al., 1979). Viruses with basic 
residues at the cleavage site have been isolated from different geographical regions 
and different host species at different times (Wood et al., 1993; Senne et al., 1996; 
Purdue et al., 1997). Table 1.2 shows a number of examples of these (adapted from 
Steinhauer, 1999). In addition to the presence of the polybasic residues at the 
cleavage site, most pathogenic strains also contain amino acid insertions compared to 
non-pathogenic strains. All of the highly pathogenic natural isolates characterized to 
date are either H5 or H7 subtype viruses (Suenaga and Kumar, 2014). 
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Table 1.2 
Examples of cleavage site sequences from natural isolates of H5 and H7 influenza 
A viruses (adapted from Steinhauer DA, 1999). 
ISOLATE CLEAVAGE SITE PATHOGENICITY 
H5 subtypes   
A/chicken/Mexico/31381/94 P Q R E  -  -  -  -  T R ↓ G - 
A/chicken/Pueblo/94 P Q R K R K  -  -  T R ↓ G + 
A/chicken/Queretaro/20/95 P Q R K R K R K T R ↓ G + 
A/duck/Ireland/113/83 P Q R K R K  -  -  K R ↓ G + 
A/turkey/Ireland/1378/83 P Q R K R K  -  -  K R ↓ G + 
A/chicken/Pennsylvania/1/83 
(CHO+) 




P Q K K  -  -  -  -   K R ↓ G 
+ 
A/duck/Singapore/645/97 P Q R E  -  -  -  -  T R ↓ G - 
A/chicken/Hong Kong/990/97 P Q R E R R R K K R ↓ G + 
A/Hong Kong/156/97 – (human) P Q R E T R R K K R ↓ G + 
A/ Hong Kong/486/97 – (human) P Q R E R R R K K R ↓ G + 
H7 subtypes   
A/tern/Potsdam/79 P E I P K  -  -  -  -  G R ↓ G - 
A/chicken/Leipzig/79 P E I P K K K  -  -  G R ↓ G + 
A/goose/Leipzig/137/79 P E I P K R K  -  -  G R ↓ G + 
A/goose/Leipzig/187/79 P E I P K K K K  -  G R ↓ G + 
A/goose/Leipzig/192/79 P E I P K K K K K G R ↓ G + 
A/duck/Victoria/76 P E I P K  -  -  -  -  K R ↓ G - 
A/chicken/Victoria/76 P E I P K K K E  -  K R ↓ G + 
A/chicken/Victoria/1/85 P E I P K K R E -  K R ↓ G + 
A/starling/Victoria/5156/85 P E I P K K R E -  K R ↓ G + 
The cleavage site differs among the HA subtypes and determines the pathogenicity 
of the strain. Highly pathogenic strains (HPAI) contain polybasic residues at the HA 
cleavage site and HA is cleaved by intracellular subtilisin-like proteases, such as 
furin, found ubiquitously in the host organism thus enabling systemic infection of the 
host (Garten and Klenk, 2008). Low pathogenicity avian influenza (LPAI) contain 
monobasic cleavage site that is cleaved by trypsin-like serine proteases, found 
                                                                                      1.8: Influenza virus replication process 
27 
mainly in the respiratory tract and either excreted from cells or bound to the plasma 
membrane, causing localized infection. 
 
1.8 Influenza virus replication process 
 
Influenza virus infection is initiated by the binding of viral haemagglutinin to the 
host receptor that contains sialic acid residues, which are present on glycoproteins 
and glycolipids (Skehel and Wiley, 2000). These sialic acid residues are found in 
different conformations (either α-2,3 or α-2,6 sialic acid linkage) and the ability of a 
virus to bind to one or both of them determines the tropism of the virus. Influenza 
viruses infecting avian species preferentially bind α-2,3 linked sialic acid, humans 
are infected by a virus binding to α-2,6 linked sialic acid, while swine influenza 
viruses recognize both (Steinhauer and Wharton, 1998; Suzuki et al., 2000). 
Mutations of the haemagglutinin receptor binding domain in as little as one amino 
acid can change the viral tropism and so enable the transmission of the virus to a new 
host (Matrosovich et al., 2000; Stevens et al., 2006).  
 
After binding of the viral haemagglutinin to the host receptor, a virus is internalized 
by endocytosis, either clathrin-dependent or clathrin-independent (Lakadamyali et 
al., 2004; Lakadamyali et al., 2006; Sieczkarski and Whittaker, 2002; Chen and 
Zhuang, 2008), or macropinocytosis (De Vries et al., 2011; De Conto et al., 2011). 
Viral entry may require co-receptors that have not been identified yet (Chu and 
Whittaker, 2004; Stray and Cummings, 2000), and a signalling pathway including 
receptor tyrosine kinases (Sieczkarski et al., 2003; Eierhoff et al., 2010; Ehrhardt et 
al., 2006). Influenza viruses enter the host epithelial cells via the apical surface 
(Gottlieb et al., 1993) with the human influenza viruses entering non-ciliated airway 
epithelial cells with high levels of α-2,6-linked sialic acid, while avian influenza 
viruses show preference for ciliated cells with α-2,3-linked sialic acid (Matrosovich 
et al., 2004).  
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After the entry, the virus is trafficked through the endosomal network (Lakadamyali 
et al., 2006; Sieczkarski and Whittaker, 2003; Lakadamyali et al., 2003), where H+ 
ions are transferred into the virion through the M2 ion channels penetrating the viral 
membrane (Bui et al., 1996; Pinto et al., 1992). Due to the low pH, conformational 
changes in HA occur that expose the HA2 (fusion peptide), which enables the fusion 
of viral and endosomal membranes (Wiley and Skehel., 1987). The acidic 
environment of endosomes also triggers the release of viral ribonucleoproteins 
(vRNPs) from matrix M1 into the cytosol and their travel to the nucleus where viral 
transcription and replication take place (Kemler et al., 1994; Babcock et al., 2004). 
All proteins in the RNP structure (PB2, PB1, PA and NP) contain a nuclear 
localization signal (NLS) (Boulo et al., 2007) which bind to the proteins of cell’s 
nuclear import machinery and enter the nucleus. 
 
Because the genome of influenza viruses is made of negative sense strands of RNA it 
must first be converted to positive sense strands of RNA, which serve as a template 
to produce new viral negative strands of RNA. Viral RNA polymerase starts the 
replication of influenza genome without a primer and by utilizing cell’s replication 
machinery. Viral mRNAs have a 3’ poly(A) tail but no 5’ cap when in the virion. 
However, viral mRNAs found in the host cell do have a 5’ cap (Plotch et al., 1978; 
Krug et al., 1976). This 5’ cap is cleaved off the cellular mRNAs by a “cap-
snatching” mechanism of PA (Dias et al., 2009; Yuan et al., 2009). PA contains an 
endonuclease activity that cleaves the 5’ cap from cellular mRNAs, which is used as 
a primer for viral transcription (Li et al., 2001). The products of viral transcription 
are positive sense mRNAs which are transported from the nucleus into the cytoplasm 
for translation on host ribosomes into viral proteins. Influenza glycoproteins HA and 
NA as well as M2 are transported to endoplasmic reticulum and Golgi apparatus for 
protein folding and glycosylation (Shors, 2013) followed by the transport to the cell 
membrane area where viral components are assembled into virions and released from 
host cell by budding. NA cleaves the glycosidic linkages of sialic acids from the cell 
receptors and newly synthesized virions in order to enable virions the exit from host 
cell by preventing viral particles to aggregate on the cell surface (Palese and 
Compans, 1976; Palese et al., 1974). 
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1.9 Influenza A viruses in swine 
 
In 1918, the world experienced a Spanish influenza pandemic which first appeared in 
humans in March 1918 in Kansas, USA. In October of the same year, farmers in 
Iowa, USA noticed respiratory symptoms in pigs that were similar to human 
influenza disease (Table 1.3). Koen concluded that this was the same disease that he 
called ‘swine influenza’ (Koen, 1919). Koen’s theory was rejected by most scientists 
at that time but in 1930 Shope proved this experimentally to be correct by extracting 
the mucus from a sick pig and using it to infect a healthy pig which later developed 
the same disease. This disease was developed also by pigs that Shope infected with 
the filtrate of the mucus from sick pigs suggesting that a pathogen causing the 
disease was not a bacterium but a virus (Shope, 1931). This first influenza virus 
isolate was A/swine/Iowa/15/30[H1N1]. Decades later many experiments have been 
conducted that proved the 1918 swine and 1930 swine viruses to be the same. In 
2009 a study with several animal models was carried out by Weintgartl and 
colleagues which supported Koen’s and Shope’s observations of a human pandemic 
1918 influenza virus being introduced into a susceptible swine population with the 
ability to infect pigs, replicate in them and spread to new porcine hosts (Weingartl et 
al., 2009). This swine influenza virus that first appeared in America was known as 
Classical swine H1N1 influenza virus. It remained antigenically very stable for 
approximately 80 years in sharp contrast to influenza viruses infecting humans 
(reviewed in Lee and Krilov, 2009) (Table 1.3).  
 
Classical H1N1 virus spread from USA to European pigs where it became endemic 
until its replacement by Eurasian avian-like H1N1 virus in 1979 which caused the 
extinction of Classical H1N1 virus in Europe (Brown, 2000). Years before, in 1970, 
European swine experienced the introduction of human H3N2 virus and its 
establishment in pigs. The same year avian H3N2 virus crossed over to pigs in Asia. 
In 1980s and especially in 1990s novel swine influenza viruses appeared in pigs in 
North America, Europe and Asia due to reassortment of human, avian and swine 
influenza viruses (reviewed in Lee and Krilov, 2009). 
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In March 2009, a novel pandemic H1N1 virus appeared in humans and later spread 
to pigs (Table 1.3). Phylogenetic analysis showed this virus to be the reassortant 
between the 1998 triple reassortant swine H1N2 circulating in North American pigs, 
and Eurasian avian-like swine H1N1 virus endemic in European swine. The origin of 
gene segments of the progenitor triple reassortant H1N2 virus was avian (PB2 and 
PA), human (PB1) and swine (HA, NP, NS). The progenitor Eurasian avian-like 
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Table 1.3  
Comparison of evolutionary timeline of human and swine influenza viruses, 1918 – 
2009 (adapted from Lee and Krilov, 2009). 






 known appearance and initial 
epidemic of human H1N1 in Kansas, 
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pandemic begins in August 1918. 
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 known appearance of Classical swine 
H1N1 in Cedar Rapids, Iowa, October 1918. 
1930  
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 isolated by Shope 





 isolated by Smith, 





Human H1N1 disappears. Human 
H2N2 first appears (a human H1N1 
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 documented case of swine 
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swine H1N1 - Minnesota 
 
1976 
A novel swine H1N1 outbreak in 




Human H1N1 reappears after 20 
years, genetically close to a 1950 





 appears and becomes 
established in European and Asian swine as 




 appears (a human H3N2 and 




 appears (a human H1N1 + 
swine H3N2 reassortant) and becomes 
established in European and Asian swine. 
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After 80 years, 1
st
 new North American swine 
viruses appear: Triple reassortant swine H3N2 
(Classical swine H1N1 + human H3N2 + 
unknown avian A virus). Reassortant swine 
H3N2 (Classical swine H1N1 + human 
H3N2). Reassortant swine H1N2 (Classical 
swine H1N1 + triple reassortant swine 
H3N2). Reassortant swine H1N1 (Classical 
swine H1N1 + triple reassortant swine 
H3N2). Reassortant swine H1N1 (Classical 






 appears (a 
reassortant of reassortant swine 
H1N2 and a swine (avian) H1N1). 
Pandemic H1N1 2009 virus spreads from 
people to pigs. 
                                                                                          1.10: Influenza A viruses in humans 
32 
1.10 Influenza A viruses in humans 
 
Early descriptions of influenza epidemics and pandemics (that were caused by 
influenza A type viruses) date back to 12
th
 century (reviewed in Cunha, 2004). 
Historical records reveal that influenza epidemics appeared in 1173 (England, 
Germany, Italy), 1323 (Italy, France), 1387 (Florence), 1411 (Paris), 1414 (Paris, 
Italy), 1427 (Paris). The whole of Europe experienced influenza epidemics in 1510, 
1557, 1580, 1761 and 1788 (reviewed in Cunha, 2004).  
 
The first known pandemic outbreak occurred in 1580 in Europe which followed the 
1580 epidemic, and spread to Asia and Africa. The subsequent pandemics appeared 
in 1729, 1732 and 1781. The 1781 pandemic was very severe occurring first in North 
America and spreading to South America and most of Europe. The pandemics of the 
19
th
 century appeared in 1830, 1833 and 1889. The 1889 pandemic originated in 
Russia and is therefore known as the Russian flu. Later this pandemic spread to 
Europe, North America, further to Latin America, Asia, New Zealand, Australia and 
Africa. One million people died as the result of the infection with this influenza 
strain (reviewed in Cunha, 2004). 
 
The first influenza pandemic of the 20
th
 century occurred in 1918 in North America 
and then spread to Europe with American soldiers during the World War I, and later 
to the rest of the world (Table 1.3). It is generally known as the Spanish flu due to 
public and detailed follow up of the disease in Spain (reviewed in Cunha, 2004). This 
pandemic was unusually severe with older sources estimating the total number of 
deaths between 40 and 50 million (Patterson and Pyle, 1991). The current estimation 
of lives lost is between 50 and 100 million (Barry, 2005). Phylogenetic analyses of 
influenza virus sequences obtained from fixed and frozen lung tissues of people who 
died during the 1918 pandemic (Taubenberger et al, 1997; Smith et al., 2009) suggest 
that the 1918 virus was generated by reassortment between human, swine and avian 
viruses but the exact origin remains ambiguous (Smith et al., 2009b). 
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In 1957, a novel pandemic strain H2N2 emerged in humans causing the first 
outbreak in China (Table 1.3). This virus was the result of a reasssortment between 
human influenza viruses and Eurasain avian viruses (Smith et al., 2009b). The origin 
of PB2, PA, NP, MP and NS segments was from human influenza viruses circulating 
prior to 1957 while the HA, NA and PB1 segments were from an avian source (Reid 
and Taubenberger, 2003; Smith et al., 2009b). The total death toll of this pandemic, 
also called Asian flu, was between one and four millions. 
 
A decade later, in 1968, the world experienced a new pandemic caused by an H3N2 
influenza virus (Table 1.3). This was a reassortant virus with HA and PB1 genes 
acquired from avian source while all the other gene segments were from the previous 
human H2N2 virus (Smith et al., 2009b). This pandemic is known as the Hong Kong 
flu and it killed around one million people worldwide. 
 
In 1974, a first case of swine influenza in humans was documented proving that 
swine influenza viruses can infect humans (reviewed in Myers et al., 2007). Two 
years later, In January 1976, several soldiers at Fort Dix, USA complained of 
respiratory illness and in the beginning of February one of them died (Table 1.3). 
The cause of death was confirmed to be an infection with the H1N1 swine influenza 
virus closely related to the 1918 pandemic virus. As a result, a mass vaccination of 
people was carried out (Shellenbarger, 2009) which resulted in over 500 cases of 
Guillain-Barre syndrome affecting the peripheral nervous system and 25 deaths due 
to this complications. Consequently, the vaccination program was aborted. By that 
time, 24% of the USA population was vaccinated (Shellenbarger, 2009).   
 
The next large outbreak of influenza in humans occurred in 1977 in northern China 
and Russia (Table 1.3). It affected mostly young people under the age of 25. 
Antigenic and molecular studies showed that this pandemic was caused by an H1N1 
virus, very similar to those circulating in humans between 1947 and 1957 (Nakajima 
et al., 1977). Because influenza A viruses accumulate genetic changes rapidly, the 
above finding means, that the virus remained practically unchanged for 20 years 
which implies that the virus was most likely frozen and probably accidently or
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 intentionally released from a laboratory, although both Chinese and Russian 
scientists denied that (Nakajima et al., 1979). 
 
H1N1 and H3N2 viruses have been co-circulating in a human population since 1977, 
causing seasonal epidemics. With the emergence of the pandemic H1N1 influenza 
virus in 2009, seasonal H1N1 lineage disappeared (Medina and Garcia-Sastre, 2011). 
 
The first influenza pandemic of the 21
st
 century began with the outbreak of influenza 
like illness in Mexico in March 2009 (Table 1.3). The virus was H1N1 and 
originated from a reassortment between human, avian and two swine lineages (Smith 
et al., 2009a). This pandemic caused death of approximately 285,500 people 
worldwide (Dawood et al., 2012). 
 
1.11 Influenza A viruses in birds 
 
Wild aquatic birds, particularly orders Anseriformes (ducks, geese, swan) and 
Charadriiformes (gulls, terns, surfbirds, sandpipers) are considered to be a natural 
reservoir of influenza A viruses. So far, sixteen HA subtypes and nine NA subtypes 
have been isolated from wild aquatic birds, allowing 144 possible HA-NA 
combinations (Horimoto and Kawaoka, 2005). However, only 103 different HA-NA 
combinations have been observed, some of them very rarely. In wild birds, influenza 
A viruses replicate in the epithelial cells of lower intestinal tract (Taubenberger and 
Kash, 2010). Transmission of influenza A viruses between wild birds and to 
domestic birds occurs via a fecal-oral route and through contaminated water 
(reviewed in Gibbs, 2010; Taubenberger and Kash, 2010). Influenza A viruses have 
been isolated from domestic birds such as chicken, turkey, goose, duck, quail and 
pheasant. In domestic poultry, influenza A viruses replicate in both, the respiratory 
and intestinal tract. While wild birds usually remain asymptomatic, domestic birds 
often develop respiratory illness (Taubenberger and Kash, 2010). Based on their 
virulence, avian influenza A viruses can be classified as highly pathogenic avian 
influenza viruses (HPAI) or low pathogenic avian influenza viruses (LPAI) (Kalthoff 
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et al., 2010; Klenk and Garten, 1994). High pathogenicity is due to cleavage site in 
HA between HA1 and HA2, rich in basic amino acid residues (Klenk and Garten, 
1994; Stienekegrober et al., 1992). HPAI strains are usually arising in subtypes 
H5N1, H7N3, H7N7 and H7N9 (reviewed in Brown et al., 2006). 
1.12 Influenza A viruses in horses 
 
Horse influenza occurs globally and is caused by two main strains of influenza A: 
equine-1 (H7N7) and equine-2 (H3N8). Equine-2 (H3N8) causes more severe 
disease that can affect the heart muscle. The first equine influenza A virus isolate 
was obtained in 1956 (A/equine/Prague/56 [H7N7]) during an influenza pandemic in 
horses in East Europe (Webster, 1993). In 1963, an A/equine/Miami/63 [H3N8] was 
isolated in USA responsible for a large influenza epidemic among horses. In 1989, 
China experienced a severe epidemic caused by an H3N8 virus which was shown to 
be of avian origin and unrelated to the American H3N8 virus (Webster and Guo, 
1991). Phylogenetic analyses of HA sequences have shown that equine influenza 
forms two distinct lineages, the North American and European (Daly et al., 1996) 
and the American lineage evolved into two sublineages (Lai et al., 2001). Due to 
transportation of horses, the viruses causing epidemic in one geographical area 
spread to another part of the world causing influenza disease outbreaks. For example, 
the outbreaks of equine influenza in Australia and Japan, both in 2007, were due to 
an infection with viruses circulating in USA (Elton and Bryant, 2011). 
 
1.13 Influenza A viruses of other hosts 
 
Influenza A viruses also infect marine mammals (seals and whales), minks, dogs and 
cats. Between 1979 and 1980, avian origin H7N7 influenza A virus caused a severe 
epidemic in seals in USA (Webster et al., 1981). Another outbreak of influenza in 
seals in the USA occurred between June 1982 and March 1983, which was caused by 
an avian origin H4N5 virus (Hinshaw et al., 1984; Wright et al., 2007). 
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H13N2 and H13N9 subtypes were isolated from a stranded whale (Hinshaw et al., 
1986) and might have caused or contributed to its stranding (Wright et al., 2007). 
Minks can be infected with human and avian influenza viruses (Klingeborn et al., 
1985; Okazaki et al., 1983). H10N4 subtype was isolated from a dead mink in 
Sweden (Klingeborn et al., 1985; Wright et al., 2007). 
Domestic cats and zoo tigers died of H5N1 after eating infected poultry (Enserink 
and Kaiser, 2004; Wright et al., 2007). 
An outbreak of influenza caused by an equine H3N8 virus occurred in racing dogs in 
Florida in 2004 and spread to the general dog population (Crawford et al., 2005). 
 
1.14 Transmission of influenza viruses between different hosts  
 
Successful transmission of influenza A viruses between different hosts depends on 
several viral and host factors. 
 
1.14.1 The role of viral surface glycoproteins 
 
The HA protein is the major surface glycoprotein. It mediates two important 
functions in virus replication: binding to the appropriate receptor on the host cell and 
fusion between viral and endosomal membranes. HA of avian viruses preferentially 
binds to the N-acetylneuraminic acid α2,3-galactose (NeuAcα2,3Gal) form of sialic 
acid receptors and human viruses preferentially bind to NeuAcα2,6Gal sialic acid 
receptors. Different HA subtypes require various mutations at the receptor-binding 
domain to switch binding between α2,3 and α2,6-linked sialic acid receptors. For H2 
and H3, mutations Gln226Leu and Gly228Ser are required to switch from avian to 
human binding specificity. In H1, the Glu190Asp is critical for adaptation to human-
like receptor binding (Matrosovich et al., 2006b). For H5, contradictory findings 
have been recorded depending on the type of strain used in the study. However, 
similar mutations than those in H3 might play a role in higher binding ability to α2,6-
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linked sialic acid and still retaining the ability to bind to avian-like receptors (Shinya 
et al., 2005; Stevens et al., 2006; Yamada et al., 2006). Avian-swine viruses isolated 
until 1984 from European pigs recognized both types of receptors, while viruses 
isolated after 1985 were strictly binding α2,6-linked sialic acid receptors. A 
Ser142Leu substitution in HA contributed to the loss of binding to α2,3-linked 
receptors (Ito et al., 1998) and mutations Glu190Asp and Gly225Glu were probably 
responsible for initial changes in receptor-binding specificity (Matrosovich et al., 
2000). 
 
Receptor affinity can also be modulated by glycosylation and sialyation of the HA 
head domain. Compared to viruses from aquatic birds and pigs, human H1 viruses 
are more glycosylated (Inkster et al., 1993). It has been postulated that this 
hyperglycosylation of the HA in combination with compensating NA stalk deletion, 
modifies the aquatic bird virus prior to developing virulence in chickens (Perdue et 
al., 1995; Matrosovich et al., 1999; Banks et al., 2000, 2001; Baigent and McCauley, 
2003). The NA plays a minor role in determining host-range specificity, compared to 
HA. However, it is critical that NA’s cleavage specificity is functionally compatible 
with HA’s receptor-binding properties, along with the stalk length of the NA. Like 
HA’s specificity, also NA can cleave sialic acid specifically in the form of α2,3 
and/or α2,6 linkage. This specificity still needs to be characterized but it was shown 
that the specificity of NA (N8) is associated with amino acid sites 275 and 144 (Saito 
and Kawano, 1997). It is also known that when HA shows a smaller degree of 
affinity to its receptor, also NA’s specific activity is reduced (Baigent and McCauley, 
2003). 
 
1.14.2 The role of viral ribonucleoproteins (RNP) 
 
RNP’s contribute to determining host-range specificity through three main 
mechanisms: (i) increasing genetic diversity of variants with high adaptation and 
transmission potential in the new host; (ii) interaction with host proteins that enables 
a suitable environment for efficient virus replication; (iii) generation of escape 
mutants that avode the innate immune system of the new host. Adaptation of the viral 
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variant to a new host through RNP occurs either directly in the new host, or in an 
intermediate host (Naffakh et al., 2008), same as for the surface glycoproteins. Due 
to strong physical and functional interaction of PB2, PB1, PA and NP, these proteins 
seem to share similar evolutionary pathways, which suggests co-evolution (Naffakh 
et al., 2008). 
 
52 host-associated signatures were identified throughout the influenza viral genome 
(Chen et al., 2006) and 35 of them are found in the proteins of the RNP (2 in PB1, 8 
in PB2, 10 in PA and 15 in NP). It was shown that not only HA and NA of the 
human origin are needed for a sufficient replication of a virus in mammals but also 
the internal segments (Naffakh et al., 2008). The most significant genetic signature 
for host adaptation is located at residue 627 of PB2. 
 
Most human viruses harbour Lys at this position, while avian viruses usually contain 
Glu. In 1918 H1N1 virus, the PB2 was of avian origin but the amino acid at position 
627 was Lys (Taubenberger et al., 2005). This substitution was also observed in 
many of the human H5N1 isolates and human H7N7 isolates from the fatal 
pneumonia cases in the 2003 Netherlands outbreak (Fouchier et al., 2004). However, 
swine and equine isolates of avian-like lineages retained the Glu at this position, 
suggesting less selective pressure for this residue in both species (Shinya et al., 
2007). Also, the 2009 pandemic H1N1 virus which is thought to have originated 
from the swine influenza virus, contains Glu at this position (Chen and Shih, 2009). 
Beside its role in virulence and host range adaptation, PB2-627 plays a role in tissue 
tropism of the virus. 
 
Human viruses that contain Lys at position 627 in PB2 replicate well at 33°C but 
avian viruses with the same substitution do not. Considering that the body 
temperature of birds is 41°C where avian viruses replicate, cold sensitivity of the 
polymerase proteins limits the replication of avian viruses in the upper respiratory 
tract of humans and thus limits human-to-human transmission (Naffakh et al., 2008). 
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The amino acid site 375 of PB1 seems important for the adaptation of avian viruses 
to a human host. Asn is present at this position in most avian species, while most 
human viruses have Ser at this same position. However, this position is not classified 
as a genetic signature because some human H3N2 viruses have Asn at this position 
and many avian isolates have Ser (Taubenberger et al., 2005). 
 
In combination with Glu627Lys, other amino acid residues are associated with high 
replication and pathogenicity of one strain of H7N7 and many H5N1 isolates in mice 
and humans. These residues are PB2-701, PB2-714, PA-97, PA-615, PA-624 and 
NP-319 (Naffakh et al., 2008). 
 
1.14.3 The role of host receptors 
 
Infection of a host cell starts with the interaction of viral HA and host cell receptors. 
Specific receptors for influenza viruses are still unknown, however, sialic acid 
receptors are recognized as receptor determinants for those viruses. Sialic acids are 
nine-carbon acid sugars that are bound to the termini of oligosaccharide chains of 
glycolipids and glycoproteins, forming α-glycosidic linkage (Matrosovich et al., 
2006b). Two main species are: N-acetylneuraminic acid (Neu5Ac) and N-
glycolylneuraminic acid (Neu5Gc), which are bound to sugars in the form of α2,3- or 
α2,6-linkage (Matrosovich et al., 2006b). 
 
The distribution of these receptors differs between hosts and even organs of the same 
species. Pekin ducks express α2,3-linked sialic acid in the intestine and in the 
tracheal epithelial cells. Both types of receptors are equally expressed in vascular 
endothelium and tubular cells in the kidney, endocardium and alveolar cells. 
Chickens also express mainly α2,3-linked sialic acid in the intestine, however, 
tracheal epithelial cells express 10 times as much α2,6-linked sialic acid as α2,3-
linked sialic acid. Both types of receptors are expressed in different organs with the 
dominance of α2,6-linkage in the kidney vascular epithelial cells (Kuchipudi et al., 
2009). Turkeys express both types of receptors on tracheal cells in approximately 
equal amounts, whereas intestinal walls harbour mostly the α2,3-linkage (Pillai et al., 
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2009). Quails show the abundance of both types of receptors in both the trachea and 
the intestine (Wan and Perez, 2006).  
 
Humans express α2,6-linkages on tracheal epithelial cells, while α2,3-linkages are 
expressed on alveolar pneumocytes and on the ocular and lacrimal duct epithelial 
cells, which could explain infections of the lungs with H5N1 HPAI viruses (Nelli et 
al., 2010; Nicholls et al., 2007; Chan et al., 2009) and conjunctivitis because of the 
infection with avian influenza viruses, especially H7 and H9 subtypes (Olofsson et 
al., 2005). 
 
Pigs express large amounts of α2,6- and α2,3-linked sialic acid receptors on their 
tracheal epithelial cells (Nelli et al., 2010) and since they are considered as a mixing 
vessel, both avian and human as well as swine influenza viruses can infect epithelial 
cells, which can result in the generation of reassortant viruses.  
 
1.14.4 Host immune system 
 
Immunity against influenza is dependent on the presence of natural barriers that 
prevent virus replication, vaccination or pre-infection of the host with homologous 
and/or heterologous virus and genetic makeup of the host (Belser et al., 2010). 
 
1.14.5 Environmental factors 
 
Beside host- and virus-related factors, the transmission of influenza viruses depends 
strongly on environmental factors such as weather conditions, social organizations, 
host behaviour, stability of the virus in nature, mode of transmission and virus load 
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1.15 The epidemiology of influenza A viruses 
 
Influenza A viruses infect a wide variety of warm-blooded animals and humans. 
Human viruses circulate yearly in epidemics with a peak in winter months. 
Occasionally (every few decades), an antigenically novel strain appears as a 
pandemic virus. Influenza is estimated to kill 30,000 people annually in the United 
States alone. Every few years, additional 10,000-15,000 deaths occur due to 
influenza. When a pandemic occurs, it infects 20% to 40% of the population in a 
single year and usually raises death rates dramatically above normal levels. Human 
pandemic influenza A viruses emerged four times in the last 100 years: in 1918 
(H1N1 subtype), in 1957 (H2N2), in 1968 (H3N2) and in 2009 (H1N1). How and 
when novel influenza emerge as pandemic strains and their precise mechanism of 
pathogenesis are still not understood (reviewed in Clark and Lynch, 2011). 
 
Within influenza A virus type there are currently 18 different hemagglutinin and 11 
different neuraminidase subtypes (Fouchier et al., 2005; Webster et al., 1992; Tong 
et al., 2012; Tong et al., 2013) but only three HA (H1, H2, H3) and two NA (N1, N2) 
have caused human epidemics, as defined by sustained, widespread, person-to-
person transmission (Palese and Shaw, 2007).  
 
1.16 The evolution of influenza A viruses 
 
Influenza viruses evolve by three different mechanisms: (1) antigenic drift is enabled 
by viral RNA polymerase lacking the ‘proofreading’ mechanism therefore not being 
able to correct errors during replication (reviewed in Forrest and Webster, 2010). As 
a result, point mutations arise in the newly replicating viral genome which consist of 
insertions, deletions and substitutions. New viruses evolve relatively slowly by 
stepwise mutation and selection, (2) antigenic shift is a larger change of a viral 
genome and is associated with two different processes: (i) reassortment can occur 
when the same host cell is infected with at least two different influenza A viruses that 
exchange gene segments leading to the generation of a novel virus with a different 
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combination of gene segments (McHardy and Adams, 2009), (ii) direct transmission 
of an influenza virus from one host to another and its establishment in the new host, 
(3) recombination which can be non-homologous and homologous. Large amount of 
evidence exists for non-homologous recombination in influenza A viruses but less so 
for homologous recombination (reviewed in Forrest and Webster, 2010; reviewed in 
Cox and Subbarao, 2000). 
 
Evolutionary rates are highest for influenza A virus compared to influenza virus 
types B and C. Within A type, avian influenza viruses evolve significantly more 
slowly than influenza A viruses of other hosts, both at the nucleotide and amino acid 
levels. The reason for that is attributed to wild birds being the reservoir of these 
viruses. The evolutionary rate is at equilibrium in wild aquatic birds, suggesting the 
optimal adaptation of viruses to these hosts. Even if amino acid substitutions occur 
they do not provide selective advantage so mutations do not always result in amino 
acid changes. Mammals and land-based poultry exhibit accumulation of mutations 
resulting in amino acid substitutions (Webster et al., 1992). 
 
Evolutionary rate varies among segments in influenza A viruses. H3 HA are evolving 
faster than PA, PB1, PB2, NP and M1 genes. 57% of mutations in H3 HA are silent, 
whereas in PB2 gene more than 90% are silent (Webster et al., 1992). H3 HA 
evolves with a rate of 4 x 10-3 nucleotide substitutions per site per year and HA1 
part of the H3 HA evolves with the rate of 5 x 10-3 nucleotide substitutions per site 
per year (Webster et al., 1992; Hay et al., 2001). Mutations in HA are very important 
for influenza viruses because they confer antigenic variation and enable the virus to 
escape the host’s immune system. The rates of mutation accumulation in H1N1 
viruses seem to be similar to evolutionary rates of H3 HA (Hay et al., 2001). 
 
PB2 segment codes for an internal protein, therefore only a limited level of immune 
pressure is imposed on this protein. There are also structural constraints limiting PB2 
from genetic change. M1 and M2 proteins are both encoded in the same gene 
segment and under different selective pressures: in M1, 96% of mutations are silent, 
in M2 only 66% (Webster et al., 1992). The M2 is therefore under strong selective 
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pressure, while M1 is well adapted to mammalian hosts. The segment encoding NS1 
and NS2 proteins also exhibits differences in evolutionary rate among these two 


















































Bioinformatics is an interdisciplinary scientific field, combining life sciences with 
computational biology with the aim of developing methods for retrieving, storing, 
organizing and analyzing biological data (Ouzounis, 2012). 
 
Bioinformatics is a young scientific discipline reaching back only approximately 20 
years. Between 1996 and 2001, databases with biological data (nucleotide sequences, 
molecular structures, expression profiles, full genomes) and key computational 
algorithms were in place and increasing in size (Ouzounis and Valencia, 2003). 
Therefore, the scientific community and industry saw opportunities in combining 
experimental work with computational research (Hatzimanikatis, 2000; Palsson, 
2000; O'Donnell, 2000; Reed, 2000). The expectations of this new field were great 
and as a result funding of bioinformatics substantially increased (Aldridge, 2001) and 
also was covered extensively by media (Ouzounis, 2012). Between 2002 and 2006, 
bioinformatics was making deeper and intertwined connections with science, for 
example, it introduced the terms of personalized medicine (Gurwitz et al., 2006) and 
synthetic biology (de Lorenzo et al., 2006) and paved the way of robotics and 
automation platforms into medicine (Ilyin et al., 2004; Ritchie, 2005). Because of the 
latter, bioinformatics became a matter of discussion from the standpoint of public 
health, ethics, law, education and social issues (Maojo and Martin-Sanchez, 2004; da 
Fontoura Costa, 2004). Since 2007, bioinformatics became a part of life sciences, 
such as biodiversity conservation planning (Faith and Baker, 2007), network biology 
(gene and protein interaction networks) (Gatenby and Frieden, 2007), cancer studies 
(Hanauer et al., 2007), genomic medicine (Butte, 2008), drug discovery (Chen and 
Chen, 2008), biomarker discovery (Simpson et al., 2008), literature mining 
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(Krallinger et al., 2008), genome assembly (Pop, 2009), protein design (Suarez and 
Jaramillo, 2009), metagenomics (Kyrpides, 2009), infectious diseases (Berglund et 
al., 2009), phenotyping (Thorisson et al., 2009) and others. Future challenges for 
bioinformatics remain in the fields of food production, fuels and energy sources, 
materials, health and environment (Ouzounis, 2012). 
 
2.1.1 R programming language 
 
R is a programming language that can be freely downloaded and used for statistical 
computing and graphics production. It is widely used for developing statistical 
software (Fox and Andersen, 2005; Vance, 2009) and data analysis (Vance, 2009). R 
can be used with a command line interface; but several graphical user interfaces are 
also available. 
 
The source code for R is written in C, Fortran, S and R. Users with advanced 
knowledge can use code written in different programming languages such as C, C++ 
(Eddelbuettel and Francois, 2011), Java (Temple Lang, 2010) and Pyton for 
manipulating R objects directly. But also many of R’s functions are written in R 
itself. Many user-written packages for specific functions are submitted to the R 
project (Anonim, 2013) and are subsequently available for download as add on 
packages. Advantages of R are its inbuilt functions and its static graphics that 
produces high quality figures, suitable for publication.  
 
Throughout this work, R has been used to perform initial sequence processing, 
statistical analyses, and generation of selected figures.  Additional packages 
including the ape phylogenetics package (Paradis et al., 2004) and random forest 
machine learning package (Liaw and Wiener, 2002) have been employed for more 
specialised analyses and their use is described in chapters Amantadine resistance in 
swine influenza A viruses and Oseltamivir resistance in human seasonal A/H1N1 
influenza viruses. 
  




Phylogenetics is a scientific field that studies the evolutionary relationships among 
organisms or genes (Maser et al., 2001), demographic changes and migration 
patterns of species (Edwards, 2009), the origin, transmission and epidemiology of 
pathogens (Marra et al., 2003; Grenfell et al., 2004) and other (Gray et al., 2009; 
Paten et al., 2008; Ma, 2011). The input for phylogenetic studies is most often 
molecular sequencing data but also morphological data matrices. The result of 
phylogenetic studies is a phylogeny, which is a hypothesis about the evolutionary 
history of taxonomic units. Phylogeny is represented graphically by a phylogenetic 
tree (Strimmer and von Haeseler, 2009).  
 
2.2.1 Phylogenetic tree 
 
A phylogenetic tree is a diagram, showing the inferred evolutionary relationships 
among different biological species or among different strains of the same species and 
it is based upon similarities and differences in their physical or most commonly their 
genetic characteristics. This diagram is called a phylogenetic tree because it 
resembles the structure of a tree and also for referring to the different parts of the 
diagram as a root, branch, node and a leaf. The phylogenetic tree has several parts. 
The taxa represent biological species and nodes represent the most recent common 
ancestor of those taxa. The taxa joined together are descended from a common 
ancestor. Taxa are usually represented as tips of the branch. Branches connect nodes 
and represent genetic relationships with the length of the branch usually representing 
some measure of evolutionary change. The branches determine tree’s topology. A 
group of taxa with the same common ancestor (i.e. A, B, C on Figure 2.1) are called 
a cluster or clade and have a monophyletic origin. Internal nodes are generally 
called hypothetical taxonomic units, as they cannot be directly observed. External 
nodes are called tips or leaves and represent actual viruses that have been sampled 
and their sequences determined by sequencing. The numbers associated with each 
node, represent a measure for the support for the node, which is usually between 0 
and 1 (but also given as percentages) where 1 means maximal support. These values 
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are calculated by using bootstrapping (section 2.2.5) and Bayesian posterior 
probabilities (2.2.6) (Rambaut, 2013, Strimmer and von Haeseler, 2009). 
  
Phylogenetic trees can be rooted or unrooted. Rooted trees have a node, called a 
root, which represents a common ancestor of all taxa shown in a tree. The root node 
joins the outgroup (i.e. H and I in Figure 2.1) and ingroup taxa (all taxa but the 
outgroup) and therefore represents their common ancestor. Rooted trees are therefore 
directional, since all taxa evolved from the root. This outgroup is phylogenetically 
close enough to all the taxa but far enough to be a clear outgroup. Unrooted trees 
show the relatedness of the taxa without making assumptions about ancestry.  While 
unrooted trees can always be generated from rooted ones by simply omitting the root, 
a root cannot be inferred from an unrooted tree without some means of identifying 
ancestry; this is normally done by including an outgroup in the input data (Theobald, 
2012, Strimmer and von Haeseler, 2009).  
 
Figure 2.1 shows a scaled phylogenetic tree, where the length of horizontal lines 
gives the amount of genetic change. The longer the horizontal line (branch), the 
larger the amount of change. The scale for the amount of change is found at the 
bottom of the phylogenetic tree (Figure 2.1), where the number 0.04 and the bar 
underneath show the length of the branch that represents an amount of genetic 
change of 0.04. The unit for this value, which is also the unit of the branch length, 
are usually nucleotide substitutions per site. This value is calculated from dividing 
the number of changes (substitutions) by the length of the sequence. The vertical 
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Figure 2.1 
A structure of a phylogenetic tree. Taxa are the biological species or their genes and 
are represented as tips of the branches. Branches show the amount of genetic 
change and are connected with nodes, which present the common ancestor of a 
group of taxa, called a (monophyletic) clade or cluster. The root is a common 
ancestor of every taxonomic unit in the tree. The outgroup is a taxonomic unit for 
inferring rooted trees. The scale is used to measure the amount of genetic change in 
branches. The numbers at nodes represent support for nodes. Figure made by the 
author. 
 
2.2.2 The coalescent theory 
 
Coalescent theory is a model of the distribution of alleles that are shared by every 
individual within the population with the attempt to trace the origin of these alleles 
retrospectively (back through time) to a single ancestral copy. A phylogenetic tree 
helps trace the alleles back through different lineages to see where they come back 
together (coalesce). The point where alleles coalesce is called the most recent 
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flow, no natural selection and no recombination. However, there are advanced 
methods available that incorporate coalescent theory and include recombination, 
selection and population demographic models (Arenas and Posada, 2007). 
 
2.2.3 A measure of evolutionary pressure, dN/dS versus dN-dS 
 
Evolutionary pressure on nucleotide sites encoding proteins can be quantified by 
dN/dS, which is the ratio of the substitution rate at silent sites (dS) and the ratio of 
substitution rate at non-silent sites (dN). Silent sites are the ones where substitution 
does not result in a change of an amino acid in a protein and non-silent sites are the 
ones where the substitution causes the change in amino acid sequence. dN/dS can be 
larger than 1 and is a hallmark of positive selection acting upon site(s). dN/dS can be 
equal to 1 and that indicates neutral selection or in other words, no selection. If 
dN/dS is smaller than 1, then that is a sign of a purifying (stabilizing) selection 
(Kryazhimskiy and Plotkin, 2008). 
 
Another measure of the amount of selective pressure acting upon nucleotide sites is 
dN-dS. This is the difference between the rate of non-synonymous substitutions at 
non-silent sites and the rate of synonymous substitutions at silent sites. dN-dS value 
can be positive or negative. If positive, it means that there are more non-synonymous 
mutations than synonymous at a particular site. If negative, the reverse is true. 
 
2.2.4 Models of sequence evolution 
 
Different models of DNA sequence evolution have been proposed. They differ in the 
number of free parameters they use to describe the rate of one type of nucleotide 
substituting another during evolution. Earliest models that are also the simplest have 
none or a few free parameters. It is desirable to reduce the number of free parameters 
because they are often unknown and have to be estimated from the data (Strimmer 
and von Haeseler, 2009).  
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Nucleotide substitutions can be divided into two groups: transversions (Tv) and 
transitions (Ts). Transversions are substitutions where a purine is substituted by a 
pyrimidine or vice versa (A↔C, A↔T, G↔C, G↔T) (Fig 2.2). Transitions are 
substitutions of a purine with a purine (A↔G, TsR) and a pyrimidine with a 




The six possible nucleotide substitution processes used in models of DNA evolution: 
transitions (substitutions of a purine with a purine and substitutions of a pyrimidine 
with a pyrimidine) and transversions (substitutions of a purine with a pyrimidine and 
substitutions of a pyrimidine with a purine) (adapted from Strimmer and von 
Haeseler, 2009). 
 
The simplest substitution model is JC69 model proposed by Jukes and Cantor in 
1969 with no free parameters. It assumes equal nucleotide frequencies and equal 
mutation rates (Strimmer and von Haeseler, 2009). 
 
Nucleotide frequencies (π): 





Mutation rates (μ): 
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K80 model was proposed by Kimura in 1980 and it assumes that frequencies of 
nucleotides are equal just like in the JC69 model. 
 
Nucleotide frequencies (π): 





However, K80 model distinguishes between transitions and transversions rates that 
were first denoted as α and β, respectively. Later, the rate of transversions was set to 
1 and the ratio of transition/transversion rate was denoted as K which is the only free 
parameter of the K80 model (Strimmer and von Haeseler, 2009). 
 
In 1981 Felsenstein proposed the F81 model. This model is an extension of the JC69 
model and it assumes that nucleotide frequencies (π) are not equal. 
            
F81 model has three free parameters (πA, πG, πC) (Strimmer and von Haeseler, 2009). 
 
Hasegawa, Kishino and Yano proposed the HKY85 model in 1985. This model 
combines some features of K80 model and F81 model. It recognizes the ratio of 
transitions and transversions as K (like the K80 model) and it assumes unequal 
nucleotide frequencies (like F81 model). The number of free parameters is four 
(transition/tansversion rate ratio and three nucleotide frequencies) (Strimmer and von 
Haeseler, 2009). 
 
Tamura and Nei proposed the TN93 model in 1993. This model assumes that 
transitions A↔G have a different rate compared to transitions C↔T. All types of 
transversions are assumed to occur at the same rate, which is allowed to be different 
to the rates of transitions. This model also assumes unequal nucleotide frequencies. 
This model has five free parameters (transition/transversion rate, purine transition 
rate/pyrimidine transition rate, three nucleotide frequencies) (Strimmer and von 
Haeseler, 2009). 
                                                                                                                      2.2: Phylogenetics 
53 
GTR model (General time-reversible model) was proposed by Tavaré in 1986. This 
model assumes that all six types of substitutions occur at a different rate. 
                              
GTR model also assumes that nucleotide frequencies (π) are different. 
            
This model has eight free parameters (five substitution rates and three nucleotide 
frequencies) (Strimmer and von Haeseler, 2009). 
 
Shapiro, Rambaut and Drummond proposed the SRD06 model in 2006. This model 
refers to a particular combination of models used for analyzing nucleotide sequences, 




 codon positions and 
3
rd
 codon positions and then applies independent HKY85+gamma substitution 
models to those two partitions. SRD06 inherited different nucleotide frequencies and 
a transitions/transversions ratio parameter from the HKY85 model (Shapiro et al., 
2006). Gamma distribution is used to model the nucleotide substitution rate 
heterogeneity over sites. 
 
2.2.5 Methods for constructing phylogenetic trees 
 
The maximum parsimony tries to find a topology of a tree that can be explained by 
smallest amount of character changes (i.e. substitutions), where each position in the 
aligned sequences is a character and the nucleotide or amino acid at that position is a 
state (Vandamme, 2009). Therefore, the parsimony criterion states that the best tree 
describing the data is the tree that supposes the least evolutionary change to explain 
observed data (hence maximally parsimonious).  
 
The disadvantage of maximum parsimony is that parsimony only works well if rates 
of evolution are slow and branches are short (Felsenstein 2004; Felsenstein 1981a; Li 
1997). When rates of evolution are high, or when some branches are very long, or 
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when the number of possible character states is limited, the output tree is not a true 
tree. This is often true for nucleotide sequences, which have only four possible 
character states (A, C, T, or G). In cases such as these, other phylogenetic methods 
can be more accurate than parsimony (Theobald, 2012). 
 
Another commonly used method for determining phylogenetic trees is maximum 
likelihood (ML) (Edwards and Cavalli-Sforza 19643; Felsenstein 1981b; Fisher 
1912). ML finds the tree and evolutionary parameters that produce the observed data 
with the highest probability. In other words, ML calculates the probability of a tree 
on a given set of data, using a specific evolutionary model. The supposition is that a 
topology with a higher probability of reaching the observed state is preferred to a 
topology with a lower probability. The method searches for the tree with the highest 
probability or likelihood. The disadvantage of ML is that with the increasing number 
of taxa included in the dataset, the number of possible trees as well as the computing 
time grow exponentially, therefore an exhaustive search of all possible tree 
topologies is not possible (Theobald, 2012,Vandamme, 2009). 
 
PhyML is a software for inferring maximum likelihood phylogenies from nucleotide 
or amino acid datasets. Since its first introduction in 2003 (Guindon and Gascuel, 
2003), this software has been developed further to improve its performance and 
reduce the computation time needed. Older version of Phyml used NNI (nearest 
neighbour interchange) which exchanges two subtrees that are connected by a single 
edge (Guindon and Gascuel, 2003). However, NNI tree searches sometimes become 
trapped in suboptimal maxima of the likelihood function, therefore SPR (sub tree 
prune and regraft) moves were introduced to PhyML (Hordijk and Gascuel, 2005) 
that explore the space of tree topologies. The second implementation of PhyML was 
the introduction of the approximate likelihood-ratio test (aLRT) (Anisimova and 
Gascuel, 2006). This approach is combined with NNI moves and compares each 
subtree configuration around the internal branch of interest to two alternative 
configurations that are defined by NNI moves around that branch. Then it computes 
the likelihood values of these two alternative topologies and performs an aLRT test, 
which is based on the logarithm of the ratio between the likelihood value of that tree 
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and the likelihood value of the best alternative tree (Guindon et al., 2010). With this 
upgrade, PhyML can resolve trees’ phylogenies very accurately (depending on 
various parameters chosen by the user) but can be time consuming and also, the input 
file is preferred to be between 3 and 500 sequences of less than 2,000 characters 
long. 
 
In this PhD, PhyML was used in only one research chapter (Amantadine resistance in 
swine influenza A viruses) to analyze a relatively large dataset of MP sequences’ 
alignment from three different hosts. 
 
RAxML (Randomized Accelerated Maximum Likelihood) is a software suitable for 
inferring phylogenies of very large datasets (several thousand sequences) under 
maximum likelihood. This program encompasses four different ways for obtaining 
bootstrap support and also a bootstopping option (Pattengale et al., 2010) that 
enables RAxML to automatically determine the number of bootstrap replicates 
needed for a stable support value (Stamatakis, 2014). RAxML is able to correctly 
analyze not only nucleotide and amino acid datasets but also binary data, 
morphological data with multiple states, RNA secondary structure data and data 
containing single nucleotide polymorphisms (SNPs). RAxML can also be used to 
assess which regions of a gene in question show a strong phylogenetic signal and 
these regions can therefore be used for amplification (Stamatakis, 2014). There are 
also other improvements of PhyML (parallel versions, post-analysis of trees, vector 
intrinsics, memory saving) (Stamatakis et al., 2014). 
 
In this PhD, RAxML was used only in one research chapter (Amantadine resistance 
in swine influenza A viruses) for analysis of a very large dataset of MP sequences. 
 
All distance methods transform character data into a matrix of pairwise distances, 
one distance for each possible pairing of the taxa under study. Distance methods are 
used almost exclusively with molecular data. Several of the distance methods are 
guaranteed mathematically to converge on the correct tree as more data is included 
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(Theobald, 2012). The most simple distance matrix is merely the number of character 
differences between two taxa, such as the number of nucleotide differences between 
two DNA sequences (Theobald, 2012).  
 
The neighbor-joining (NJ) algorithm takes as input a distance matrix specifying the 
distance between each pair of taxa. The algorithm starts with a completely 
unresolved tree, whose topology corresponds to that of a star network, and iterates 
over the following steps until the tree is completely resolved and all branch lengths 
are known. NJ is joining the pairs of neighbouring taxa connected by a single interior 
node until every possible taxa pair is connected to yield the shortest tree. So, NJ joins 
two taxa by introducing the shortest possible internal branch. Optimal topology of 
the tree is the one that minimizes the tree length, when summing the branch lengths 
together (Theobald, 2012; Vandamme, 2009). 
 
In this PhD, NJ was used in the chapter Reassortment in swine influenza A viruses 
for constructing phylogenies of all eight segments of swine influenza A viruses 
separately and comparing them against each other in order to assess for reassortment 
among segments.  
 
Bootstrapping is a statistical method for assessing the reliability of the branches in a 
phylogenetic tree (Felsenstein 1985). In other words, bootstrapping analysis gives a 
way to judge the strength of support for clades on phylogenetic trees. In a bootstrap 
analysis, a fictional dataset is created by sampling data randomly with replacement 
from the real dataset until a new dataset is created of the same size. That means that 
some data will not be included in the bootstrap sample at all, while others will be 
included once or more. This process is done repeatedly (hundreds or thousands of 
times), and the parameter of interest is estimated from each fictional dataset. Then, 
for each bootstrap data set, a tree is constructed and the percentage of a certain clade 
in a tree is calculated (Felsenstein 1985). These bootstrapped phylogenies will likely 
have different topologies. The parts of the bootstrapped trees that are in common are 
ascribed a high confidence, while the parts that vary extensively are assigned a low 
confidence. A number is written by a node, which reflects the percentage of 
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bootstrap trees which also resolve a particular clade (Efron et al., 1996, Theobald, 
2012,Vandamme, 2009). 
 
2.2.6 Bayesian inference methods 
 
Markov chain is a collection of random variables with the probability distribution of 
states where the state of the next random variable in the sequence, given the past and 
current states, depends only on the current state. Monte Carlo methods are 
computational algorithms (simply sets of instructions) for randomly sampling from a 
probability distribution. They are a form of computer simulation of some 
mathematical or physical process. The Monte Carlo expression comes from the 
analogy between a casino and random number generation. These two concepts have 
been put together (MCMC) for solving problems in Bayesian inference and 
elsewhere. MCMC first constructs a Markov chain of random variables which 
converges to the desired probability distribution after a certain (large) number of 
steps. The state of the chain is then used as a sample from this distribution (Ronquist 
et al., 2009).  
 
Using MCMC, parameters of models are estimated and the likelihood of the model 
given the data is calculated. Then new parameters are proposed and the likelihood is 
calculated again. If the new likelihood is better (lower value), the new parameters are 
accepted but if the new likelihood is worse, then the new parameters are also 
accepted with a probability dependent on the ratio of the new and old likelihoods. 
This is how a chain of accepted parameters and their corresponding likelihoods is 
made. At the start of the chain, the likelihood of the models and its parameter 
estimates are still growing (improving) therefore are not in the equilibrium yet and 
are therefore discarded as burn-in. When the chain reaches the equilibrium, the 
distribution of parameter estimates reaches approximately the true distributions. So 
taking a sample of the parameters and posterior likelihoods after removing the burn-
in period, gives an approximate of the true values. 
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BEAST (Bayesian Evolutionary Analysis Sampling Trees) is an advanced method 
for testing evolutionary hypotheses or constructing phylogenies. It incorporates the 
coalescent theory. BEAST includes several program packages for Bayesian MCMC 
analysis of molecular sequences. It enables the construction of rooted, time-measured 
phylogenetic trees with an inferred molecular clock (strict or relaxed). It also enables 
the user to choose the appropriate nucleotide substitution model and population 
demographic model (Drummond and Rambaut, 2007). 
 
BEAST is based on Bayesian Markov chain Monte Carlo (MCMC) method for 
phylogenetic reconstruction. MCMC is a stochastic algorithm that produces 
estimates of a target distribution of choice, based on a sample. Stochastic process is a 
process, which is independent of a previous process (e.g. DNA substitution) and is in 
a particular state for a random amount of time before transiting to another state. In 
BEAST, the target distribution is the posterior distribution of a set of evolutionary 
parameters on a given set of molecular sequences. The most noted feature of BEAST 
is a resulting set of rooted trees incorporating a time scale. This is achieved by 
modelling the rate of molecular evolution on each branch of the tree. In the simplest 
case, this rate can be uniform across the tree, where the rate is known in advance or 
estimated from calibration information. BEAST was the first to introduce the relaxed 
molecular clock that does not assume a constant rate across lineages (Sanderson, 
1997; Thorne et al., 1998; Rambaut and Bronham, 1998; Yoder and Yang, 2000; 
Kishino et al., 2001; Sanderson, 2002; Thorne and Kishino, 2002; Aris-Brosou and 
Yang, 2003), which is one of the biggest advances in molecular phylogenetics 
(Drummond and Rambaut, 2007). 
 
Another big advantage of BEAST is a single coherent framework of different 
evolutionary models that complement each other. These models are nucleotide 
substitution models, demographic models, tree shape priors, molecular clock models 
and others. This means that simpler model components have been brought together to 
construct a complex evolutionary model in order to avoid oversimplifying, which is 
still present in many evolutionary analysis packages. It also enables the user to tailor 
                                                                                                                      2.2: Phylogenetics 
59 
the analysis according to its own specific set of questions by choosing model 
specifications (Drummond and Rambaut, 2007). 
 
In this PhD, BEAST was used in all three research chapters. In the chapter 
Reassortment in swine influenza A viruses, BEAST was used to construct a set of 
1000 trees for each segment for each subtype studied and the topology of those trees 
was further compared in R to calculate the topology distance and so estimate the 
reassortment among segments. In the chapter Amantadine resistance in swine 
influenza A viruses, BEAST was used to determine the origin (time and host) of this 
resistance in swine influenza viruses. In the chapter Oseltamivir resistance in human 
seasonal influenza A/H1N1 viruses, BEAST was used to infer the time of oseltamivir 
resistant strains appearance and the relationship among resistant strains. 
 
MrBayes is a program for constructing phylogenetic trees based on Bayesian 
phylogeny using a variant of MCMC called Metropolis coupled Markov chain Monte 
Carlo (MC
3
) (Geyer, 1991). It has first been introduced in 2001 and implemented 
since then. MrBayes has a command-line interface and reads in an alignment of 
nucleotides or amino acids. The user can choose prior information such as the 
nucleotide substitution model and molecular clock. The output options are samples 
of ancestral states, site rates, site dN/dS ratios, branch rates and node dates. Many of 
the statistics can be output for visualization in FigTree (Rambaut, 2007) or other 
software (Huelsenbeck and Ronquist, 2001; Ronquist et al., 2012). 
 
In this PhD, MrBayes has been used initially to construct trees based on alignments 
of influenza segments’ DNA. However, MrBayes failed to construct trees for several 
datasets therefore it has not been used further. 
 
2.2.7 Methods for detecting reassortment 
 
Reassortment can be detected based on the topology of taxa on a phylogenetic tree. 
For example, if one taxon from dataset X has reassorted, it is found elsewhere on a 
tree for the dataset Y (Figure 2.3). 






Two phylogenetic trees (one for dataset X and one for dataset Y) with identical 
topologies except for one taxon (B, in red) where reassortment occurred. Figure 
made by the author. 
 
Kosakovsky Pond et al (2006) developed GARD (Genetic Algorithm Recombination 
Detection) which is a novel method for recombination detection in either biological 
or simulated sequences. The method is likelihood-based and uses a genetic algorithm 
that searches multiple sequence alignments for evidence of recombination. GARD is 
a robust method that screens multiple sequence alignments in order to find the 
evidence of phylogenetic incongruence. It also identifies the number and location of 
recombination breakpoints and sequences involved in putative recombination events. 
The advantage of this method is that it can be run in parallel on a cluster of 
computers and so it can screen for recombination in large datasets, it has better 
power and accuracy compared to other methods for recombination detection and it 
also gives good statistical properties for methods aimed at detecting positive 
selection. Because recombination is quite widespread in certain viruses (HIV-1, 
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evolutionary analyses tools, such as phylogenetic reconstruction (Posada and 
Crandall, 2002), molecular clock inference (Schierup and Hein, 2000) and the 
detection of positively selected sites (Shriner et al., 2003). Therefore, methods that 
can detect recombination events are an important part of every phylogenetic analysis. 
GARD has been implemented as language scripts in HyPhy, enabled to run in an 
MPI environment (Kosakovsky Pond et al., 2005). GARD can be freely accessed 
on:  http://www.datamonkey.org/GARD/ and enables the user to: (i) upload an 
alignment of sequences to screen. The number of sequences and their length is 
periodically increased; (ii) select an appropriate model of nucleotide evolution 
(Kosakovsky Pond and Frost, 2005) and the distribution for modelling site-to-site 
variation in substitution rates; (iii) run GARD that screens for recombination; (iv) 
visualize and download the results of analysis, which include the number and 
location of breakpoints, improvement in AIC score, phylogenetic trees based on each 
non-recombinant breakpoint and other; (v) result files and also scripts for running the 
analyses can be downloaded and run locally (Kosakovsky Pond et al., 2006). 
 
In this PhD, GARD was used in the chapter Reassortment in swine influenza A 
viruses in order to detect if there is any reassortment among all pairs of segments 
(concatenated sequences) and also for quantifying the amount of reassortment found. 
 
Nagarajan and Kingsford (2011) presented a method, called GiRaF (Graph-
incompatibility-based Reassortment Finder), that can find reassortments in a given 
collection of sequences by using data-mining techniques. GiRaF can identify the set 
of isolates arising from a reassortment. The method is based on comparing 
distributions of trees by constructing an ‘incompatibility graph’ and mining it for 
phylogenetic differences. Results of the authors of Giraf show that GiRaF can 
identify precisely recent reassortments as well as complex reassortment histories. 
GiRaF can efficiently analyze large datasets (Nagarajan and Kingsford, 2011). 
 
In this PhD, GiRaF was used initially for detecting reassortment in influenza 
sequences. However, the results of this method were difficult to interpret therefore 
they were not included in my thesis. 
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2.2.8 Machine learning methods 
 
CART (Classification and Regression Tree Analysis) methodology was first 
introduced in 1984 by Breiman et al. The term CART refers to two types of decision 
trees that can be constructed with this method. First, classification trees where the 
variables are categorical and the tree helps to identify a class within which a target 
variable falls into. Second, regression trees where the variables are continuous and 
the tree helps to predict their values. CART is used for constructing prediction 
models from data. These models are obtained by partitioning the data in a binary 
recursive way. The term binary refers to the fact that each group of variables, 
represented by a node in a decision tree, can only be split into two groups. So, each 
node (called parental node) can be split into two further nodes (called child nodes). 
The term recursive refers to the fact that this process of binary partitioning can be 
repeated over and over again. The data is split into two parts, one part has samples 
with a particular variable larger or equal to a threshold, and the other has samples 
which have values smaller than a threshold. Thus, a parental node gives rise to two 
child nodes and these two child nodes each give rise to two further child nodes. The 
larger the distance between the nodes (depth) the more significant is the split (Figure 
2.4). The term partitioning refers to the dataset being split into parts or partitioned 
(Lewis, 2000). The partitioning is completed when is no longer possible to continue 
the tree building process. That is usually when there is only one value in each of the 
child nodes. Each value of the target variable at the end of the node represents a leaf 
(Fig 2.4). The tree that is created is usually overfit. That means that this tree fits 
every value of the variable in the dataset used to create that tree. So, this tree would 
not fit other independent datasets (Lewis, 2000). The parts of the decision tree that 
are more likely to represent an overfit are later parts of the tree. Therefore, tree 
pruning has been introduced into the CART methodology. It begins at the last level 
(the terminal nodes) which is pruned away. As more and more nodes are pruned 









A decision tree constructed by using CART. Each group of variables in the dataset 
(parental node) is split into two parts (child nodes). Values of the variables are called 
leaves. Nodes names and leaves names are omitted for clarity. The figure made by 
the author. 
 
In this PhD, CART was used in the chapter Oseltamivir resistance in human seasonal 
A/H1N1 influenza viruses, to determine the association between amino acid sites 
from two different proteins. 
 
 
root node (parental node) 
child node 
leaves 
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Random Forest is an extension of the tree learning paradigm. This method is robust 
to over-fitting and gives better predictive performance than CART (Breiman, 2001). 
Individual trees are constructed similarly to CART with the difference that splits are 
determined on a random subset of the available amino acids at each leaf. Because the 
number of trees is created by growing them on bootstrap samples of the training data 
this method includes the word ‘forest’. So, this method constructs a defined number 
of decision trees where splits are determined on the selected subset of variables at 
each leaf. To assess the predictive power of the models tested, it is important to use 
10-fold crossvalidation. That means that sequences (the database) are randomly split 
into 10 parts with one part used as a test dataset and the 9 remaining parts of 
sequences used as a training dataset. This is repeated 10 times. To interpret the 
random forest models, the ‘permutation accuracy importance’ (PAI) measure is 
applied, which shows the importance of each amino acid site to predict phenotype 
(Breiman, 2001). To calculate the PAI, the values of amino acids at each site are 
randomly permutated as to break any link with the phenotype response. Next, the 
accuracy of the model to predict phenotype using this permutated and all other 
unpermutated amino acid sites is measured. The greater the change to the model’s 
accuracy, the more important the amino acid site to predict the phenotype. Amino 
acid sites are then ranked according to their impact on the accuracy of the model in 
order to identify the most important amino acid sites for the prediction of the 
phenotype. 
 
In this PhD, random forest was used in the chapters Oseltamivir resistance in human 
seasonal A/H1N1 influenza viruses, and Amantadine resistance in swine influenza A 
viruses. In both chapters this method was used to determine which amino acid sites 
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2.2.9 Method for detecting co-evolving sites 
 
A Bayesian graphical model (BGM) is a directed acyclic graph with nodes and 
edges (arrows) that represent variables and the relationships among the variables, 
respectively. So, edges (arrows) represent dependencies between variables (nodes). 
The degree of dependency of a certain node on the other is expressed by a probability 
value. Variables represented by nodes can be observable quantities or even unknown 
parameters or hypotheses. Nodes that are connected are dependent and the direction 
of the arrow indicates the mode of dependency (Figure 2.5, for example, C depends 
on A). Each node is associated with a probability value for each dependency (Lee 
and Abbott, 2003). A Bayesian graphical model is constructed on the basis of 
nucleotide sequences and a phylogenetic tree of those sequences. The phylogenetic 
tree can be provided by the user or constructed by the software for BGM analysis. 
 
In this PhD, Bayesian graphical models were used in the chapter Amantadine 
resistance in swine influenza A viruses to assess which amino acid sites from 
different genome segments, shown to be functionally associated, are co-evolving and 













A structure of a Bayesian graphical model with nodes representing variables (i.e. 
amino acid sites), edges representing relationships among the variables, and 
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2.2.10 Methods for detecting amino acid sites under selection 
 
Methods for identifying sites under selection on a site-by-site basis have been 
proposed. These methods can be divided into three classes and are complementary. 
First class includes the counting methods that count the number of non-synonymous 
and synonymous substitutions in the dataset. Second class of methods are called 
random effects models and they calculate the distribution of evolutionary rates across 
sites and then infer the rate for each individual site based on that distribution. Third 
class are fixed effects models and estimate the ratio of non-synonymous to 
synonymous substitutions for every site (Kosakovsky Pond and Frost, 2005). 
 
The first class is a counting method SLAC (Single Likelihood Ancestor Counting) 
and is used to estimate the number of nonsynonymous and synonymous mutations 
that have occurred at each codon in the dataset. This method is a modification of the 
approach first described by Suzuki and Gojobori (1999), and can reconstruct the 
ancestral sequences by using parsimony (Suzuki and Gojobori, 1999) or methods 
based on likelihood (Nielsen 2002; Nielsen and Huelsenbeck 2002; Suzuki 2004). 
SLAC counts the number of non-synonymous and synonymous substitutions 
occurring on the branches of the tree (i.e. changes between nodes and their 
immediate ancestors). SLAC is fast computationally and estimates site specific rates 
directly from each site. The disadvantage of SLAC is underestimation of the number 
of substitutions that have taken place in a dataset if a dataset is small. So, SLAC can 
calculate wrongly the rate at which sites are evolving. However, SLAC can correctly 
detect non-neutral evolution in large datasets (Kosakovsky Pond and Frost, 2005). 
 
REL assumes that both dN and dS vary across sites independently. REL calculates a 
distribution of substitution rates across sites and then infers the rate at which 
individual sites evolve (Kosakovsky Pond and Frost, 2005). REL is the most 
powerful of these three methods but is susceptible for type I errors (false positive 
result), particularly on small datasets (Kosakovsky Pond and Frost, 2005).  
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FEL is a derivate of the model first proposed by Yang and Swanson (2002), who 
suggested that sites evolve under different dN/dS.  FEL is similar to SLAC in terms 
of not making any assumption regarding the distribution of rates across sites. On the 
other hand, FEL is slower than SLAC and can be difficult to use due to the large 
number of parameters involved, for example models of nucleotide substitution 
(Kosakovsky Pond and Frost, 2005; Nielsen, 1997). 
 
In this PhD, only SLAC method was used. It was used in the chapter Amantadine 
resistance in swine influenza A viruses in order to detect the amount of evolutionary 
changes on codons where adamantine resistance can occur in avian sequences (wild 
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Reassortment is the mixing of genetic material into new combinations. The 
prerequisite for the reassortment event of influenza viruses is that a host cell is 
infected with at least two different strains of influenza viruses of the same type (the 
subtypes can differ, also the host origin can be different). Influenza viruses have a 
segmented genome, which makes the exchange of viral genetic segments within the 
infected cell possible. Therefore, some segments come from one influenza strain and 
some from another. The new reassortant strain carries properties of both parental 
lineages. Reassortment is responsible for the major genetic shifts in influenza 





century. The 1957 and 1968 pandemic influenza strains were caused by reassortment 
between an avian and a human influenza virus. The 2009 pandemic H1N1 virus 
resulted from the reassortment between avian, human and swine influenza viruses 
(Hood, 2006). 
 
3.2 Host restriction 
 
Avian hosts, especially waterfowl, present the major reservoir for influenza A 
viruses. Occasionally, certain influenza A strains cross the species barrier from the 
avian host into a mammalian host, such as swine, humans and horses (Webster et al., 
1992). The consequence can be the epizootic and endemic outbreaks and 
establishment of these new lineages in the recipient host populations. Out of 18 
haemagglutinin subtypes and 11 neuraminidase subtypes known so far, only 3 HA 
and 2 NA subtypes have become established in the human population and caused 
epidemics and occasional pandemics. One preventing factor for other viral subtypes’ 
establishment in humans is the receptor specificity of the virus (either α-2,3-linked or 
α-2,6-linked sialic acid receptors) and the availability of the appropriate receptor in 
the host (Connor et al., 1994; Ito et al., 1998a; Matrosovich et al., 2000; Rogers and 
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D’Souza, 1989). The α-2,3-linked sialic acid receptors are found only in small 
amounts and only in the lower respiratory tract of humans, therefore transmission of 
avian influenza A viruses is not frequent although direct infection can occur (CDC, 
2008; CDC, 2014). Swine influenza A viruses can adhere to both types of receptors 
and both types of receptors are found in equal abundance in swine lungs. Therefore, 
as human and avian influenza A viruses can infect pigs, consequently, pigs have been 
suggested to play a role in facilitating the adaptation of avian viruses to human hosts 
(Ito et al., 1998a; Scholtissek et al., 1985). 
 
3.3 Pigs as mixing vessels - mixing vessel hypothesis 
 
The “mixing vessel” hypothesis was first introduced by Scholtissek et al. (1985) who 
reasoned that swine can be infected with either swine, human or avian influenza 
virus at the same time. This multiple infection could produce reassortant viruses 
between swine and avian/human viruses, which have the potential to be transmitted 
back to humans and so introduce unique viruses into the human population. The 
reassortant viruses could then cause human pandemics. The basis for this hypothesis 
was the finding that antigens and genome segments between swine, human and avian 
influenza seem similar. Also, the susceptibility of swine to infection by human and 
avian viruses was proven. Support for this hypothesis was found at the molecular 
level with the discovery that avian and human influenza viruses have preferential 
binding to specific receptor types. There are three parts to the mixing vessel 
hypothesis: 1) swine are susceptible to avian and human influenza A viruses; 2) 
reassortment of swine/avian/human viruses occurs in the pig and 3) pigs can transmit 
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3.4 A brief history of reassortment events in swine 
 
In influenza A viruses, segments usually correspond to host type, however, there 
have been reassortments among segments as well as various cross-species 
transmissions, the outcome of which are the new genotypes or clades (dos Reis et 
al., 2009; Dunham et al., 2009; Schultz et al., 1991; Smith et al., 2009). These 
events led to: (i) the transmission of H1N1 from birds to swine, creating the H1N1 
Eurasian avian-like swine lineage clade found predominantly in Europe and Asia; (ii) 
reassortment between Eurasian avian-like swine H1N1 and human viruses, resulting 
in the establishment of H1N2 and H3N2 reassortants in swine in Europe; (iii) the 
complex reassortment of swine, avian and human H1N1, H1N2 and H3N2 viruses 
that created the swine triple-reassortant viruses, circulating predominantly in North 
American swine from 1990s onwards; (iv) reassortment between the H1N1 Eurasian 
avian-like swine influenza viruses (i) and swine triple-reassortant viruses (iii), 
creating the 2009 H1N1 human pandemic strain (Brown et al., 1998; Castrucci et 
al., 1993; Garten et al., 2009; Olsen, 2002; Pensaert et al., 1981; Smith et al., 
2009; Webby et al., 2000; Zhou et al., 1999). 
 
3.5 Antigenic drift in swine influenza versus human influenza viruses 
 
Antigenic drift is the accumulation of point mutations in the influenza virus’ genome 
due to the error prone RNA polymerase of influenza viruses. Consequently, these 
mutations cause the viruses to be antigenically different from their parent viruses 
(Gerhard and Webster, 1978). In commercial swine herds, there is less pressure to 
select for antigenic changes compared to humans for two main reasons: (i) a high 
proportion of susceptible individuals at any given time because of a high birth rate 
and a lifespan of no more than six months; (ii) no widespread use of vaccines for 
swine in Europe. This means that evolutionary pressures on HA and NA are not 
expected to be the same in swine and humans – for swine H3 antigenic drift rate is 
much lower  (de Jong et al., 2007; Lorusso et al., 2011). For seasonal influenza 
viruses in humans we see the correlated lineages in all segments being driven by the 
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HA and NA subtype, however, in swine the persistence and transmission of the 
internal polymerase coding segments regardless of the HA and NA subtype was 
observed. Therefore, for swine, the polymerase segments are the primary heritable 
units which acquire different surface glycoproteins (HA and NA) through 
reassortment. To counteract herd immunity in humans, the antigenic drift (antigenic 
novelty) is driving the dynamics of influenza strains (Garten et al., 2009; Boni, 
2008; Russell et al., 2008; Smith et al., 2004). There is very little reassortment in 
humans, so the external HA and NA subtypes broadly correspond to the internal gene 
segments. 
 
3.6 Swine influenza A viruses in Europe  
 
Swine influenza is considered to be an important disease of swine in Europe. The 
characteristics of the viruses circulating in Europe share some similarities with 
strains circulating in North America and Asia but there are also a number of 
differences. The epidemiology and etiology of swine influenza in Europe have 
historically been different from other parts of the world and therefore also 
approaches for its’ control remain different (Zell et al., 2013). 
 
3.6.1 Classical H1N1 
 
This virus was introduced into pig populations around 1918 (Smith et al., 2009) and 
was endemic in European swine until the emergence of avian-like H1N1 virus when 
it disappeared (Brown, 2000). It was antigenically relatively stable with no evidence 
of involvement in virus reassortment (Brown et al. 1997). 
 
3.6.2 Human-like H3N2 viruses 
 
Under natural conditions pigs can become infected with prevailing human subtypes. 
In the 1970s H3N2 viruses were isolated regularly from European pigs (Tumova et 
al. 1976; Ottis et al. 1982). Since 1984 these viruses caused frequent outbreaks of 
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clinical influenza in pigs in Europe (Aymard et al. 1985; Haesebrouck et al. 1985; 
Pritchard et al. 1987). Although related closely to the prototype human viruses, swine 
human-like H3N2 viruses have antigenic differences in the surface glycoproteins 
(Haesebrouck and Pensaert 1988; Brown et al. 1995). The HA gene of the human-
like H3N2 virus has experienced considerable antigenic variation due to genetic drift 
and this led to an increase in the epizootics of this virus (DeJong et al. 1999). These 
recent viruses are only distantly related to the early strains. 
 
3.6.3 Avian-like H1N1 viruses 
 
These viruses have dominated pig populations in Europe since 1979. They are 
antigenically distinct from the Classical swine H1N1 viruses but related to avian 
H1N1 isolated from ducks (Pensaert et al. 1981; Scholtissek et al. 1983). Because 
these avian-like H1N1 viruses replaced the Classical H1N1 lineage in Europe, it 
suggests they had the selective advantage (Campitelli et al. 1997; Brown, 2000) 
because of their evolutionary distance from the viruses previously found in swine. 
This lineage came into pigs from birds and became established in European pigs 
where it remains the dominant strain in many European countries.  
 
3.6.4 H1N2 viruses 
 
These viruses were first isolated in the late 1980s and are derived from the Classical 
swine H1N1 and human-like swine H3N2 (Gourreau et al. 1994). Their HA gene 
segment was inherited from the Classical swine H1N1 lineage and the NA segment 
was derived from the human-like swine H3N2 virus. At first these viruses did not 
spread widely but in 1994 H1N2 viruses related antigenically to human and human-
like swine viruses became endemic in pigs (Brown et al. 1995; Van Reeth et al. 
2000; Marozin et al. 2002). Occasionally H1N2 viruses with different HA appear but 
do not persist. Also H1N2 viruses with a novel NA appeared in Germany in 
Dotlingen and Cloppenburg in 2005 (Zell et al. 2008). 
 
 




In March 2009, a novel H1N1 virus was detected in humans in Central America. It 
contained a unique gene constellation not previously reported in humans or pigs 
(Garten et al. 2009). Two gene segments were derived from avian strains of North 
American lineage, one gene from human influenza, three gene segments from the 
Classical swine lineage and two segments from the Eurasian swine lineage (NA and 
MP). The precise origin of this virus is uncertain as there is a gap in its ancestry. 
However, the most likely origin are pigs as at least seven of eight segments are 
similar to those of viruses circulating in pigs (Smith et al. 2009). This virus had not 
been detected in European pigs before its discovery in the human population 
(Kyriakis et al. 2011). 
 
3.6.6 Reassortment in European swine influenza A viruses 
 
Lycett et al. (2012) studied the co-circulation of influenza strains and how this can 
lead to the generation of reassortants. They estimated the rate of virus reassortment 
in European swine and they found that after the formation of the Eurasian avian-like 
swine clade, there were two introductions of human seasonal lineage H1 HA and two 
of classical swine lineage H1 HA. They also found two introductions of human H3 
HA and N2 NA seasonal lineages, respectively. The estimated median TMRCA of 
the N2 NA introductions was 1983 (H1N2 into England, Continental Europe and 
Asia) and 1986 (H3N2 into Continental Europe and Asia). For both of these 
introductions, they also estimated the TMRCA of the European sequences only, since 
these formed separate subclades from the Asian isolates. The first introduction of 
H1N2 into Europe had the median TMRCA of 1988-1989 (95 % highest posterior 
density (HPD) interval: 1984–1991). The predominantly H3N2 introduction into 
Europe occurred around 5 years later, with a median TMRCA of 1994 (95 % HPD: 
1990–1998). These multiple introductions of HA and NA segments resulted in a mix 
of subtypes in the Eurasian swine clade (as defined by the internal protein-coding 
segments).  
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Lycett et al. (2012) found that the median rate at which the Eurasian swine N1 switch 
to human seasonal-origin N2 on the polymerase backbone is 0.13 exchanges/year. 
The human seasonal-origin N2 switching to Eurasian swine N1 is 0.17 
exchanges/year, which is not significantly different.  For HA switching, the most 
significant rates were between Eurasian swine H1 and human seasonal-origin H1 
(0.37 exchanges/year for the H1 human seasonal-origin to H1 swine Eurasian 
direction; for the opposite direction the median rate was 0.16 exchanges/year). Lower 
rates – but still significant – were found for H1 swine Eurasian and H3 human 
seasonal-origin, and H3 human seasonal-origin to H1 swine Classical. The rates 
between the two swine lineages (H1 swine Eurasian and H1 swine Classical) and two 
human seasonal-origin lineages (H1 and H3) were not significant. The rates for 
H1N1 Eurasian swine to/from H1N2 human seasonal-origin were almost the same as 
those for H1 swine Eurasian to/from H1 human seasonal-origin. Especially the rate 
for H1N2 changing to H1N1 Eurasian was high (0.4 exchanges year
−1
), whilst the 
reverse rate was significantly lower (0.16 exchanges year
−1
). The rates between 
swine lineages H1N1 swine Eurasian and H1 swine Classical N1 swine Eurasian, and 
the two human seasonal-origin lineages (H1N2 human seasonal-origin and H3N2 
human seasonal-origin) were not significant. 
 
3.7 Swine influenza A viruses in Asia 
 
The circulation of swine influenza A viruses is more complex in Asia than in North 
America and Europe because of constant importation of pigs from these two 
continents. Apart from these viruses, there are also several lineages found only in 
Asia (Zhu et al., 2013). 
 
3.7.1 H1N1 viruses 
 
The Classical swine virus that first appeared in 1918 in USA was first observed in 
Chinese pigs that same year (Chun, 1919). Later it spread to the rest of Asia (Yip, 
1976; Yamane et al. 1978; Das et al. 1981; Shortridge and Webster, 1979; 
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Kupradinun et al. 1991). With the spread of H1N1 Russian influenza viruses there 
was also one case of human to pig transmission in Thailand (Nerome et al. 1982). 
After avian-like H1N1 appeared in European swine, it was also isolated from 
Chinese pigs and circulated with the Classical swine H1N1 (Guan et al. 1996). It was 
phylogenetically distinct from the European viruses and formed a separate lineage 
(Brown, 2000). There were sporadic appearances of the European avian-like swine 
H1N1 viruses in China in 2007 (Liu et al. 2009), introductions of non-pandemic 
human-like H1N1 in Japan and China (Katsuda et al. 1995; Yu et al. 2007, 2009a) 
and also reassortants of North American and European lineages (Choi et al. 2004; 
Song et al. 2003; Pascua et al. 2008; Chutinimitkul et al. 2008; Takemae et al. 2008). 
In southern China and southeast Asia, the Classical swine H1N1 lineage continues to 
be endemic (Guan et al. 1996; Peiris et al. 2009; Qi et al. 2009). 
 
3.7.2 H3N2 viruses 
 
Human-like H3N2 was first isolated in swine in Taiwan in 1969 after the Hong Kong 
pandemic (Kundin, 1970). After that the evolution of this lineage has been quite 
complex, especially in Southeast Asia. In the early 1980s the H3N2 virus was 
isolated in China with the human-like HA and NA and Classical internal gene 
segments (Shu et al. 1994; Nerome et al. 1995). Around the same time, two triple-
reassortant H3N2 viruses, unrelated to the reassortants of the North America or 
Europe, were isolated from Chinese pigs (Yu et al. 2008). In 1999, the European 
reassortant human-like swine H3N2 viruses emerged in chinese pigs. Just two years 
later, further reassortment with the Classical swine H1N1 virus was observed and 
that formed triple reassortant strains (Yu et al. 2008). European reassortant human-
like swine H3N2 viruses also recombined with human-like H1 or H3 strains 
(Takemae et al. 2008; Chutinimitkul et al. 2008). 
 
3.7.3 H1N2 viruses 
 
These viruses were derived from the genetic reassortment of human-like swine H3N2 
and Classical swine H1N1. In Asia, they were first isolated in Japan in 1978 
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(Sugimura et al. 1980) and became established in Japan and Taiwan (Yoneyama et 
al. 2009; Tsai and Pan, 2003). However, in Korea, the North American reassortant 
H1N2 with the Classical swine HA spread widely (Choi et al. 2002a; Pascua et al. 
2008). Also reassortant H1N2 viruses with the Classical H1 and the remaining gene 
segments from the Eurasian avian-like swine lineage were isolated from pigs in 
Thailand (Chutinimitkul et al. 2008; Takemae et al. 2008). Different reassortant 
H1N2 viruses have been observed in China, most of them are the product of genetic 
reassortment between Classical swine viruses and European reassortant or North 
American triple reassortant viruses (Smith et al. 2009; Yu et al. 2009b). 
 
3.8 Swine influenza A viruses in North American swine 
 
Coincidently with the 1918 human pandemic that killed from 50 to 100 million 
people worldwide (Murphy and Webster, 1996; Barry, 2005) influenza was clinically 
recognized in pigs during the late summer and autumn of 1918 in the Midwestern 
United States (Koen, 1919; Easterday and Hinshaw, 1992). The first swine isolates 
were collected and studied by Shope in 1930 (Shope, 1931). Those were the ancestral 
lineages of the Classical swine lineage circulating till today. Other subtypes of swine 
influenza have been isolated in Europe and Japan, mostly H3N2 and H1N2 
(Sugimura et al., 1980, Nakajima et al., 1982, Ottis et al., 1982, Yasuhara et al., 
1983, Mancini et al., 1985, Castrucci et al., 1994 and Campitelli et al., 1997; Nerome 
et al., 1985, Gourreau et al., 1994, Brown et al., 1995, Brown et al., 1998, Ouchi et 
al., 1996, Ito et al., 1998b; Van Reeth et al., 2000). From 1930 through the mid-
1990s, influenza in North American pigs was caused almost exclusively by infection 
with Classical H1N1 swine viruses. The studies between 1997–1998 (Olsen et al., 
2000) revealed an unexpected and substantial increase in H3 seropositivity, and 
H3N2 viruses began to be isolated from pigs in both the US and Canada during this 
time (Karasin et al., 2000a; Zhou et al., 1999). Subsequently, reassortment between 
H3N2 viruses and classical H1N1 swine viruses led to the appearance of second 
generation H1N2 reassortant viruses (Karasin et al., 2000b and Karasin et al., 2002). 
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3.8.1 Classical H1N1 viruses 
 
This virus strain was first recognized in pigs in 1918 in USA and that coincided with 
the human influenza pandemic. It was not until 1930 that the first influenza was 
isolated (Shope, 1931) and shown to cause the respiratory disease in pigs similar to 
human influenza. This strain was subsequently recognized as a Classical H1N1 
influenza virus and remained relatively stable genetically and antigenically until the 
late 1990s. 
 
3.8.2 H3N2 viruses 
 
Although the Classical H1N1 lineage was predominant in pigs in the USA until mid-
1990s, sporadic appearances of H3 were also observed between 1988 and 1989 but 
lacked to form a stably transmissable lineage (Chambers et al., 1991). In 1998, there 
were severe outbreaks of swine influenza disease observed in several US regions. 
The causative agent for these outbreaks was recognized as the H3N2 subtype and 
formed two genetically different lineages. The initial virus was a double reassortant; 
its gene segments were similar to those of the Classical lineage (PB2, PA, NP, MP, 
NS) and human seasonal H3N2 virus circulating in 1995 (PB1, HA, NA). The other 
lineage of this H3N2 virus was a triple reassortant and contained gene segments from 
the Classical swine viruses (NP, MP, NS), human seasonal H3N2 (PB1, HA, NA) in 
combination with the avian virus (PB2, PA) (Zhou et al., 1999). The double 
reassortant did not become established but the triple reassortant became widespread 
in the pig population in the USA (Webby et al., 2000). This constellation of human 
seasonal H3N2 PB1, avian lineage (PB2, PA) and swine lineage (NP, MP and NS) is 
conferred to as the triple reassortant internal gene (TRIG) cassette (Vincent et al., 
2008). Since 1998 there were at least three introductions of human H3 into swine 
population, leading to phylogenetic clusters I, II and III (Richt et al., 2003; Webby et 
al., 2004). The cluster III became dominant in North America and continued to 
evolve into clade IV (Olsen et al., 2006). The H3N2 viruses further reassorted with 
the extant Classical H1N1 viruses resulting mostly in reassortants that possess the 
TRIG. The H1N1 viruses containing the HA and NA from the Classical H1N1 and 
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the TRIG from the triple reassortant H3N2 viruses are referred to as reassortant 
H1N1. The viruses that contain the HA from the Classical H1N1 and NA and TRIG 
from the triple reassortant H3N2 are H1N2 viruses (Karasin et al., 2002; Webby et 
al., 2004). There were also further genetic drift variants of these reassortant viruses 
observed (Webby et al., 2000, 2004; Richt et al., 2003; Olsen et al., 2006; Choi et al. 
2002b; Karasin et al. 2002; Webby et al., 2004). Further, H3N1 and triple reassortant 
with TRIG and avian H2 were observed; the later forming the novel triple reassortant 
swine H2N3 in 2006 (Ma et al., 2007). Introduction of H1 viruses with the human 
H1N2 HA was observed in Canada (Karasin et al. 2006). Since 2005, H1N1 and 
H1N2 viruses that have HA and NA segments similar to human seasonal H1N1 and 
H1N2 viruses from around 2003 have emerged (Vincent et al. 2009). 
 
3.8.3 H1N1pan09 viruses 
 
In spring 2009 an outbreak of severe human influenza in Mexico was associated with 
a novel pandemic H1N1 virus that was isolated from humans in California. It 
possessed a unique genome with six gene segments (PB2, PB1, PA, HA, NP and NS) 
most closely related to the triple reassortant viruses from North America and with the 
MP and NA genes derived from the Eurasian swine lineage (Dawood et al. 2009). 
This novel virus became known as ‘swine flu’ due to the phylogenetic origin of its 
genome segments. However, infection of humans was not connected to exposure to 
pigs (Dawood et al. 2009). Immediately after the onset of infection with this 
pandemic virus in humans, cases of infection of pigs were reported in different areas 
of the world (Wahid, 2013). It was later shown that the H1N1pan09 spread from 
humans to pigs with subsequent sustained pig-to-pig transmission. Phylogenetic 
analyses of all eight gene segments of this pandemic virus revealed that none of these 
gene segments cluster tightly with the genes of swine influenza viruses circulating in 
the USA prior to the outbreak of 2009 pandemic in humans (Lorusso et al. 2011; 
Smith et al. 2009). So, neither the 2009 pandemic H1N1 nor closely related 
progenitor viral genes were present in U.S. swine influenza viruses prior to 2009 
(Lorusso et al. 2011). However, there is a gap in genetic surveillance of swine 
influenza viruses and therefore the ancestor lineages of the pandemic 2009 virus 
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were circulating undetected in pigs for approximately a decade (Smith et al., 2009). 
A closely related progenitor virus with the same eight gene constellation has yet to 
be identified in swine or other species, although a 2004 swine virus with 7/8 of the 
2009 pandemic H1N1 genome was identified in Hong Kong, China (Smith et al. 
2009). The 2009 pandemic virus was found to cause sustained human-to-human 
transmission but also transmission from human-to-swine (Howden et al. 2009), 
swine-to-swine (Lange et al. 2009; Brookes et al. 2010) and swine-to-human 
(Weingartl et al. 2010). This virus was shared between people and pigs and has 
therefore the potential to further change the epidemiology of influenza viruses in 
human and swine populations. 
 
3.8.4 Reassortment in the North American swine influenza 
 
Nelson et al. (2012) estimated the extent of genomic reassortment in influenza A 
viruses circulating in North American swine by performing a phylogenetic analysis 
of whole genome viral sequences sampled during 1998-2011. The highest amounts 
of reassortment were detected between the H3 and the internal gene segments (PB2, 
PB1, PA, NP, MP and NS) and the lowest reassortment frequencies were observed 
among the H1pdm and neuraminidase segments, particularly N1. They also observed 
less reassortment among specific HA-NA combinations that were more prevalent in 
swine, which might suggest that some genome constellations may be evolutionary 
more stable. More than 100 human cases of novel reassortant swine-origin H3N2 
influenza viruses were identified since July 2011 and this reassortant continues to be 
monitored closely for pandemic potential (CDC, 2012; Lindstrom et al., 2012). The 
combination of six triple reassortant internal genes (TRIG) is conserved in North 
American swine and has remained prevalent since 1998. Overall, their data indicate 
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3.9 Study on reassortment in swine influenza viruses by Khiabanian et al 
(2009) 
 
Khiabanian et al (2009) used the publicly available full-genome sequences of swine 
H1N1, H1N2, H3N2 deposited in the Influenza Virus Resource of the NCBI to study 
the reassortment patterns in swine influenza A viruses. Their approach used several 
statistical methods. First, for each segment the sequences were aligned using the 
Smith-Waterman algorithm and the normalized Hamming distances only at the third 
codon positions were calculated, to eliminate the effects of evolutionary pressure due 
to positive selection. Second, in order to find the possible reassortant strains the 
method first introduced by Rabadan et al. (2008) was used. In this method, the 
number of nucleotide differences between the segments of any two strains is 
calculated. Assuming that the segments have proportional substitution rates at the 
third codon positions, the differences between two segments of two strains should be 
proportional if the two segments have a common origin. If not proportional, there has 
been a reassortment event – the histories of the two segments are different. 
Therefore, when the distances between two segments of different strains are plotted 
against each other, the points corresponding to possible reassortment events lie off 
the diagonal.  
 
They confirmed that HA and NA reassort more frequently than the other segments. 
They also found that one of the polymerase segments, PB1, reassorts quite 
frequently. However, the use of Hamming distances rather than a statistical model of 
nucleotide substitution (see Methods) means the distances would have been 
underestimated and the power of these studies to detect reassortment therefore 
reduced.  
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3.10 The aim of study 
 
In this thesis chapter swine influenza virus evolution with particular reference to 
reassortment was studied. The focus was on interactions between different swine 
influenza A segments and extent of their co-evolution. The first question to answer 
was whether some segments associate more strongly. Does reassortment between 
segments coding for internal proteins occurs less often in swine than in the segments 
that code for surface proteins haemagglutinin and neuraminidase? Based on the 
observation that an A/H1N1pan09 virus had Eurasian avian-like MP and NA 
segments, this chapter tried to answer the question if these two segments always 
reassort together. Also, within and between subtypes reassortment were compared. 
 




A dataset of full genome 507 H1N1 swine sequences, 115 H1N2 swine sequences 
and 226 H3N2 swine sequences was downloaded separately from two databases: 
NCBI FLU (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) and GISAID 
(platform.gisaid.org/epi3/frontend). The sequences were isolated from January 1
st
 
1970 to December 31
st
 2012.  
 
3.11.2 Phylogenetic analysis 
 
H1N1, H1N2, H3N2 sets of sequences (all 8 segments separately) were analysed in 
BEAST v1.6.1 with the GTR (for MP and NS segments) or SRD06 (for all other 
segments) nucleotide substitution model, a relaxed clock (uncorrelated lognormal) 
and a constant population size demographic model with an MCMC chain length of 
200,000,000 and 10% burn-in. These BEAST posterior samples were further 
subsampled to create sets of 1000 post burn-in trees for each segment, MCC 
(maximum clade credibility) trees were also created from the post burn-in samples. 
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Taxa in the MP MCC tree were manually annotated using different colours for 
different clades in FigTree (Rambaut, 2007), and then this same colouring scheme 
was applied to all the other segment trees, enabling a visual tree comparison and 
identification of reassorting clades.   
 
3.11.3 Distance in topology 
 
To compare the topology of two trees (i.e. the branching order) a distance topology 
measure can be used (Penny and Hendy, 1985; Rzhetsky and Nei, 1992). In 
particular, the dist.topo function within R package ape (Paradis, 2009) using the 
PH85 measure was used. Here the topological distance is defined as twice the 
number of internal branches defining different bipartitions of the tips (Penny and 
Hendy, 1985). Rzhetsky and Nei (1992) proposed a modification of the original 
formula to take multifurcations into account which is also implemented with the 
dist.topo function. 
 
The topological distance measure was used as a means to assess for stronger/weaker 
association among the segments. The lower the value for the topological distance 
between two segments, the closer their topologies of trees – the segments share a 
common phylogenetic history. In the case of a higher value of the distance in 
topology, this can reflect the reassortment event(s) between the segments.  
 
Since the distance in topology score value depends upon the number of taxa in the 
trees as well as the difference in tree structure, the scores of trees with randomised 
tip labels were calculated in order to provide a suitable comparative measure. In 
particular, 5%, 10%, 15% and 20% of tips were randomised and scored against the 
unrandomised sets.  
 
The topology distance was used to compare two sets of 1000 post burn-in trees (the 
first tree from set 1 against the first tree from set 2, the second tree from set 1 against 
the second tree from set 2 etc). 
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Also, the distance in topology values for each segment were normalised according to 
the formula:  
        
                             
 
 
Where S1 is segment 1 and S2 is segment 2. 
 
So, the self-values for each segment (i.e. HA-HA) were set at a value 1 and values of 
other segment pairs were comparable to the self-values. This was done because 
segments have different lengths and their self-values differ (i.e. MP-MP and NS-NS 
self-values are higher as these two segments are shorter compared to other virus’ 
segments). 
 
Wilcoxon test was used to test the pairs of segments if the difference in topology 
score is statistically supported.  
 
Two questions were adressed: (1) if there is evidence that e.g. segment1-segment2 is 
reassorted compared to segment1-segment1 (self) by distance topology score – if the 
distance in topology score for segment1-not segment1 is always higher than 
segment1-segment1(self), and the confidence intervals do not overlap, the Wilcoxon 
statistical test should show that the distributions are different, so there is 
reassortment. 
 
(2) Is e.g. segment1-segment2 more or less reassorted than segment1-segment3; if 
the value from the Wilcoxon test for segment1-segment2 is significantly higher than 
segment1-segment3 then there is less correlation between segment 1 and segment 2 
than segment 1 and segment 3. For the Wilcoxon test, all values were divided by the 
value of segment(x)-segment(x) compared to all other pairs of segments and the 
normalised values obtained were considered as the p-value. The p-value of ≤0.05 
was considered as significant. The self comparisons (on the diagonal) after 
normalisation are 0.5 (i.e. half of the samples are higher than the other half). 
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Because the same test (Wilcoxon test) was performed on a large number of different 
samples (each segment pair compared to another segment pair), the p-value 0.05 can 
no longer be considered as a threshold for significance because of the problem of 
multiplicity. This means that when increasing the number of hypotheses in a test, the 
likelihood of different events is also increasing (Streiner and Norman, 2011). One of 
the approaches to deal with multiplicity is the Bonferroni correction which needs to 
be applied in order to counteract the problem of multiple comparisons. Therefore, the 
p-value 0.05 has to be divided by the number of tests performed (Streiner and 
Norman, 2011) and this new value has to be considered as a measure of significance. 
In the case of this study, there are two different ways to present results of the 
Wilcoxon test. The first is on the segment level where for each segment studied, 
there are 64 possible comparisons of two segment pairs, therefore 0.05/64 equals 
0.0008 (the p-value). The second approach is to present results on a genome level 
where the number of tests is 64x8, therefore 0.05/(64x8) equals 0.0001. For the 
purpose of this study, the results were interpreted on a segment level. 
 
Next, simulated sequences were generated based on the real influenza virus 
sequences in a java simulator (adapted by Dr S Lycett) utilising the SeqGen 
functionality within BEAST (Drummond and Rambaut, 2007) by choosing the length 
for simulated sequences which was the same as for the real sequences (without stop 
codons). The nucleotide substitution model chosen was HKY and gamma was the 
same as for the real sequences. BEAST analysis of simulated sequences was done in 
BEAST v1.6.1 using 500,000,000 generations, GTR nucleotide substitution model, a 
relaxed molecular clock and a constant demographic model. For each set of 
simulated sequences corresponding to the length of real influenza genomic segments, 
the BEAST trees sets (1000 in each set) were compared against each other to assess 
their topology distance. Shorter segments have higher distance topology scores 
because the tree inference is more uncertain for shorter segments. Hence to show that 
this was indeed the case, sequences of different lengths (but using the same true tree) 
were simulated and the distance topologies done. 
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R environment v2.14.1 was used. For determining the distance in topology score 
between sets of trees for pairs of segments, a script written by Dr Lycett was used. 
This reads the trees in the BEAST output files, compares sets of 1000 BEAST trees 
and outputs the distance in topology measure for each comparison utilising the 
dist.topo function within package ape. For obtaining boxplots of the distance in 
topology measure for each segment pair, the boxplot function was used from 
grDevices library. For performing the tip perturbations, an all-in-one script (written 
by Dr Lycett) was used which reads in BEAST MCC tree (nexus format), performs 




GARD analysis was run for each pair of segments for swine H1N1, H1N2, H3N2 in 
order to detect reassortment, which is shown by improvement in c-AIC. The majority 
of sequences of H1N1 subtype were isolated from Asia (252/507), followed by North 
America (186/507) and Europe (65/507). For H1N1 only, the dataset of 507 
sequences was randomly split in 10 files and the first 5 files were joined together and 
realigned, so obtaining 230 sequences. The subsampled H1N1 sequences followed 
the same distribution as the original H1N1 dataset: the majority of sequences were 
from Asia (116/230), followed by North America (81/230) and Europe (31/230). The 
reason for making the dataset smaller was the problem (with the c-AIC error) where 
the number of sites vs number of sequences (i.e. number of observations vs number 
of parameters to infer) was too large. For H1N2 and H3N2 where the datasets were 
smaller, the number of sites is about the same but the number of sequences is fewer, 
so there are fewer parameters to estimate from the same number of sites.  
 
A positive c-AIC score indicates reassortment (recombination); and if only one 
breakpoint is detected in the concatenated file, and if the location of the breakpoint is 
near the join, then this is interpreted as evidence of reassortment. 
 
GARD analyses were submitted to a server cluster Eddie of the University of 
Edinburgh, which runs as a command-line interface. 
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To prepare the sequence files for GARD analysis, R environment v2.14.1 was used. 
For concatenating two pairs of segment sequences, base, ape and seqinr libraries 
were used. For H1N1 only, 230 sequences out of 507 were extracted randomly with: 
(i) the use of libraries ape and igraph for extracting identical sequences and leaving a 
file with unique sequences for MP segment, (ii) matching unique sequences for MP 
to other segments with ape library, (iii) concatenating sequences as described above. 




To assess how much reassortment there is in swine H1N1, H1N2 and H3N2 
sequences separately, two lines of evidence were constructed: (i) the results from 
distance in topology measure and (ii) the results from GARD. 
  
The first compares each segment to another segment in all possible combinations in 
order to see which segments reassort more strongly than others. In support of the 
distance in topology measure, tip randomisations have been conducted to be able to 
indicate the equivalent percentage of tip randomisation corresponding to a particular 
numerical score (e.g. a score of 300 might be equivalent to 10% randomisation in a 
particular dataset). 
 
Also, since trees inferred from shorter sequences are likely to be less accurate, larger 
distance in topology scores from segments with shorter sequences are expected. 
Consequently, a normalisation scheme was also applied because segments differ in 
length and that affects the distance in topology measure. Simulations were also 
performed to verify this point.  
 
For the second line of evidence, concatenated sequences of two segments in all 
combinations were made and analysed in GARD and the resulting c-AIC score was 
recorded. The higher this score the more reassortment there is between two 
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segments. Also, the Δc-AIC value obtained from GARD analysis was recorded. The 
higher this value, the more reassortment there is between two segments. 
 
3.12.1 Within subtypes reassortment 
 
3.12.1.1 Large scale clade structure and reassortments 
 
First, phylogenetic trees of each segment were constructed for each subtype, 
coloured according to different clades and compared against each other (Figures 3.1–
3.9). The MP tree of swine H1N1 sequences (Figure 3.1) shows clear separation of 
two clades. The red clade contains the majority of North American sequences and 
also Asian sequences, while the blue clade contains Eurasian sequences. The MCC 
trees for other 7 segments were compared to the MCC tree of MP visually to assess 
for reassortment. The HA tree (Figure 3.2) also forms two separate clades; one clade 
is coloured only blue – Eurasian sequences, while the other is mostly red – North 
American and some Asian sequences. Similarly, the NA tree (Figure A1) is almost 
entirely separated into two clades, not well mixed in colour. Therefore, MP of swine 
H1N1 does not reassort frequently with HA and NA. The NP segment (Figure A2) is 
also well separated in two differently coloured clades but with some blue coloured 
strains in the red clade. Therefore, there has been more reassortment of NP with MP 
compared to HA or NA. The situation is similar in the tree for NS (Figure A3) where 
the colours are slightly mixed. The trees for polymerase segments PA (Figure A4), 
PB1 (Figure 3.3) and PB2 (Figure A5) are similar to each other with partial mixing 
in one clade while there is none in the other. Swine H1N2 MP tree (Figure 3.4) also 
separates in two well defined clades with a similar reassortment pattern than swine 
H1N1. One clade stays mostly un-reassorted, while the other mixes up. The two 
segments with most of reassortment seen are HA (Figure 3.5) and NA (Figure A6) 
for swine H1N2 – compared against the MP tree. Other segments reassort less with 
MP (Figures A7-A10). The majority of colour mixing (reassortment) is obvious from 
trees of swine H3N2 where all 7 segments reassort with the MP (Figures 3.7–3.9, 
A11–A15). 
 




The MCC tree of MP for swine H1N1. Strains in the two major clades are shown by 
the same colour for each of the 3 figures (3.1 – 3.3). Departures from this pattern in 




The MCC tree of HA for swine H1N1, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 
 




The MCC tree of PB1 for swine H1N1, coloured according to two clades in MP. 






The MCC tree of MP for swine H1N2. Strains in the two major clades are shown by 
the same colour for each of the 3 figures (3.4 – 3.6). Departures from this pattern in 
trees for the other segments indicate reassortment.   





The MCC tree of HA for swine H1N2, coloured according to two clades in MP. 





The MCC tree of PB1 for swine H1N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 





The MCC tree of MP for swine H3N2. Strains in the two major clades are shown by 
the same colour for each of the 3 figures (3.7 – 3.9). Departures from this pattern in 




The MCC tree of HA for swine H3N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 





The MCC tree of PB1 for swine H3N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 
 
3.12.1.2 Distance in topology results 
 
The trees for all pairs of segments were compared and the original and normalised 
distance in topology measures were calculated (Tables B1-B3, 3.1–3.3, Figures B1-
B48). These results show that the comparisons of coloured trees for each segment for 
the detection of reassortment are reflected in the distance in topology analysis. For 
H1N1, the largest values (so the most of reassortment) are seen for all other segments 
with polymerase segments (PB1, PB2, PA) and both glycoproteins (HA, NA). 
Similarly, for H1N2 polymerase segments reassort frequently with HA, NA and NS. 
Other segments reassort mostly with all three polymerase segments and HA. For 
H3N2 the segments reassorting the most are polymerase segments and both 
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Table 3.1 
Normalised distance in topology scores for swine H1N1 using dist.topo (PH85). 
 
Segment PB2 PB1 PA HA NP NA MP NS 
PB2 1.00 1.92 1.78 1.97 1.79 1.99 1.70 1.75 
PB1  1.00 1.90 2.09 1.86 2.06 1.74 1.81 
PA   1.00 1.94 1.74 1.92 1.65 1.72 
HA    1.00 1.85 1.85 1.70 1.76 
NP     1.00 1.83 1.62 1.65 
NA      1.00 1.71 1.73 
MP       1.00 1.54 
NS        1.00 
 
Table 3.2 
Normalised distance in topology scores for swine H1N2 using dist.topo (PH85). 
 
Segment PB2 PB1 PA HA NP NA MP NS 
PB2 1.00 2.48 2.47 3.05 2.46 2.77 2.38 2.57 
PB1  1.00 2.54 2.97 2.49 2.79 2.44 2.59 
PA   1.00 3.00 2.54 2.73 2.54 2.70 
HA    1.00 2.76 2.34 2.50 2.60 
NP     1.00 2.58 2.32 2.42 
NA      1.00 2.41 2.41 
MP       1.00 2.25 
NS        1.00 
 
Table 3.3 
Normalised distance in topology scores for swine H3N2 using dist.topo (PH85). 
 
Segment PB2 PB1 PA HA NP NA MP NS 
PB2 1.00 1.98 1.89 2.16 1.94 1.98 1.86 1.81 
PB1  1.00 1.86 2.13 1.98 1.95 1.84 1.84 
PA   1.00 2.12 1.92 1.94 1.84 1.80 
HA    1.00 2.10 1.85 1.82 1.98 
NP     1.00 1.94 1.81 1.77 
NA      1.00 1.74 1.81 
MP       1.00 1.64 
NS        1.00 
 
The distance in topology measure score was also calculated on randomized tips for 
comparison (Figures 3.10–3.12, B49-B69). For H1N1, the distance in topology 
measure score is between 700 and 800, which is the score we would get if 25% of 
tips were randomised. For H1N2, this score is between 150 and 200, which is again 
the score if 25% of tips were randomised on a tree. For H3N2, the score for distance 
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in topology is between 300 and 400, which is the same as 25% of the tips on a tree 
were randomised. The percentage of randomised tips can be thought of an 




Distance in topology for swine H1N1 MP if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 




Distance in topology for swine H1N2 MP if tips are randomized. The percentage of 




Distance in topology for swine H3N2 MP if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
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Third, for Wilcoxon test, all the numbers in the table were divided by 810000 
because the segment self-comparisons (i.e. MP-MP) to any other segment pair are 
810000 regardless of the dataset (H1N1, H1N2, H3N2). Then the self-comparisons 
(on the diagonal) are 0.5 (i.e. half of the samples are higher than the other half). 
Tables with results from the Wilcoxon test (B4–B27) and tables with normalised 
values from the Wilcoxon test (Tables 3.4–3.6 and B28–B48) are asymmetric, 
therefore the direction of reading them is important. The segment pair comparisons 
in these tables should be read as a row against a column.  
 
After applying the Bonferroni correction, the results become significant if their p-
value is ≤0.0008. In this study, there are no results with a p-value ≤0.0008, therefore, 
the p-value 0.05 was kept as a threshold of significance. These results are still valid 
because of a very conservative nature of a Bonferroni correction but are indicative 
rather than conclusive.  
 
Looking at the normalised MP-X table for swine H1N1 (Table 3.4), where X is any 
segment, it can be seen that for example MP-NS compared to MP-NA is 807088 
(Table B5), so the p-value of this reassortment event is: 807088/810000=0.996 
(Table 3.4). MP-NA compared to MP-NS (Table B5) is 2912, so the p-value of this 
reassortment occurring is: 2912/810000=0.004 (Table 3.4). That means that the 
segment MP reassorts more frequently with the NA segment than with the NS 
segment because the p-value for the MP-NA reassortment event is lower and also 
significant compared to the MP-NS pair, where the p-value is insignificant.  
 
Considering the same three segments (MP, NA, NS) for swine H1N1 in another 
order, it can be seen that NA-MP versus NA-NS (Table B29) gives a probability 
0.649 and for NA-NS versus NA-MP the p-value is 0.350 (both p-values 
insignificant). Therefore, when evaluating if one segment reassorts with the other, it 
is important to consider the direction of reassortment, where the segment is either a 
donor or a recipient.  
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Normalised values from the Wilcoxon test for MP pairs for H1N2 and H3N2 are 
given in tables 3.5 and 3.6, respectively. 
 
Table 3.4 




MP-HA MP-MP MP-NA MP-NP MP-NS MP-PA MP-PB1 MP-PB2 
MP-
HA 
0.5 1 0.462 0.883 0.988 0.760 0.264 0.508 
MP-
MP 
0 0.5 0 0 0 0 0 0 
MP-
NA 
0.538 1 0.5 0.917 0.996 0.803 0.291 0.123 
MP-
NP 
0.117 1 0.083 0.5 0.903 0.274 0.030 0.123 
MP-
NS 
0.012 1 0.004 0.097 0.5 0.028 0.0003 0.011 
MP-
PA 
0.240 1 0.197 0.726 0.972 0.5 0.078 0.256 
MP-
PB1 
0.736 1 0.709 0.970 0.999 0.922 0.5 0.733 
MP-
PB2 
0.492 1 0.454 0.877 0.989 0.744 0.267 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
The results of Wilcoxon test with significant p-values are indicative of reassortment. 
Only p-values lower than 0.10 are listed here for H1N1 due to a large number of 
segment pairs with a p-value lower than or equal to 0.050: HA-PA vs HA-MP 
(0.005), HA-PB1 vs HA-MP (0.001), HA-PB1 vs HA-NS (0.003), MP-NA vs MP-
NS (0.004), MP-PB1 vs MP-NS (0.0003), NA-PA vs NA-MP (0.001), NA-PA vs 
NA-NS (0.007), NA-PB2 vs NA-MP (0.003), NA-PB2 vs NA-NS (0.005), NP-HA 
vs NP-MP (0.007), NP-NA vs NP-MP (0.005), NP-PB1 vs NP-MP (0.004), NP-PB1 
vs NP-NS (0.008), NS-HA vs NS-MP (0.004), NS-NA vs NS-MP (0.002), NS-PA vs 
NS-MP (0.002), NS-PB2 vs NS-MP (0.003), PA-HA vs PA-NS (0.006), PA-NA vs 
PA-NS (0.004), PA-PB1 vs PA-NS (0.007), PB1-HA vs PB1-NS (0.003), PB1-NA 
vs PB1-NS (0.002), PB2-NA vs PB2-MP (0.004), PB2-NA vs PB2-NS (0.008), PB2-
PB1 vs PB2-MP (0.007) (Tables 3.4 and B28-B34). 
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That means that the first pair of segments in the comparison reassorts significantly 
more frequently than the second pair of segments (Figure 3.13). Most frequently 
reassorting segments in H1N1 (second segment in the first pair of segments, red 
circle in Figure 3.13) are NA, PB1, HA, PA, PB2, respectively. Least frequently 
reassorting segments in this subtype (second segment in the second pair of segments, 








Two segment pairs compared in terms of reassortment with the p-value showing the 
significance of the first segment pair reassorting more frequently than the second 
pair of segments. The red circle indicates the segment reassorting frequently and 
the blue circle indicates the segment reassorting infrequently. 
 
Table 3.5 
Normalised values from the Wilcoxon test for MP H1N2 pairs. 
p-
value 
MP-HA MP-MP MP-NA MP-NP MP-NS MP-PA MP-PB1 MP-PB2 
MP-
HA 
0.5 1 0.655 0.780 0.872 0.435 0.589 0.696 
MP-
MP 
0 0.5 0 0 0 0 0 0 
MP-
NA 
0.345 1 0.5 0.643 0.756 0.295 0.440 0.554 
MP-
NP 
0.220 1 0.357 0.5 0.625 0.187 0.311 0.417 
MP-
NS 
0.128 1 0.244 0.375 0.5 0.109 0.209 0.304 
MP-
PA 
0.565 1 0.705 0.813 0.891 0.5 0.643 0.738 
MP-
PB1 
0.411 1 0.560 0.689 0.791 0.357 0.5 0.606 
MP-
PB2 
0.304 1 0.446 0.583 0.696 0.262 0.394 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
HA-PA vs HA-MP (0.005)
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For H1N2 segment pairs only two such pairs had a p-value lower than 0.10: HA-PA 
vs HA-NA (0.007) and HA-PB2 vs HA-NA (0.005) (Table B35). Other segment 
pairs with a p-value between or equal to 0.010 and 0.050 are: none for MP segment, 
NA-PB1 vs NA-HA (0.050), NP-HA vs NP-MP (0.036), NS-PA vs NS-MP (0.028), 
PA-HA vs PA-MP (0.049), PA-HA vs PA-PB2 (0.044), PB1-HA vs PB1-MP 
(0.034), PB2-HA vs PB2-MP (0.011), PB2-HA vs PB2-NP (0.024), PB2-HA vs 
PB2-PA (0.035), PB2-HA vs PB2-PB1 (0.040) (Tables 3.5 and B35-B41). 
 
Looking at the list above to determine the most frequently and infrequently 
reassorting segments according to figure 3.13 it can be seen that the segment 
reassorting most in H1N2 is HA, followed by PB1, PB2, PA. The segment 
reassorting least is MP. 
 
Table 3.6 




MP-HA MP-MP MP-NA MP-NP MP-NS MP-PA MP-PB1 MP-PB2 
MP-
HA 
0.5 1 0.796 0.524 0.976 0.424 0.254 0.354 
MP-
MP 
0 0.5 0 0 0 0 0 0 
MP-
NA 
0.204 1 0.5 0.208 0.875 0.146 0.063 0.108 
MP-
NP 
0.476 1 0.792 0.5 0.977 0.393 0.222 0.321 
MP-
NS 
0.024 1 0.125 0.023 0.5 0.015 0.003 0.008 
MP-
PA 
0.576 1 0.854 0.607 0.985 0.5 0.305 0.422 
MP-
PB1 
0.746 1 0.937 0.778 0.997 0.695 0.5 0.621 
MP-
PB2 
0.646 1 0.892 0.679 0.992 0.578 0.379 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
In H3N2 the pairs of segments with significant p-values lower than 0.010 are: HA-
NP vs HA-MP (0.003), HA-PA vs HA-MP (0.003), HA-PB1 vs HA-MP (0.002), 
HA-PB2 vs HA-MP (0.001), HA-PB2 vs HA-NA (0.007), MP-PB1 vs MP-NS 
                                                                                                                              3.12: Results 
101 
(0.003), MP-PB2 vs MP-NS (0.008), NP-HA vs NP-MP (0.001), PA-HA vs PA-MP 
(0.003), PA-HA vs PA-NS (0.002), PB1-HA vs PB1-MP (0.002), PB1-HA vs PB1-
NS (0.002), PB1-HA vs PB1-PA (0.006), none for NA, NS and PB2 segments 
(Tables 3.6, B42-B48). 
 
The list above of segment pairs with significant p-values shows that the most 
frequently reassorting segment in H3N2 (according to Figure 3.13) is HA and least 
frequently reassorting segments are MP and NS. 
 
Because the distance topology score (not normalised) depends on the segment length 
(the shorter the segment length, the larger the distance topology score), simulated 
sequences were generated based on the real influenza virus sequences in SeqGen 
(adapted by Dr S Lycett). Shorter segments could have higher distance topology 
scores because the tree inference is more uncertain for shorter segments. To test this, 
sequences of different lengths were simulated using the same true tree and then the 
distance topologies done. When comparing real versus simulated sequences (Figures 
B70 – B72), we see the largest values of distance in topology for MP-MP and NS-NS 
pairs for H1N1, H1N2 and H3N2, which supports the above findings of MP and NS 
being the segments with lowest tree accuracy. 
 
3.12.1.3 Reassortment detection using GARD 
 
GARD is a method for recombination detection on a set of sequence alignments. It is 
based on likelihood and uses a genetic algorithm for identifying recombinant 
sequences (Kosakovsky Pond et al., 2006). GARD analysis has been conducted for 
each pair of segments for swine H1N1, H1N2, H3N2 separately in order to further 
quantify the extent of reassortment in swine influenza A viruses. c-AIC (not shown) 
and Δc-AIC values (Tables 3.7–3.9) have been extracted. c-AIC values are 
dependent on the length of the segment but Δc-AIC values are not and are therefore 
easier to interpret (personal obsevation). For H1N1 (Table 3.7) the highest Δc-AIC 
values – therefore most reassortment - are for H1N1 as follows: HA-PB2, HA-PA, 
HA-PB1, HA-NP, NA-PA, NA-PB2, NA-PB1. For H1N2 (Table 3.8) the highest Δc-
                                                                                                                              3.12: Results 
102 
AIC values are: HA-PA, HA-PB2, HA-PB1, HA-NP, NA-PB2, NA-PA, HA-MP, 
NA-PB1, NA-NP. For H3N2 (Table 3.9) the highest Δc-AIC values are: HA-NP, 
HA-PB1, HA-PB2, HA-PA, NA-PB2, NA-NP, NA-PA, NA-PB1. For all three 
subtypes there is a similar pattern of segments reassorting most strongly. Most 
frequent reassortment events are between HA and polymerase segments, between 
HA and NP, and between NA and polymerase segments. 
 
Focusing on polymerase segments only, GARD reveals that the most frequent 
reassortment events are between the PB2 and HA (H1N1), PA and HA (H1N2), PB1 
and HA (H3N2). Comparing the Δc-AIC values for polymerase segments against all 
other segments, it is evident that out of the polymerase segments, it is the PB1 
segment that displays highest values (most reassortment) for H1N2 and H3N2. For 
H1N1, PB1 and PB2 perform equally well and better than PA. 
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Table 3.7 




HA MP NA NP NS PA PB1 PB2 
HA 0 4257.76 4709.34 6995.99 4818.44 8574.56 8165.21 10073.2 
MP  0 3228.59 2346.82 1814.6 2764.35 2134.51 1994.64 
NA   0 4301.25 3283.14 6909.35 6388.67 6751.57 
NP    0 1933.41 2828.41 2925.71 2388.99 
NS     0 1982.97 1301.14 2576.46 
PA      0 3294.23 2188.77 
PB1       0 4656.17 
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Table 3.8 
The results for GARD H1N2 pairs of sequences (Δc-AIC). 
Δc-
AIC 
HA MP NA NP NS PA PB1 PB2 
HA 0 6867.09 3947.14 7744.54 5157.88 10997.4 8244.31 10946.6 
MP  0 4564.51 2211.65 2198.05 3332.19 3548.18 2424.09 
NA   0 5494.45 4029.06 7156.75 5574.91 7289.85 
NP    0 2603.72 2951.54 3943.11 2695.61 
NS     0 3215.44 3765.65 3109.01 
PA      0 3521.81 2455.7 
PB1       0 3693.31 
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Table 3.9 
The results for GARD H3N2 pairs of sequences (Δc-AIC). 
Δc-
AIC 
HA MP NA NP NS PA PB1 PB2 
HA 0 6994.29 5589.76 12206.7 7413.91 9233.99 10933.1 9770.62 
MP  0 5402.13 3450.16 2519.93 4254.79 5854.09 5214.91 
NA   0 9592.46 6612.76 9458.07 9024.56 9815.32 
NP    0 4844.93 5412.69 7858.96 7459.45 
NS     0 4280.26 5080.84 3443.92 
PA      0 5627.42 6742.35 
PB1       0 7116.92 
PB2        0 
 
3.12.2 Between subtypes reassortment 
 
3.12.2.1 Large scale clade structure and reassortments 
 
To visually assess for the recombination events of influenza virus segments between 
different subtypes, neighbour-joining (NJ) trees were constructed for H1, H3, N1, N2 
separately (Figures C1-C4) and for each internal segment separately with all three 
subtypes combined (Figures 3.14-3.19). The tree topologies were visualised in 
FigTree v1.3.1 (Rambaut, 2007). Taxa were coloured according to joined HA and 
NA subtype. Tree topologies and colour mixing were compared to assess for between 
subtype reassortment for glycoproteins (Figures 3.14–3.19). Green colour indicates 
H1N1 subtype, orange colour is for H1N2, violet for H3N2. All internal segments 
that have sequences from all three subtypes included, reveal good mixing in colour, 
meaning there is reassortment among internal segments and HA and NA from 
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different subtypes. Tree topologies differ when compared against each other. MP and 
NP trees are more similar to each other and trees for polymerase segments show 
some similarities too. This indicates that segments have a common evolutionary 




NJ tree for MP (H1N1, H1N2 and H3N2 subtypes sequences). Green colour is for 








NJ tree for NP (H1N1, H1N2 and H3N2 subtypes sequences). Green colour is for 






NJ tree for NS (H1N1, H1N2 and H3N2 subtypes sequences). Green colour is for 
H1N1 subtype, orange colour is for H1N2 subtype, violet colour is for H3N2 subtype. 
 





NJ tree for PA (H1N1, H1N2 and H3N2 subtypes sequences). Green colour is for 




NJ tree for PB1 (H1N1, H1N2 and H3N2 subtypes sequences). Green colour is for 
H1N1 subtype, orange colour is for H1N2 subtype, violet colour is for H3N2 subtype. 
 






NJ tree for PB2 (H1N1, H1N2 and H3N2 subtypes sequences). Green colour is for 




The aim of this chapter was to identify the reassortment patterns between different 
segments of swine influenza A viruses within three separate subtypes, and to 
quantify the amount of reassortment found. The questions asked were: Is there more 
reassortment among surface glycoproteins HA and NA compared to internal 
segments? Which segment pairs are most likely to reassort and what is the 
probability of this reassortment? The dataset comprised 507 H1N1 sequences, 115 
H1N2 sequences and 226 H3N2 sequences (all full genome). The methods used were 
the measure of distance in topology of trees of different segments, and GARD. The 
first method was supported by a statistical test (Wilcoxon test). 
 
First, MCC trees for each segment were constructed and coloured according to 
different clades in MP. MP segment was chosen because mutations conferring drug 
resistance occur in this segment. Unlike NA where drug resistance mutations appear 
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also, matrix proteins M1 and M2 encoded by the MP segment are highly conserved 
among influenza A subtypes (Tompkins et al., 2007). This approach was the first 
step in determining if there is any reassortment present and it revealed there is 
reassortment happening within different subtypes. To get a better insight on the 
reassortment event, it would be better to colour initially not just the MP tree and 
compare other trees against it but also initially colour trees based on other segments 
and compare the rest to them (all possible combinations). 
 
Second, to quantity the reassortment found, the sets of 1000 BEAST trees were 
compared against each other to estimate the distance in topology of these trees for all 
segment pairs. For H1N1 and also H3N2 the results were not overlapping due to 
large datasets but for H1N2 the confidence intervals were overlapping due to smaller 
dataset. However, this lower number of sequences represents all of the sequences 
submitted to both NCBI and GISAID databases on a date of downloading. The study 
presented in this chapter focused mainly on within subtype reassortment which is 
much more difficult to quantify than between subtype reassortment because there are 
no subtype labels to use in case of within subtype reassortment, so a discrete trait 
analysis is not possible. That is why the dist.topo measure approach is appropriate. 
For example, the study by Lu et al (2014), which investigated the reassortment 
patterns of internal segments between different subtypes of avian influenza, was 
based on a discrete traits analysis with HA, NA or joined HA-NA subtypes being the 
discrete traits on MCC trees for six internal segments. In this case, the discrete trait 
analysis was possible because of a large number of subtypes that were used as 
discrete traits. Similarly, Lu et al (2014) assessed the reassortment rates of six 
internal segments based on HA, NA and joined HA-NA subtypes. In contrast, the 
analysis of reassortment described in this chapter compared all the segments against 
each other. 
 
Third, GARD analysis was used to detect evidence for reassortment. This type of 
analysis was used in the study by Lycett et al (2012) but not in the study of Nelson et 
al (2012) and Khiabanian et al (2009). Lycett et al (2012) estimated reassortment 
rates between swine H1N1, H1N2 and H3N2 influenza viruses’ neuraminidase and 
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haemagglutinin subtypes on a polymerase backbone, in terms of exchanges/year 
focusing on Eurasian swine influenza viruses only. Nelson et al (2012) studied 
reassortment in North American swine influenza viruses by performing the 
phylogenetic analysis on whole genome sequences and using different subtypes of 
swine influenza as discrete traits. The study by Khiabanian et al (2009) focused on 
all three subtypes from different geographic regions. However, most of the strains  in 
the study by Khiabanian et al (2009) were isolated in USA. The study described in 
this chapter encompassed swine influenza viruses of subtypes H1N1, H1N2 and 
H3N2 (like in the study by Lycett et al (2012) and Khiabanian et al (2009)), however  
the sequences were isolated from different parts of the world. Also, this study 
focused largely on intrasubtype reassortment. The reason for this is that GARD is 
slow and unable to analyse larger (more than few hundred sequences) datasets. 
 
The results presented here show that the segments most prone to reassortment are 
HA and NA as well as all three polymerase segments for all three subtypes. This is 
consistent with the results by Khiabanian et al (2009) who found that HA and NA 
reassort more frequently than internal segments but also PB1 reassorts quite 
frequently. The disadvantage of the study described in this chapter was its focus 
largely on reassortment within three subtypes separately, which showed very similar 
results. Because swine are considered to be a mixing vessel for reassortment, 
therefore the host with the largest probability of harbouring reassortment events, the 
results of this study may not reflect the overall reassortment patterns and their extent. 
However, the methods used for this study would not be appropriate for the study of 
between subtype reassortment. Namely, the sets of 1000 BEAST trees can be 
constructed for a joined dataset of all three subtypes but when used for the distance 
in topology measure calculation, only sequences of six internal segments could be 
compared against each other. The reason for that is when comparing a set of trees for 
an internal segment against an external segment (e.g. MP vs HA-H1) a set of 
phylogenetic trees made on a set of MP sequences from all three subtypes would be 
compared against a set of phylogenetic trees made on a set of HA-H1 sequences, 
which would include only subtypes H1N1 and H1N2 but not H3N2. Next problem 
when analysing the between subtype reassortment with methods used in this study 
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would be a small dataset (less than 300 sequences) that is required for the GARD 
analysis. Therefore, the existing datasets of 507 sequences for H1N1, 115 sequences 
for H1N2 and 226 sequences for H3N2 would have to be subsampled with more than 
half of the sequences not included in the joined dataset. That would mean a huge loss 
of information. 
 
This study of the reassortment focused on the MP tree for each subtype, which 
revealed moderate level of reassortment. If the colouring was to be done according to 
an HA tree it would probably show different results because in swine influenza 
viruses the primary heritable units are (internal) polymerase segments which acquire 
external HA and NA through reassortment. Therefore, different swine influenza 
viruses with the same polymerase unit can have different HA and NA molecules. 
Because MP is the most infrequently reassorting segment (together with NS), 
different results for MP coloured on the basis of HA tree can be expected as HA is 
the most frequently reassorting segment. For between subtype reassortment, MP and 
other internal segments’ trees were constructed and coloured according to joined 
HA-NA subtype. These trees revealed moderate levels of reassortment of internal 
segments between subtypes based on colour mixing. Therefore, a higher level of 
between subtype reassortment can be expected than within subtype reassortment.  
 
Comparing results of MP vs polymerases shows that MP reassorts infrequently with 
polymerases within subtype but between subtype this particular comparison (MP vs 
polymerases) is not possible based on the coloured phylogenetic trees for internal 
segments (Figures 3.14 – 3.19) because trees are coloured against HA-NA subtypes. 
  
The high susceptibility of swine for infection with different influenza viruses due to 
high levels of appropriate receptors for infection, poor vaccination of swine and large 
numbers of swine at farms all contribute to swine being the perfect environment for 
reassortment events to occur. Influenza virus infections are so highly prevalent in 
swine causing endemic infections. Also infections of wild birds with influenza A 
viruses are endemic due to birds being the natural reservoir for the huge majority of 
influenza A virus subtypes. Therefore, the evolution of influenza viruses infecting 
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swine or wild birds is different from the evolution of influenza viruses infecting 
humans or domestic birds. In humans, HA and NA are major heritability units and 
because there is not much reassortment happening in human influenza viruses, HA 
and NA evolution corresponds largely to the evolution of internal segments. In birds, 
there is also a vast amount of reassortment happening among internal segments with 
the exception of low pathogenic H5N1 and H9N2 subtypes, which do not reassort 
very much, probably due to their high prevalence in domestic birds, which are more 
physically isolated from other birds than in natural environment offering therefore 
less opportunity for reassortment (Lu et al., 2014).  
 
The results of the study described in this chapter showed that HA segment is the 
most frequently reassorting segment and is reassorting mostly with polymerase 
segments. The second segment reassorting very frequently is NA and it is also 
reassorting mostly with polymerase segments. The study also showed that the 
segments reassorting very infrequently are MP and NS. 
 
The contribution of work described in this thesis chapter is in the quantification of 
reassortment events in swine influenza A viruses with some of the methods not used 
before for this purpose. Also, most of the studies on reassortment in swine influenza 
A viruses focused only on a certain geographical region and used smaller datasets 
with sequences spanning shorter time range while the study described in this chapter 
considered global swine influenza A sequences with a large dataset isolated over 43 
years. The importance of this study lies in the identification of segments frequently 
reassorting together, in the identification of segments reassorting least and in the 
probability of these events. Namely, some of other studies only identified segments 
with highest rates of reassortment but not the segments least likely to reassort. 
Overall, this study confirmed previous studies which found HA and NA segments to 
be the most frequently reassorting segments and also provided evidence that these 
two segments do not reassort together but with the polymerase segments which some 
other studies did not point out. This study also provided evidence that MP and NA 
segments which were found reassorting together when the A/H1N1pan09 was 
formed, reassort very infrequently therefore the reassortment between these two 
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segments is not a general event. So, this study used some novel methods and 
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4 Amantadine resistance in swine influenza A viruses 
 
4.1 Adamantane drug resistance in influenza A viruses 
 
Anti-influenza drugs are used in humans for the treatment and prevention of 
influenza disease caused by seasonal epidemic strains and occasionally by pandemic 
ones (Sheu et al., 2008; Maltezou, 2008; Hota and McGear, 2007). There are two 
classes of antiviral drugs available: the adamantanes amantadine and rimantadine 
(blocking the ion channels of M2 in the viral envelope and preventing virion 
uncoating and the release of genome segments into the cytoplasm) and 
neuraminidase inhibitors oseltamivir and zanamivir (blocking the neuraminidase and 
preventing budding of newly synthesized virions from the host cell). However, H3N2 
resistance to adamantanes rose dramatically worldwide during the 2005-2006 
influenza season thus influenza prophylaxis and treatment predominantly relied upon 
neuraminidase inhibitors only (Maltezou, 2008; Hota and McGear, 2007; Tang et al., 
2008; Deyde et al., 2007; Kiso et al., 2004; Bright et al., 2005). The use of 
adamantanes is restricted by a rapid emergence of resistant strains that retain full 
virulence and transmissibility. Drug-resistance conferring mutations in M2 can occur 
at five different amino acid sites. One out of these 5 mutations is enough for the virus 
to develop adamantane resistance (Boivin et al., 2002; Hay et al., 1986). Amantadine 
and rimantadine resistant mutants are cross-resistant with no evidence of fitness 
impairment (Belshe et al., 1988).  
 
The primary way for the prevention of influenza infections in humans is vaccination. 
When vaccination is unavailable or in cases of individuals who have not been or 
cannot be vaccinated, antiviral agents serve as an alternative. For many years the 
only antiviral agents available were amantadine and rimantadine (Belshe et al., 1988; 
Dolin et al., 1982; Tominack and Hayden, 1987). Despite the long and widespread 
use of adamantanes in humans, the global frequency of resistant strains in A/H3N2, 
isolated between 1991 and 1995, remained very low (0.8%) (Ziegler et al., 1999). 
However, in the year 2004 the amantadine resistance in A/H3N2 rose to 12.3% 
(Bright et al., 2005). By next year, different countries reported higher incidence of 
                                       4.2: Structure and mechanism of M2 ion channel of influenza A virus 
117 
resistant strains: 14.5% in the United States, 72% in South Korea and 96% in China 
(Bright et al., 2005). On the other hand, amantadine resistance in A/H1N1 remained 
much lower: on a global scale it reached 15.5% of all strains isolated (Deyde et al., 
2007). 
 
4.2 Structure and mechanism of M2 ion channel of influenza A virus 
 
M2 protein contains 97 residues with its N- and C-termini directed toward the 
outside and inside the virion, respectively. It contains one internal hydrophobic 
transmembrane domain of 19 residues that spans the membrane once, 23 N-terminal 
extracellular residues – without the N-terminal methionine residue which is removed 
(Tobler et al., 1999), and 54 residues that form the cytoplasmic tail (Lamb et al., 
1985). M2 is a homotetramer in its native state (Sugrue and Hay, 1991; Holsinger 
and Lamb, 1991). It is an integral membrane protein which functions as a pH-
regulated selective proton channel sensitive to the pH environments (Lamb et al., 
1994; Holsinger et al., 1994). The channel is formed by the four transmembrane 
helices where the His37 residue is the pH sensor and Trp41 is the gate (Pinto et al., 
1992a; Tang et al., 2002; Pinto et al., 1997b).  
 
There are three different sites where drug resistance mutations are known to appear 
in the M2 protein: (i) mutations that face the interior of the channel pore and are all 
located on the N-terminus and close to pore-binding site (V27A, A30T, S31N, 
G34E); (ii) mutations in spaces between the helices that are located at the N-terminus 
and are close to the pore-binding site (L26F); (iii) mutations in spaces between the 
helices that are located at the C-terminus which is outside the pore-binding site but 
may affect it allosterically (L38F, D44A). There are also mutations of pore-facing 
residues His37 and Trp 41 occurring but are deleterious to the virus because these 
two residues are crucial for proton conductance and channel gating (Figure 4.1) (Gu 
et al., 2013). 











Drug-resistance mutations on different positions of the M2 protein. In green, the 
mutations of residues at the pore-facing positions (V27A, A30T, S31N, G34E). In 
red, mutations in spaces between the helices that are located at the N-terminus and 
are close to the pore-binding site (L26F). In blue, mutations at the C-terminal site. 
The pore-binding site is indicated by an arrow. For clarity, only three helices of M2 
are shown (from Gu et al., 2013). 
 
4.3 M2 ion channel inhibitors: amantadine and rimantadine 
 












) are in use for 
influenza indications. The structure of amantadine is a tricyclic 10-carbon ring with a 
primary amine group on the superior pole (Figure 4.2). Amantadine was first shown 
to possess an anti-influenza activity in 1964/1965 in cell culture and in ferret and 
mouse model (Davies et al., 1964; Tsunoda et al., 1965). In 1966 it was approved for 
the prophylaxis and treatment of Asian pandemic influenza A/H2N2 virus infections 
in the USA. In 1976 it was approved for all influenza A infections after further 











Chemical structures of amantadine and rimantadine (M2 ion channel inhibitors) 
(from Tisdale, 2009). 
 
Rimantadine is a closely related derivative that shares the same hydrocarbon ring 
structure. The difference from amantadine structure is in incorporation of a carbon 
with a methyl group between the nitrogen and adamantine ring. Rimantadine was 
approved for clinical use in 1993 in USA. Both amantadine and rimantadine are very 
stable after long term storage (over 25 years at ambient temperature) and retain full 
antiviral activity (Scholtissek and Webster, 1998). 
 
4.4 Agricultural amantadine usage 
Influenza viruses are important pathogens of not only humans but also poultry and 
swine. Swine influenza virus infection causes an acute and highly contagious 
respiratory disease and is common in pig populations globally due to the incomplete 
vaccination in pigs as well as the absence of the use of the drug in pigs. The anti-
influenza drug amantadine has however been widely used for agricultural purposes in 
domestic poultry. After the 1983 outbreak of avian influenza in chickens in 
Pennsylvania, amantadine was routinely added to water supply for commercial 
poultry as a means of preventing the avian influenza infections in USA (Webster et 
al., 1985). Amantadine is licensed only for human use, however, its use in Chinese 
poultry production has been reported (WHO, 2013). It is believed that the 
amantadine resistance of influenza viruses appeared in avian influenza because of 
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wide use of this drug by Chinese poultry farmers in late 1990’s in order to limit avian 
influenza infections. Chinese companies producing this drug were selling the 
amantadine to Chinese farmers for 10 dollars per pound of the drug (Ayaz, 2012). 
Researchers from the US Department of Agriculture Laboratory showed that avian 
influenza viruses develop drug resistance in a few days after receiving amantadine. 
The amantadine has been available and used for the treatment as well as prevention 
of infection with avian influenza viruses. Amantadine resistance of H5N1 was 
reported in 1997 and the use of this drug in Chinese poultry farming was spread for 
years prior to that (Ayaz, 2012). 
 
Influenza A viruses can infect many species of mammals and birds. The wild birds 
are the reservoir for all influenza A subtypes known except for H17N10 and H18N11 
which were found in bats (Tong et al., 2012; Tong et al., 2013). Novel influenza 
viruses can emerge from birds and infect mammalian species including humans. It 
has been speculated that the domestic pigs serve as the intermediate ‘mixing vessel’ 
for some human and avian viruses because the respiratory epithelium of pigs 
possesses sialic acid receptors for both avian and human viruses. This way novel 
reassortant influenza viruses are created in pigs that have the potential to be 
transmitted to humans. Along with acquiring new genetic segments, the reassortant 
viruses can acquire drug-resistance conferring mutations also. 
 
4.5 Proposed mechanisms of amantadine drug resistance acquisition 
and spread 
 
Adamantane resistance has become widely spread in the human A/H3N2 influenza 
population in the 2005-2006 influenza season. In nearly every case of influenza in 
US studied, the cause for resistance was a single substitution of serine with 
asparagine at site 31 (S31N) in the M2 ion channel protein. S31N is one of 5 amino 
acid replacements in the M2 protein known to be linked to adamantane resistance. 
Theoretically, two evolutionary mechanisms could be responsible for the global 
spread of adamantane resistance in human and/or swine influenza virus. First, the 
                                            4.6: Studies of amantadine drug resistance in influenza A viruses 
121 
high level of amantadine use in some countries could confer sufficient individual 
selective advantage to facilitate the spread of S31N mutation (Regoes and 
Bonhoeffer 2006). Alternatively, the spread of S31N may be unrelated to drug 
selection pressure and instead result from its interaction with advantageous mutations 
located elsewhere in the viral genome. Such interactions could take the form of either 
genetic ‘hitch-hiking’, which is the process by which an allele may increase in 
frequency by virtue of being linked to a gene that is positively selected (Barton, 
2000). In this case the S31N mutation is pulled to fixation because of its physical 
linkage to beneficial mutations, such as those in the haemagglutinin protein (HA) that 
facilitate immune escape (Bush et al. 1999; Smith et al. 2004). Another mechanism is 
genetic epistasis. Epistasis is a phenomenon in which the fitness of an allele at one 
locus depends on the presence of an allele at another (see section 5.6).  In epistasis 
natural selection for a characteristic other than adamantane resistance could favour a 
specific combination of mutations which include S31N.  
 
4.6 Studies of amantadine drug resistance in influenza A viruses 
 
4.6.1 The study by Krumbholz et al (2009) 
 
In the study of Krumbholz et al. (2009), a molecular epidemiological investigation of 
European swine Eurasian avian-like influenza viruses, analysis of their amantadine 
resistance phenotype and a genetic analysis of the MP segment was performed. A 
phylogenetic analysis encompassed human, swine, avian and equine MP sequences. 
A phylogenetic tree was inferred using Bayesian MCMC analysis. The resulting tree 
(Figure 4.3) indicates that the MP sequences of the European avian-like clade 
constitute a monophyletic branch. Krumbholz et al. (2009) found it surprising that all 
amantadine-resistant swine strains (as deduced from the S31N substitution) cluster in 
a single clade with A/sw/Schwerin/103/89 (H1N1) being closest to the root. The 
respective node is supported with high posterior probability (1.0). Beside the S31N 
mutation, additional substitutions (A26F, L26I, V27A, V27I, A27T) could be traced. 
None of them emerged independently of the S31N substitution. 
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Krumbholz et al (2009) investigated the susceptibility of Eurasian avian-like swine 
influenza A viruses to amantadine. They found that all resistant strains harboured the 
S31N substitution, which prevents binding of amantadine to the M2 protein. Several 
isolates contained an additional mutation, V27A, which enables resistance by another 
mechanism: amantadine-binding is retained but M2 still functions as a proton 
channel (Astrahan et al., 2004). Krumbholz et al. (2009) made two observations: the 
emergence of the amantadine resistance in the M2 gene was a single event as 
demonstrated by a monophyletic resistant clade. So, the susceptible H1N1 strains 
were replaced by resistant H1N1 strains. They also concluded that a reassortment 
event took place, which introduced resistance to H3N2 and H1N2 strains. They 
discuss that pigs in Europe have most likely not been treated with amantadine as 
there is no documentation of that, so the amantadine resistance rise is probably due to 
a natural cause. In humans, this resistance has been increasing rapidly in the absence 
of amantadine use for treatment. Two mechanisms may be responsible: (i) 
spontaneous mutations with low incidence (Ziegler et al., 1999) and their fixation in 
the presence of drug treatment (Shiraishi et al., 2003), (ii) hitch-hiking where 
amantadine-resistance conferring mutation is linked to a mutation at another genomic 
site that enhances viral fitness. Krumbholz et al (2009) turned down both options as a 
cause for amantadine resistance in Eurasian swine influenza A viruses but left the 
possibility of a bottleneck effect (Domingo and Holland, 1997) open for discussion. 
The study of Krumbholz et al. (2009) also indicated negative selection on codons 30, 
31, 34 which are known to confer amantadine resistance. On site 31, only two codons 
were observed, either coding for serine (amantadine susceptible) or asparagine 
(amantadine resistant) in human or swine strains. That is probably because S31N is 
the only mutation that maintains both structural constraints (i.e. formation of a proper 
transmembrane helix which is able to tetramerize) and functional constraints of the 
M2 protein (i.e. proton channel activity even in the presence of amantadine). 
Substitutions of alanine 30 and glycine 34 were not observed in the Eurasian swine 
influenza viruses. 




Phylogenetic analysis of 113 MP sequences of influenza A virus isolated from 
Eurasia. Sequences were isolated from different hosts (swine, avian, equine and 
human) and were of different subtypes. Blue and red colours indicate amantadine 
susceptible and amantadine resistant strains, respectively (Krumbholz et al., 2009). 
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The study indicated that Eurasian swine lineage appeared in 1979 [node age: 26.83 
years before 2006, 95 % highest posterior density (HPD) interval: 26.14−33.39 years 
before 2006) and amantadine-resistance (S31N substitution) may have emerged in 
1988 (node age: 17.8 years before 2006, range of the 95 % HPD interval: 
17.09−22.55 years before 2006). 1979 as the year of emergence of European swine 
influenza A viruses was also inferred by Ludwig et al (1995). 
 
Codon-based tests were performed to identify natural selection at single amino acid 
sites. Positive (diversifying) selection, i.e. excess of non-synonymous substitutions, 
and negative (purifying) selection, i.e. excess of synonymous substitutions, were 
investigated using different maximum-likelihood methods (SLAC, FEL and IFEL). 
Several codons were suggested to be restrained by negative selection: (i) codons 30, 
31 and 34 which confer amantadine resistance and (ii) codons 32, 50, 51, 58, 67 and 
71. Positive selection was suggested for codon 19 in the IFEL method. All three 
methods showed a similar pattern of dN−dS differences. However, the SLAC and 
IFEL methods were found to be more conservative, resulting in fewer suggestions for 
natural selection. 46 of 97 codons (47.4 %) were invariant. The mean substitution rate 
of this dataset was 0.54 substitutions/site and the mean dN/dS was 0.60. They found 
that diverse selective forces act on the M2 proteins of porcine and human influenza 
A viruses. 
 
4.6.2 The study by Furuse et al (2009) 
 
The study by Furuse et al. (2009) investigated the mechanisms for emergence and 
spread of amantadine resistance by analysing the MP gene of influenza A viruses 
from different host species. They detected drug resistance-associated mutations on 
positions 26, 27, 30 and 31 but not at position 34. Also double mutants were found 
(positions 27 and 31). Most frequent mutation was at position 31 (S31N). The drug 
amantadine has been available since 1966, however the drug-resistant mutations 
spread after the year 2000. They were found in different subtypes, isolated from 
different hosts at different geographical locations. Strains with the mutations at 
positions 26, 27 and 30 were found only sporadically – they did not spread and 
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eventually disappeared. The same study also evaluated dN/dS ratios for influenza A 
viruses isolated from different hosts. The value above 1 means positive selection on 
the codon and the value below 1 means negative selection (Kosakovsky Pond et al., 
2007; Suzuki and Gojobori, 1999). The value of 1 is for neutral selection. dN/dS was 
above 1 for amino acid sites 26 (1.35) and 27 (4.42) and below 1 for sites 30 (0.21) 
and 31 (0.83). Furuse et al. (2009) investigated the differences in selective pressures 
between hosts and found no significant differences between human and swine 
viruses. Human viruses experienced higher selection pressure at sites 26 and 31 than 
viruses from other hosts. On sites 27 and 30, human influenza viruses were under 
smaller selection pressure than avian viruses but the difference was not significant. 
Furuse et al. (2009) also estimated the change in selective pressure in 
 
Figure 4.4 
dN/dS ratio for human influenza A virus in M2 sequences on amino acid positions 
where mutations that confer resistance to adamantanes can occur. dN/dS values 
larger than 1 mean positive selection, dN/dS values smaller than 1 mean negative 
selection, dN/dS value equal to 1 means neutral selection (adapted from data by 
Furuse et al., 2009). 
 
human influenza A viruses with time and found that the entire selection pressure 
became smaller with time for the entire MP segment. The dN/dS value increased 
since 1966 (when amantadine became available) for amino acid sites 26, 27 and 30, 
where resistance-conferring mutations can occur (Figure 4.4). For the site 31, the 
dN/dS value decreased. Furuse et al (2009) also constructed phylogenetic trees of 
influenza A viruses from different hosts for both lineages – North American clade 
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and Eurasian avian-like clade which suggested that the acquisition of the drug 
resistance-conferring mutations is due to point mutations and not by obtaining the 
MP segment by reassortment from other hosts or subtypes (Figure 4.5). This finding 
is contradictory to the conclusions of Schmidtke et al (2006) who suggested the 
reassortment between human and swine viruses to be the cause of the rise and spread 
of amantadine resistance in humans. Schmidtke et al (2006) also suggested further 
rise in the amantadine resistance due to further reassortment between swine and 
human viruses but Furuse et al (2009) found amantadine resistance in human and 
avian viruses did increase after the year 2000 but it did not come from swine. 
However, Furuse et al (2009) could not explain the rapid increase in the amantadine 
resistance, especially after 2000 when the usage of amantadine dropped because of 
the availability of a new drug oseltamivir. 
 
Figure 4.5 
Phylogenetic trees for the MP gene segment constructed using RAxML are shown. 
The trees are marked with host-specific lineages and their profiles (a) and 
amantadine resistance mutations shaded in colors by mutation positions (b). The 
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4.7 The aim of study 
 
In this study the origin of amantadine resistance in swine influenza A viruses was 
investigated. The initial hypothesis was that resistance came into swine influenza 
virus from avian influenza viruses infecting wild birds when the avian influenza 
virus switched host from wild birds to swine host forming the Eurasian avian-like 
swine clade. We hypothesized that amantadine drug resistance could have been 
transmitted from avian influenza viruses into swine host once or multiple times due 
to the agricultural use of the drug in poultry especially in China where wild birds can 
come into contact with domestic poultry and become infected with the resistant avian 
virus circulating in poultry. Alternative hypothesis was that resistance appeared in 
swine influenza virus spontaneously due to potential use of the drug in swine. With 
the progression of the work, the study focused on the possibility of the spread of 
amantadine drug resistance-conferring mutations being unrelated to agricultural drug 
use in swine and/or poultry but being due to epistatic linkage to some other sites in 
the viral genome that are positively selected for. This way, drug resistance could 
spread in influenza A virus population with genetic hitch-hiking. Considering that a 
few studies on this subject have already been made but are contradictory, decision 
was made to do the study with phylogenetic and bioinformatics methods to elucidate 
the mechanism of amantadine drug resistance appearance and rise within a swine 
host. 
 
4.8 Methods and data 
 
Four datasets were used in this study to address different research questions. 
 
4.8.1 Dataset 1 
 
This dataset was created to focus on the prevalence of amantadine drug resistance 
mutation S31N in the M2 gene of human and swine influenza viruses, isolated in 
different time periods. 
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Influenza A sequences were obtained from the NCBI flu database 
(www.ncbi.nlm.nih.gov/genomes/FLU) using a set of predefined parameters: host 
(swine or human), country/region (any), segment 7 (MP), subtype (any), sequences 
length (full-length plus to allow for sequences without a start and/or stop codon); 
additional filters were: pandemic (H1N1) 2009 viruses (include), the FLU project 
(include), lab strains (exclude), vaccine strains (exclude), lineage defining strains 
(include). The FLU project includes sequences that come mostly from large scale flu 
genome sequencing projects and usually contain complete genomes and detailed 
source information (http://www.ncbi.nlm.nih.gov/genomes/FLU/help.html#project). 
Sequences were exported as txt files and automatically aligned using function 
Muscle. The sequences were then manually checked, nucleotides before the start 
codon (ATG) and after the stop codon (either TAA, TAG, TGA) were removed so 
that segments were of appropriate length (982 nucleotides). 
 
On February 1st 2011, all available full-length sequences for matrix proteins (MP) of 
swine H1N1 (369 sequences), swine H1N2 (93 sequences) and swine H3N2 (106 
sequences) were downloaded from the NCBI FLU database. For human influenza 
virus MP, there were 1.050 sequences of pandemic H1N1, 1.430 sequences of 
seasonal H1N1 and 2.808 sequences of seasonal H3N2. After aligning and trimming 
the sequences (so that they start with a start codon and stop with a stop codon) the 
M2 sequences were extracted from MP and resistance at amino acid position 31 was 
determined. The sequences were divided into three groups: from 1950 to 1966 
(before the availability of amantadine), from 1967 to 1999 (from the availability of 
amantadine and before the availability of oseltamivir) and from 2000 to 2011 (after 
the availability of oseltamivir). Sequences from before 1950 were not analysed for 
prevalence of resistance mutations in M2.  
 
4.8.2 Dataset 2 
 
This dataset was used to answer the question: when and where (which host) did the 
amantadine drug resistance appear first? 
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Swine MP sequences were searched for in the NCBI FLU database as described for 
the Dataset 1. Avian and human influenza A sequences were subsequently manually 
added to swine influenza A sequences according to the geographic location, avian 
species, susceptibility or resistance to amantadine and subtype. Alltogether there 
were 389 sequences, of which 72 were avian, 8 human and 309 were swine. They 
were also searched for in the NCBI FLU database with BLAST and were collected 
from 1931 to 2010. With BioEdit resistance codons in segment 7 (MP) were 
removed to avoid sequences appearing more similar to each other because of 
potential resistance. Those codons were in M2 gene of the MP segment (which also 
codes for M1 protein) on positions 26, 27, 30, 31, 34. The resistance mutations on 
these positions are L26F, V27A, A30T, S31N, G34E. 
 
4.8.2.1 Phylogenetic analysis 
 
Maximum likelihood phylogenetic analysis was conducted on the 389 MP nucleotide 
sequences (with all five resistance-conferring codons removed) in PhyML on the 
Haldane cluster with 1000 bootstraps, gamma distributed rates among sites and 
gamma parameter 4. The output tree file was opened in FigTree v1.3.1 (Rambaut, 
2007). Sequences that clustered within the Eurasian avian-like swine clade and North 
American swine clade were then separated from the other MP sequences, XML files 
were created via BEAUTi v1.6.1 (Drummond and Rambaut, 2007) and BEAST 
analysis with discrete traits (strains susceptible or resistant to adamantanes) and 
Markov jumps was run. Discrete trait analysis enables to determine which was first, 
susceptibility or resistance on a certain branch and Markov jumps analysis enables to 
determine where on the branch the change occurred. The parameters used were: GTR 
nucleotide substitution model, relaxed clock (uncorrelated lognormal) to allow 
potentially different rates for the human, avian and swine strains and because it was 
preferred over a strict clock by Bayes factor test (larger than 55), constant 
demographic model, 200 million generations (the chain length). Two independent 
runs were then combined in LogCombiner (Drummond and Rambaut, 2007) with 
removed burn-in of 10%, further down-sampled to 1900 trees and by using 
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TreeAnnotator (Drummond and Rambaut, 2007) the maximum clade credibility tree 
(MCC) was annotated.  
 
4.8.3 Dataset 3 
 
This dataset served for the estimation of dN/dS ratio on codons where adamantine 
resistance can occur. Also overall dN/dS ratio was estimated. 
 
Avian and swine MP nucleotide sequences were searched for in the NCBI FLU 
database as described for Dataset 1. The downloaded sequences encompassed the 
entire database as on the date June 4
th
 2013. The number of sequences was 7,023 of 
avian MP and 2,817 sequences of swine MP. Maximum likelihood analysis was 
performed in RAxML on the Haldane cluster for avian and swine sequences 
separately. Avian sequences were further separated into domestic and wild, and 
swine sequences were separated into Classical and Eurasian avian-like swine clades. 
dN/dS was estimated in HyPhy (SLAC) for those four sequence groups. 
 
4.8.4 Dataset 4 
 
The purpose of this dataset was to find the mechanism responsible for the acquisition 
and rapid spread of amantadine drug resistance mutation S31N. This dataset served 
for determining the association between different amino acids in different proteins, 
which could potentially present epistatic interactions between those segments, and 
for determining the extent of co-evolution between the associated amino acid sites. 
 
A new dataset of 236 sequences for matched HA, NA, MP was downloaded for 





 2008. The date of downloading was 1
st
 June 2013. According to the 
Neighbour-joining tree of MP with 1000 bootstraps these sequences fall into 
Eurasian and Classical lineages. The aim of this study is to look for interactions 
between mutations in pairs of 3 segments with machine learning (the methods of 
machine learning are described in chapters Methods and Oseltamivir resistance in 
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human seasonal influenza A/H1N1 viruses) to answer the question: Are there any 
amino acid sites in M2, M1, HA and NA that have an evolutionary interaction to the 
amantadine drug resistance/susceptibility in M2? Next, BGM in HyPhy 
(www.datamonkey.org) were used to elucidate which amino acid sites, determined to 
be associated, are co-evolving. More precisely, the purpose of this analysis was to 
find out which amino acid site is influencing another amino acid site to mutate. For 
this purpose, maximum likelihood trees were constructed in MEGA v4 (Tamura et 
al., 2007) for HA, NA and MP segments, separately. Next, a file with concatenated 
sequences of M2, M1, HA, NA was constructed and saved as a nexus file, which 
included also a maximum likelihood tree for either, HA, NA or MP set of sequences. 
For comparison, also a file with concatenated sequences but no maximum likelihood 
tree was constructed and analysed. The files of concatenated sequences with or 
without a maximum likelihood tree were then subjected to a BGM analysis in HyPhy 
separately for each pair of amino acids, shown by Random Forest analysis to be 
associated. The result was a posterior probability of one amino acid site influencing 
the other amino acid site in terms of evolution. These results of posterior 
probabilities for each amino acid pair were joined together in an excel file and 
imported into Cytoscape v3.0.1 (Su et al., 2014). The output from Cytoscape was a 




4.9.1 Dataset 1 
 
This dataset was used to estimate the prevalence of amantadine drug resistance 
mutation S31N in influenza A viruses, isolated from two different hosts in different 
time periods. Resistant mutations were most prevalent on position 31; estimated 
prevalence for swine H1N1 ranged from 16.2% (1967 – 1999) to 74.6% (2000 – 
2011), for swine H1N2 from 41.9% (2000 – 2011) to 85.7% (1967 – 1999) and for 
swine H3N2 from 6.9% (1967 – 1999) to 44.2% (2000 – 2011) (Table 4.1, Figure 
4.6). While human seasonal H1N1 influenza A virus shows a low prevalence of 
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resistance at position 31 (3.9%), seasonal H3N2, which alternates with H1N1, that 
also predominates in the human population until 2009 shows high prevalence 
(47.2%) at that position (Table 4.1, Figure 4.6).  
 
Table 4.1 
Prevalence of S31N mutation in M2 gene for swine and human sequences studied. 
 prevalence of S31N mutation in M2 (%) 
 1950 - 1966 1967 - 1999 2000 - 2011 
swine    
H1N1 22.2 16.2 74.6 
H1N2 / 85.7 41.9 
H3N2 / 6.9 44.2 
    
human    
H1N1 seasonal 0 0.6 3.9 
H1N1 pandemic / / 100 




The prevalence of S31N mutation in M2 divided into host, subtypes, and time period 
of isolation: 1950-1966 (before the availability of amantadine), 1967-1999 (after the 
availability of amantadine and before the availability of oseltamivir), 2000-2011 (after 
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The human pandemic H1N1 virus that originated in swine and has the potential to 
transmit back to swine and for reassorting with other influenza A viruses was 100% 
resistant at position 31 (Table 4.1, Figure 4.6). There was no continential bias 
regarding the origin of sequences as for all groups of sequences, the majority of them 
were isolated from North America, Asia and Europe. Human seasonal H1N1 and 
H3N2 also had a large number of sequences from Australia. 
 
4.9.2 Dataset 2 
 
This dataset served for determining the origin of amantadine drug resistance (which 
host) and for estimating the time of the amantadine drug resistance appearance. 
 
 
4.9.2.1 Maximum likelihood analysis 
 
PhyML was used to conduct a phylogenetic analysis of MP coding region for swine 
influenza A sequences (H1N1, H1N2, H3N2 subtypes) with avian influenza A 
sequences and human influenza A sequences of different subtypes added to see an 
adamantane resistance in this virus. From Figure 4.7A two major clades are seen: (i) 
viral strains of resistant Eurasian swine influenza A sequences with the resistant 
H5N1 avian viral lineage and some other avian and human sequences, and (ii) 
susceptible North American swine influenza A viruses with some resistant swine and 
susceptible avian viral sequences. Resistance was assigned by presence of resistant 
mutations. Figure 4.7B shows a susceptible avian strain (A/avian/goose/Leipzig 
Germany/1877/1979 H7N7 suscep) sharing a common ancestor with a susceptible 
swine strain (A/swine/France/WVL4/1985 H1N1 suscep). This susceptible swine 
strain shares the common ancestor with the first resistant swine strain (A/swine/Italy 









PhyML tree for avian, swine and human MP sequences from Dataset 2. (A) Avian, 
swine and human sequences of MP segment either resistant or susceptible to 
adamantanes, with bootstrap values. Earliest resistant swine sequences are 
captured within a red box. (B) The cut-out of a part of a tree from figure 4.7A (red 


















In order to estimate when the first resistant swine sequence emerged and to which 
sequences does it cluster closest to, Bayesian MCMC approach implemented in 
BEAST was used. This was done in order to answer questions: Is the 
phylogenetically closest sequence to first resistant swine sequence, avian or swine 
influenza A? Is this closest sequence resistant or susceptible? 
 
First, BEAST analysis with discrete traits was done for the North American clade. 
Most of the sequences in this clade are susceptible to adamantanes with the most 
recent strain dating to 2010.7. The first resistant sequence is from 1996 
(A/swine/Saitama (Japan)/1996/H1N2), which shares a common ancestor with the 
susceptible sequence A/swine/Ehime (Japan)/1/1980/H1N2. This MRCA dates back 
to 1979 (HPD = 30.3 – 32.0 => 1978.7 – 1980.4) (Figure 4.8). Clearly the resistance 
occurred in swine in Japan and was not transmitted from avian influenza A, as there 
are no resistant avian influenza A sequences in a North American clade in this 
dataset. Second cluster of resistant swine influenza A strains is from Canada, all 
2004 and they also share a MRCA with a susceptible strain from the same country; in 
this case Canada and with a resistant strain from Japan. Also, there are three separate 
introductions of resistance with just one strain each time (an H1N2 strain from Hong 
Kong, an H1N2 strain from South Dakota and an H3N2 strain from Oklahoma. They 
seem to have all occurred in swine spontaneously. 




BEAST phylogenetic tree of North American swine clade with some avian 
sequences coloured according to susceptibility (red) or resistance (blue) to 
adamantanes, with discrete trait analysis and Markov jumps, with posterior support. 
 
Next, BEAST analysis with discrete traits was conducted for the Eurasian clade. In 
order to investigate which was first: a susceptible strain developing into a resistant 
one or vice versa, an analysis with discrete trait resistance or susceptibility to 
adamantanes was performed. At the node, representing the most recent common 
ancestor of an H7N7 strain isolated from goose in 1979 (Leipzig, Germany) which is 
susceptible, and an H5N3 strain isolated from tern in 1959 (South Africa) which is 
resistant, was most likely susceptibility (p=0.8488) (Figure 4.9). The most recent 
common ancestor of an H1N1 swine strains isolated from Italy in 1987 which is 
resistant, of other resistant strains, and of a swine susceptible clade is most likely 
susceptible (p=0.9511) and then mutated into a resistant strain (Figure 4.9). 
 
A susceptible avian goose strain from Germany, isolated in 1979 shares a common 
ancestor with three susceptible swine strains in Eurasian swine clade from France, 
the Netherlands and Italy. They share a common ancestor with a completely resistant 
susceptible 
resistant 
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clade of swine sequences. The most recent sequence in this dataset dates back to 
2010.685 and the TMRCA of resistance appearance in swine sequences is 1979.915 
(HPD = 17.196, 30.64 – 25.1792, 30.91 => 1979.78 – 1980.05) (Figure 4.10). The 
first resistant swine strain from this dataset was isolated in 1987 in Italy with 
TMRCA to the rest of the Eurasian clade in 1982.9067 (HPD = 27.73 – 27.82 => 
1982.87 – 1982.96) (all of the strains are resistant). From the tree (Figure 4.9) it can 





BEAST phylogenetic tree of avian and Eurasian swine clades and some human 
sequences coloured according to susceptibility (red) or resistance (blue) to 
adamantanes, with discrete trait analysis and Markov jumps, with posterior support. 













A cut-out from the black box in figure 4.9 with time (in years in decimal) of 
appearance of avian-swine node (the establishment of avian influenza A virus in a 
swine host) and susceptibility-resistance node (the establishment of amantadine 
resistant swine influenza A virus). 
 
4.9.3 Dataset 3 
 
This dataset served to determine the dN/dS ratio on each of the five drug resistance 
conferring mutation sites in M2 for four subgroups of sequences: Eurasian swine 
clade, North American swine clade, domestic avian and wild avian influenza M2 
sequences. First, the maximum likelihood trees were constructed for avian (Figure 
4.11) and swine (Figure 4.12) MP sequences not separated into clades (swine) and 
avian host species. The reason for including avian sequences in this analysis is in the 
origin of the Eurasian avian-like swine clade, which is avian. The aim of this analysis 




















RAxML tree of swine MP sequences, which form two distinct clusters: North 





























dN-dS values for amino acid sites in swine M2 where resistance to adamantanes 
can occur in Eurasian clade and North American clade separately. dN-dS values 
larger than 0 mean positive selection, dN-dS values smaller than 0 mean negative 
selection and dN-dS value equal to 0 mean neutral selection. 
 
Table 4.2 
dN-dS values for swine Eurasian and North American clades and avian strains, 
separated into two groups, isolated from domestic and wild birds. 






26 -1.51 -19.27 -17.01 -31.62 
27 2.69 10.59 17.87 21.33 
30 -6.26 -13.00 -6.13 -4.50 
31 -12.87 -5.84 -3.16 -25.07 
34 -5.21 -15.00 -14.90 -20.00 




All five codons in human versus swine and avian influenza A viruses where 
resistance conferring mutations can occur exhibit differences in the patterns of 
substitution rates suggesting different selection modes. In swine and avian influenza 
A viruses only the codon 27 in M2 is under positive selection and all other under 
strong negative (purifying) selection (Table 4.2, Figures 4.13 and 4.14). In human 
influenza A viruses (according to the study by Furuse et al., 2009; Figure 4.4) codons 
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26, 27, 30 and 31 are under positive selection forces and at codon 34 there is no 
selection pressure. Codon 27 in human influenza A viruses showed greater positive 
selection than other codons, however it was still weaker than in North American 
swine clade and both avian groups, domestic and wild, on that codon. Overall dN/dS 
is comparable for both swine clades and for domestic avian influenza. Influenza A 
viruses isolated from wild birds showed lower overall dN/dS (Table 4.2), which is 
most likely the consequence of the influenza A viruses being more adapted to wild 
birds, which are the viruses’ natural reservoir. 
 
Figure 4.14 
dN-dS values for amino acid sites in avian M2 where resistance to adamantanes 
can occur in influenza A viruses, isolated from domestic and wild birds, separately. 
dN-dS values larger than 0 mean positive selection, dN-dS values smaller than 0 
mean negative selection and dN-dS value equal to 0 mean neutral selection. 
 
4.9.4 Dataset 4 
 
This dataset was used to determine if there are any evolutionary associations between 
amino acid substitutions at different sites in M2, M1, HA and NA. Further, the 
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4.9.4.1 Phylogenetic analysis 
 
The Neighbor-Joining (NJ) tree of the MP segment shows clear separation of 
influenza strains into two clades: Eurasian avian-like swine clade and Classical swine 





NJ tree of MP segment of influenza A swine sequences, isolated from Eurasia, 
coloured according to resistance to amantadine (red = resistance, black = 
susceptibility). Sequences fall into two distinct clades: Eurasian avian-like and 
Classical clades. 
 
4.9.4.2 Random Forest analysis 
 
The results of machine learning – Random Forest analysis of M2 amino acids 
associated with susceptibility/resistance to amantadine (encoded on site 31 in M2) 
showed very high sensitivity, specificity and area under the ROC curve (Figure 4.16) 
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0.999. There were 14 sites in M2 identified as significantly associated with 
amantadine resistance or susceptibility, which is encoded on site 31 in M2 (Figure 
4.17). The amino acid site in M2 with the highest mean increase in mean square error 
was site 77, which is one of the eight sites (70-77) which are responsible for efficient 
interaction with M1 and viral filament formation (morphology of the virus) 
(McCown and Pekosz, 2006). 
 
Figure 4.16 
ROC curve for M2-M2 pair of segments. The X axis represents the false positive 
rate which equals 1-specificity. The Y axis represents the true positive rate which 
equals sensitivity. The ROC curve defines the area under the ROC curve-AUC-
which can take value between 0 and 1. The larger the AUC value the better the 
model. The AUC for this model is 0.999. 
 
 




Mean increase in mean square error (%) for M2-M2 pair. The larger this value the 
more significant the association between the amino acid sites evaluated. There are 
14 amino acid sites in M2, determined as significantly associated with amantadine 
resistance/susceptibility encoded on site 31 in M2. The amino acid residue in M2 
associated most with the residue 31 in M2 is at position 77. 
 
Next, the analysis was done in order to check if there are any amino acid sites in M1, 
associated with susceptibility or resistance to amantadine (encoded in M2). The 
results of Random Forest analysis showed very high sensitivity, specificity and AUC. 
The sensitivity was 0.990, specificity was 0.992 and AUC was 0.991 (data not 
shown). There were 11 sites in M1 determined as associated with 
susceptibility/resistance to amantadine in M2 (Figure 4.18). The highest mean 
increase in mean square error in M1 was displayed by site 101, which is one of 5 
residues (101-105) that form the nuclear localization signal (Burleigh et al., 2005). 
Also, these and the surrounding residues in M1 may be important for RNA and RNP 
binding (Burleigh et al., 2005). 
 




Mean increase in mean square error (%) for M2-M1 pair. The larger this value the 
more significant the association between the amino acid sites evaluated. There are 
11 amino acid sites in M1, determined as significantly associated with amantadine 
resistance/susceptibility encoded on site 31 in M2. The amino acid residue in M1 
associated most with the residue 31 in M2 is at position 101. 
 
One site in M2 (77) and one in M1 (101) were found to be highly associated with 
amantadine drug resistance/susceptibility. From the literature it can be seen that 
amino acid 77 in M2 is one of the residues that are responsible for efficient 
interaction with M1 and viral filament formation (McCown and Pekosz, 2006). Site 
101 in M1 is one of the residues where nuclear localization signal is contained and is 
also important for RNA and RNP binding (Burleigh et al., 2005). 
 
So, the conclusion is that there are epistatic interactions between these sites and that 
site 77 in M2 is binding to site M1 and also influences viral morphology, which is 
filamentous. It has been shown that viruses with an Eurasian avian-like MP segment 
form 60% of filamentous virions and the rest are spherical, they are highly 
transmissible. On the other hand, viruses with a Classical MP segment are 
predominantly spherical and have lower transmission capability (Lakdawala et al., 
2011). 
 
In short, the conclusion is that the mechanism for the wide spread of S31N mutation 
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in M2 protein lies in its epistatic linkage to site 77 in the same protein which is one 
of the sites that bind to M1 protein and are responsible for the filamentous virion 
morphology that is highly transmissible. 
 
It has also been reported that M2 may bind to HA in an M1-independent manner 
(Rossman and Lamb, 2011). Random Forest analysis was conducted in order to 
detect associations between amino acid sites in M2-HA pair. 
 
There is one site in HA (276 in H1 numbering) that is highly associated with the 
susceptibility or resistance to amantadine, encoded in M2 (Figure 4.19). This site is a 
part of the sequence which encodes the esterase of HA1, located in the stem domain 
of HA (Sriwilaijaroen and Suzuki, 2012). It is also quite near two receptor-binding 
sites (Figure 4.20). 




Mean increase in mean square error (%) for HA-M2 gene pair. The larger this value the more significant the association between the 
amino acid sites evaluated. There are 47 amino acid sites in HA, determined as significantly associated with M2 amantadine 











The tetramer of HA from 1930 swine influenza A. Coloured are amino acid sites 276 
(red), 290 (blue) and 300 (cyan). Amino acid site 276 is associated with the amino 
acid site 31 in M2 as shown by Random Forest analysis. Sites 290 and 300 are 
receptor-binding sites and are located in the vicinity of site 276. PDB ID: 1RUY. 
Figure made by the author in PyMol v1.5.0.4. 
 
Random Forest analysis was also performed to see if there are any sites in NA, 
associated with resistance or susceptibility to amantadine. Twentysix amino acid 
sites in NA displayed association with amantadine resistance or susceptibility 
encoded in M2. One site displayed high association; that was the site 395 (N1 
numbering) (Figure 4.21), which is located on the surface and near the 380 loop 
(residues 380 – 392) that coincides with the putative calcium binding site (Figure 








Mean increase in mean square error (%) for NA-M2 gene pair. The larger this value the more significant the association between the 
amino acid sites evaluated.There are 26 amino acid sites in NA, determined as significantly associated with M2 amantadine 
resistance/susceptibility. The amino acid residue in NA associated most with the residue 31 in M2 is at position 395. 
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It can be concluded that there are epistatic interactions between segments M2 and 
NA because one residue on the surface domain of NA changes according to 
amantadine drug susceptibility/resistance pattern. 
 
Figure 4.22 
A part of a tetramer of NA polypeptides, isolated from human 1918 influenza A virus. 
Coloured is the site 395 (red) and 380 loop (blue) that contains calcium-binding site 
and is located in the vicinity of the site 395. PDB ID: 3BEQ. Figure made by the 
author in PyMol v1.5.0.4. 
 
4.9.4.3 BGM analysis 
 
BGM analysis was conducted in order to distinguish functional association between 
amino acid sites from phylogenetic linkage. The dataset was the same as for the 
above Random Forest analysis. Initially, three sets of files were submitted to BGM 
analysis: the first with concatenated sequences M2, M1, HA, NA with a maximum 
likelihood tree based on MP sequences. The second file contained the concatenated 
sequences with an HA tree and third file contained concatenated sequences with an 
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NA tree. Also, the file with concatenated sequences and no maximum likelihood tree 
was analysed for comparison.  
 
The BGM analysis of a file with a tree based on HA sequences showed that the 
amino acid site 276 in HA is changing under the influence of amino acid sites 395 in 
NA and 31 in M2 (Figure 4.23) with the posterior probability values 0.88 and 0.34, 
















The result of a BGM analysis for swine H1N1 with a maximum likelihood tree based 
on HA sequences. Nodes represent amino acid sites from four different proteins and 
edges (arrows) represent dependencies between nodes. The degree of dependency 
is expressed by a probability value. Figure made in Cytoscape v3.0.1. 
 
The file with an NA tree gave different results (Figure 4.24). M2-31 and HA-276 are 
both influencing NA-395 with high probability (0.80 and 0.78, respectively). M2-77 
and M1-101 are changing according to NA-395 which corresponds to results based 
on an HA tree (Figure 4.23). NA-395 is influencing M1-101 and M2-77 to change; 
these two interactions are absent when considering results based on an HA tree 
(Figure 4.23). 













The result of a BGM analysis for swine H1N1 with a maximum likelihood tree based 
on NA sequences. Nodes represent amino acid sites from four different proteins and 
edges (arrows) represent dependencies between nodes. The degree of dependency 
is expressed by a probability value. Figure made in Cytoscape v3.0.1. 
 
The results with an MP tree included in the nexus file of concatenated sequences 
show that the amino acid site 395 in NA influenced the amino acid site, where 
resistance to amantadine can occur (31 in M2) to change (Figure 4.25). The posterior 
probability for this event is very high (0.96). The amino acid site 31 in M2 further 
influenced the HA-276, which influenced M2-77, causing these sites to mutate. M2-



















The result of a BGM analysis for swine H1N1 with a maximum likelihood tree based 
on MP sequences. Nodes represent amino acid sites from four different proteins and 
edges (arrows) represent dependencies between nodes. The degree of dependency 
is expressed by a probability value. Figure made in Cytoscape v3.0.1. 
 
However, when submitting the file of concatenated sequences with an included 
maximum likelihood tree based on MP sequences for a BGM analysis, the software 
did not display the option for using the tree provided in the file. This option was 
displayed and used for the files with an HA and NA based tree. Therefore, the tree 
used for BGM analysis was most likely the neighbour-joining tree of concatenated 
sequences which is constructed and used during BGM analysis unless specified 
otherwise. To test this, a file with concatenated sequences but with no maximum 
likelihood tree was subjected to BGM analysis. The result (Figure 4.26) was identical 
to the results obtained using a file with an MP tree (apart from some of the values for 
posterior probability) which confirms that the BGM results for a file with an MP tree 
were constructed on a tree for concatenated sequences and are therefore not optimal 
for the interpretation of co-evolving amino acid sites from four different influenza 
virus proteins. 
 












The result of a BGM analysis for swine H1N1 with no maximum likelihood tree 
included. Nodes represent amino acid sites from four different proteins and edges 
(arrows) represent dependencies between nodes. The degree of dependency is 
expressed by a probability value. Figure made in Cytoscape v3.0.1. 
 
The co-evolving amino acid sites identified in this study are in the cytoplasmic 
domains of M1 and M2 (M1-101 and M2-77) and external parts of the virion (M2-
31, HA-276 and NA-395). The importance of these physical and functional linkages 
is probably in maintaining high transmissibility of the virus due to its filamentous 
morphology (influenced by M2-77) and evading host’s immune response (HA-276 
and NA-395). 
 
It can be concluded that the substitution from susceptible to resistant amino acid on 
site 31 in M2 is due to a hitch-hiking event, where changes in the frequency of an 
allele occur because of linkage with a positively or negatively selected allele at 
another locus (Futuyma and Douglas, 2013). These mutations are also due to 









In this chapter, four datasets were constructed in order to address different scientific 
questions. Also, different methods were used to answer those questions. Evolutionary 
analysis of full length swine influenza MP sequences available from the NCBI 
Influenza Virus Resource was one of the approaches used. Phylogenies were 
obtained which showed evolutionary relationships between swine MP sequences 
isolated from different time periods, and analysis with BEAST allowed visualisation 
of trees on an explicit time scale. Second approach used was Random Forest 
analysis, which is one of the machine learning methods. Its advantage is in high 
accuracy of predicted result values. This method was used to detect any associations 
between amino acid sites in different segments of influenza genome that might imply 
the cause of certain events, such as drug resistance mutation spread in the absence of 
a drug use. 
 
Overall, a large number of swine influenza virus MP sequences were available but 
were used in only one of four datasets constructed. The reason for this lies in the 
limitation of one of the phylogenetics methods used (BEAST), which can process a 
rather small number of sequences to ensure valid results. The second reason is in the 
decreasing number of MP sequences available when matched to sequences of other 
segments from the same isolate. Although a large number of swine influenza virus 
MP sequences have been deposited to the online database, there are only a few 
sequences of early (before 1990) Eurasian avian-like clade available. The reason is 
deficient sampling of swine isolates at that time. So, it was hard to estimate the time 
of Eurasian avian-like clade emergence and amantadine drug resistance emergence, 
both of which occurred before 1990. 
 
Phylogenetic analyses using maximum likelihood as well as Bayesian coalescent-
based inference in BEAST, confirmed the time of the Eurasian avian-like swine 
clade emergence to be in the 1979. However, due to a small number of MP 
sequences available before the year 1990, the estimation of a time of an amantadine 
drug resistance emergence in this clade of swine influenza viruses was different – 
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estimated to be around 1979 also, however, according to Krumbholz et al. (2009) 
that happened in 1988.  
 
According to Schmidtke et al. (2006) the cause of this amantadine drug resistance 
appearance and its wide spread lies in the reassortment of segments but according to 
Furuse et al. (2009) it is the point mutation. However, none of the studies conducted 
so far was able to explain the mechanism behind the rapid rise of the amantadine 
drug resistance after the year 2000 when this drug was no longer in use in humans. 
This reinforced the hypothesis, that the wide spread of S31N mutation responsible 
for amantadine drug resistance is due to genetic epistasis between different amino 
acids in different proteins as well as hitch-hiking (Futuyma and Douglas, 2013). As 
amino acid at site 77 in M2 is changing in order to efficiently interact with M1 
protein and to form filamentous virions, which are highly transmissible, the 
epistatically linked amino acid at site 31 is also changing to a conformation that still 
allows the M2 ion channel to perform its function and it just happens to also confer 
amantadine drug resistance. The observation that also HA and NA change each at 
one amino acid site (276 and 395, respectively) indicates a net of epistatically linked 
sites and confirms the proteins’ interactions in order to perform their functions. This 
was further supported by the BGM analysis, which revealed the four proteins studied 
to be changing by mutations in a dependent manner.  
 
The results of a BGM analysis are reliable for files which included HA and NA trees 
but not for a file with an MP tree. However, the results based on an HA tree differ 
from results obtained for a file with an NA tree in the direction of amino acid sites’ 
interactions. In chapter 3 (Reassortment of swine influenza A viruses) it is shown 
that swine HA and NA segments are frequently reassorting therefore the discrepancy 
in the results of a BGM analysis is most likely due to reassortment. Nonetheless, 
BGM analysis results show that there are co-evolving amino acid sites found in four 
different influenza A proteins (M2, M1, HA, NA) with some of the proteins coming 
in a physical contact therefore, there are clearly epistatic effects among M2, M1, HA 
and NA proteins. Namely, epistatic effects can take place when proteins are in a 
functional interaction which may be direct or indirect. In this case, the four proteins 
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studied are in a direct contact with one another which has been proven in laboratory 
based studies (McCown and Pekosz, 2006; Burleigh et al., 2005; Lakdawala et al., 
2011; Rossman and Lamb, 2011; Bilsel et al., 1993; Mitnaul et al., 1996; Chen et al., 
2005). However, these interactions are all between cytoplasmic domains of M2, M1, 
HA and NA. The results of the study described in this chapter show also co-evolving 
sites which are not in a physical interaction. Amino acid sites on HA and NA that are 
epistatically associated with the M2-31 site are on the surface of these two 
glycoproteins. HA-276 is near the receptor binding sites and NA-395 is near the 
calcium-binding site and one glycosylation site. Also, the M2-31 amino acid site is at 
the pore-facing side of the ion channel M2. So, HA-276, NA-395 and M2-31 are not 
found inside the virion. Hence, the epistatic interaction between HA-276 and M2-31 
as well as the epistatic interaction between NA-395 and M2-31 probably enable the 
virus to evade host’s immune response. Amino acid site M2-77 is one of the amino 
acids in this protein that enable the virus to take a filamentous form, which is highly 
transmissible. Therefore, the substitution from susceptible to resistant amino acid on 
site 31 in M2 is due to its linkage to amino acid sites in M2, M1, HA and NA 
proteins, that all enable the influenza virus to escape host’s immune system as well 
as spread efficiently to different individuals of the host species. 
 
The importance of this study is in the further elucidation of the mechanisms 
responsible for a rapid spread of an amantadine conferring mutation that took place 
in the time when amantadine usage was in decline or absent. The study offers a novel 
insight on this topic since it uses advanced methods of phylogenetics combined with 
bioinformatics as well as a machine learning method not used so far for influenza 
virus, the highly sensitive and specific method Random Forest, which can explicitly 
identify amino acid sites involved to explore the association between different 
proteins, coupled with BGM analysis showing the direction of association among 
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5 Oseltamivir resistance in human seasonal A/H1N1 
influenza viruses 
 
5.1 Oseltamivir drug resistance in human influenza A viruses 
 
Antiviral agents constitute a means for the prevention and treatment of seasonal and 
pandemic influenza (Sheu et al., 2008; Maltezou, 2008; Hota and McGear, 2007). 
Currently, there are two classes of antiviral drugs for preventing and treating 
influenza infections: M2 ion channel blockers and neuraminidase inhibitors. Since 
the rapid spread of resistance to M2 ion channel blockers that began increasing in the 
2004-2005 influenza season (5.8% of resistant viruses in Asia) and reached 15.5% 
globally in the 2005-2006 influenza season for A (H1N1) while for A (H3N2) the 
proportion of resistant viruses was 90.6% in the 2005-2006 season (Bright et al., 
2005; Deyde et al., 2007), this class of drugs is no longer recommended for 
treatment. Oseltamivir-resistant seasonal influenza A/H1N1 was detected in Europe, 
first in France, Spain, Switzerland, and the United Kingdom in week 40 of 2007 and 
spread globally in the absence of drug selective pressure in the season of 2007-2008 
(Hauge et al., 2009; Hurt et al., 2009; Meijer et al., 2009). At the end of this season 
in September 2008, the mean percentage of oseltamivir-resistant isolates was 24.3% 
in Europe, 12.3% in USA, 26% in Canada, 12% in Hong Kong and 3% in Japan 
(Casalegno et al., 2010; Lackenby et al., 2008; Dharan et al., 2009). By the 2008-
2009 season, most seasonal influenza A/H1N1 viruses were resistant to oseltamivir 
(WHO, 2009). 
 
5.2 Structure and mechanism of influenza A virus neuraminidase  
 
The influenza neuraminidase is found on the viral surface and composed of four 
identical subunits. Each subunit contains about 470 amino acids and is further 
arranged in four domains: (i) a N-terminal cytoplasmic sequence which is followed 
by (ii) a membrane-penetrating hydrophobic transmembrane domain and a (iii) thin 
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stalk of variable length, ending in (iv) a globular head domain with the enzyme 
active site (Air, 2012). 
 
The symmetry of four subunits is stabilized by a carbohydrate side chain facing 
inwards (Colman, 1991) and by metal (calcium) ions. Two calcium binding sites 
have been identified, one of them near the binding pocket (Colman et al., 1983). It is 
believed that calcium ions positively modulate NA enzyme activity during the 
release of newly synthesized virions from the cell (Chong et al., 1991).  
 
The cytoplasmic domain contains six conserved amino acids (MNPNQK), found in 
almost all influenza A subtypes. However, its function remains unknown. Viruses 
with mutations in the cytoplasmic tail show reduced budding and changed 
morphology (Barman et al., 2004; Jin et al., 1997). 
 
The transmembrane domain is variable among influenza A subtypes. It is a helix 
containing amino acids 7-29 (Krogh et al., 2001; Moller et al., 2001) with two 
functions. The first is directing the NA through the endoplasmic reticulum during 
protein folding, and the second is anchoring the NA in the membrane. 
 
The stalk is located between the transmembrane sequence and the globular head 
domain. Its structure has not been fully elucidated yet. However, it is known that it is 
of variable length and that all NA subtypes have Cys residues in the stalk and/or 
transmembrane domains, which may assist in tetramer formation. All NA stalks 
contain glycosylation sites, shorter stalks usually contain one site, full length stalks 
contain three or more. Most NAs have stalks of approximately 50 amino acids, but 
deletions of up to 18 amino acids have been found in N1 and N2 NA stalks (Blok and 
Air, 1982; Els et al., 1985).  Several studies have associated deletions in the stalks of 
N1 NA of avian viruses with transmission from ducks to land-based poultry (Munier 
et al., 2010), but the mechanism remains unknown. Deletion of the stalk does not 
change the activity of NA for small substrates but activity with complex substrates is 
reduced (Els et al., 1985; Munier et al., 2010), which suggests that lower 
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accessibility of the substrate and therefore lower activity of NA is an advantage for 
viruses replicating in chickens compared to viruses of waterfowl (Air, 2012). 
 
The globular head domain carries the active site located at the center of each subunit. 
The active site contains several conserved charged amino acid residues (Burmeister 
et al., 1992; Colman et al., 1983). The natural ligand for NA is the sialic acid and as 
NA inhibitors are analogs of sialic acid, the mechanism of their antiviral activity is 
through competition with the natural ligand and blocking the enzyme active site 
(Figure 5.1). NA inhibitors are effective against influenza A and B viruses and even 
different NA subtypes due to the conserved active site with only minor structural 
differences (Russell et al., 2006). Targeted viral function is the release of progeny 




A neuraminidase tetramer, isolated from human pandemic 2009 influenza A virus, in 
complex with oseltamivir. Oseltamivir is coloured in magenta. Blue colour presents 
six different molecules or atoms: acetate ion, beta-D-mannose, calcium ion, glycerol, 
alpha-d-mannose, N-acetyl-D-glucosamine. Glycerol is a part of NA inhibitors and 
sialic acid, acetate is used for obtaining crystallized NA, and calcium ions are 
believed to positively modulate NA activity. PDB ID: 3TI6. Figure made by the author 
in RCSB PDB Protein Workshop 4.1.0. 
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5.3 Neuraminidase inhibitors: oseltamivir and zanamivir 
 
Two neuraminidase inhibitors, oseltamivir (ethyl (3R,4R,5S)-5-amino-4-acetamido-
3-(pentan-3-yloxy)-cyclohex-1-ene-1-carboxylate, Tamiflu
TM
) and zanamivir 
((2R,3R,4S) – 4 – guanidine – 3 - (prop – 1 – en – 2 - ylamino) – 2 - ((1R,2R) - 1,2,3 
- trihydroxypropyl) -3,4-dihydro-2H-pyran-6-carboxylic acid, Relenza
TM
) are used in 
the treatment and prophylaxis of influenza caused by influenza A virus and influenza 
B virus (Figure 5.2). Oseltamivir and zanamivir have been available since 1999. 
Oseltamivir is a prodrug, a (relatively) inactive chemical, which is converted into its 
active form (oseltamivir carboxylate) by metabolic process after it is taken into the 







Chemical structures of oseltamivir carboxylate and zanamivir (neuraminidase 
inhibitors) (Gubareva et al., 2004). 
 
The primary mutations that confer resistance to oseltamivir are H275Y (N1 
numbering) (Dharon et al., 2009; Hauge et al., 2009; Meijer et al., 2009) and N295S 
(N1 numbering) in the neuraminidase protein in that order of importance. H275Y is 
found near but not directly in the substrate-binding pocket (Russell et al., 2006).  
 
5.4 Oseltamivir usage in humans 
 
Oseltamivir has been available as an anti-influenza drug since 1999 and wide spread 
resistance to it appeared in the 2007-2008 influenza season (Hauge et al., 2009; Hurt 
et al., 2009; Meijer et al., 2009). The number of oseltamivir prescriptions per 1,000 
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inhabitants per country prior to the 2007-2008 influenza season does not always 
match the proportion of resistant strains isolated in that country. For example, Japan 
reported low levels of oseltamivir resistant strains but the stockpiling of this drug 
was high (Yasui et al., 2007). On the other hand, European countries experienced 
high proportions of resistant strains but reported moderate or low usage of this drug 
(Hauge et al., 2009; Kramarz et al., 2009). So the question of what led to the 
appearance and global spread of oseltamivir resistant strains in 2007-2008 influenza 
season remains. 
 
5.5 Functional association of neuraminidase and haemagglutinin 
 
The two glycoproteins, haemagglutinin (HA) and neuraminidase (NA), embedded 
into the viral membrane of influenza have complementary functions. Numerous 
studies have shown a functional balance between them is required for productive 
infections. While HA is a receptor-binding glycoprotein (Hirst, 1941), required for 
cell entry, NA is receptor-destroying (Burnet & Stone, 1947) and active on viral 
release from the cell. The balance between them can be destroyed by various factors 
such as drug inhibition of NA. Mutations in NA can occur that allow the virus to 
persist in the presence of a drug, although with a lower replication ability in vivo (Tai 
et al., 1998; McKimm-Breschkin et al., 1998; Gubareva et al., 1997). Because of the 
functional association between NA and HA, mutations in HA have been observed 
which consequently resulted in a decreased HA activity to balance the decrease in 
NA activity (Bantia et al., 1998; Blick et al., 1998; McKimm-Breschkin et al., 1996). 




Epistasis describes non-additive interactions among genetic sites: the consequence of 
a mutation at one site may depend on the status of the genome at other sites. Epistatic 
mutations in viruses and bacteria that live under severe conditions, such as drug 
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treatment or immune pressure, allow pathogens to develop drug resistance or escape 
the immune system. These beneficial mutations are often pleiotropic: they have a 
beneficial effect but in addition to that they cause some side effects (usually 
negative) on other protein properties, such as stability (Bloom and Arnold, 2009; 
DePristo et al., 2005). These negative effects can usually be compensated by other 
mutations, making a certain combination of mutations more beneficial to the 
pathogen than single mutations alone (Sanjuan et al., 2005; Mateo and Mateu, 2007). 
This phenomenon is known as positive epistasis between mutations (de Visser and 
Elena, 2007). Epistasis can also be negative if a combination of mutations confer 
smaller benefit to the pathogen than what would be expected under additive effects 
of the individual mutations (de Visser and Elena, 2007). 
 
5.7 Methods for exploring the association between (viral) genotype and 
phenotype 
 
In the last few years, many different methods have been used to explore associations 
between genotype and phenotype using datasets of viral nucleotide sequences, 
predominantly in HIV. These methods include linear regression (Precious et al., 
2000; Wang et al., 2004), decision trees (Beerenwinkel et al., 2002), random forests 
(Murray et al., 2008), support vector machines (Beerenwinkel et al., 2001), neural 
networks (Wang & Larder, 2003) and others (Sevin et al., 2000; Beerenwinkel et al., 
2003). Many of these are based on machine learning approaches which can process 
large volumes of sequence data, incorporate multiple variants at individual amino 
acid sites and search for explicit models identifying the amino acid sites involved.  
Beerenwinkel et al. (2002) used decision trees to predict drug resistance to 14 
antiretroviral drugs from a genotype. The predictive error was in the range of 9.6% to 
15.5% and 25.4% to 32.0%, depending on the drug. The sensitivity ranged from 
58.2% to 92.5% and specificity between 62.5% and 97.2% according to drug. This 
approach was developed further by Murray et al. (2008) who introduced the case of 
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HIV-1 drug resistance determination for tenofovir random forest, yielding a 
specificity of 77%, which was higher than for decision trees (72%). 
 
5.8 Studies on mutations on different sites that are epistatically linked 
and confer resistance to oseltamivir 
 
The study by Kryazhimskiy et al. (2011) described a novel statistical method to 
detect positive epistasis between pairs of sites in a protein, based on the observed 
temporal patterns of sequence evolution. The method is based on the idea that a 
substitution at one site should rapidly follow a substitution at another site if the sites 
are positively epistatic. Kryazhimskiy et al. (2011) applied this method for detecting 
such pairs in either HA or NA of H3N2 and H1N1. They found substantial amounts 
of epistasis and determined the identities of putatively epistatic pairs of sites. 
 
In the study by Baranovich et al. (2010) the authors collected samples from influenza 
patients from Japan in two subsequent influenza seasons: 2007-2008 and 2008-2009. 
They looked for mutations in NA at site 274 (N2 numbering) and in M2 at site 31. 
They found that 0.4% influenza A(H1N1) isolates from the 2007–2008 season and 
100% of influenza A(H1N1) isolates from the 2008–2009 season possessed the 
H274Y substitution in the NA, which confers oseltamivir-resistance. Amantadine-
resistance S31N substitution in the M2 gene was detected in 62.7% influenza 
A(H1N1) isolates from the 2007–2008 season but in none of the influenza A(H1N1) 
isolates from the 2008–2009 season. All of the isolates from 2008-2009 season plus 
one strain from the 2007-2008 season were amantadine sensitive but oseltamivir 
resistant and possessed the H274Y and D357G substitutions in the NA. Viruses from 
the 2008-2009 season also possessed an additional A193T (H3 numbering) 
substitution in the receptor-binding domain of HA. In addition, isolates from 2008-
2009 season, had polymorphisms at positions 189 (G189A and G189V), 145 
(S145N), and 196 (H196R) in the HA (all in H3 numbering). 
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5.9 The aim of study 
 
The surface of HA and NA, where antibodies bind (epitopic sites) tends to evolve 
more quickly than other parts of the protein and especially more quickly than other 
viral proteins, in order to evade immunity (Suzuki, 2006; Bush et al., 1999; Wolf et 
al., 2006). Studies (for example the one by Kryazhimskiy et al. (2011)) have shown 
epistatically linked sites in HA and NA separately. Because of a functional balance 
between those two glycoproteins, we investigated the functional interaction between 
NA and HA genotype using machine learning techniques to look for correlation of 
amino acid variants in HA with oseltamivir resistance encoded in NA. 
  
5.10 Methods and data 
 
5.10.1 The dataset 
 
Full-length sequences of NA and matching HA were downloaded from the GISAID 
database for human seasonal influenza A/H1N1 virus. Sequences were isolated from 
October 1
st
 2006 to December 31
st
 2008 and submitted by CDC. After excluding 
sequences from Africa, Europe, Oceania due to low numbers, 542 sequences 
remained in the dataset which were isolated from North, South and Central America 
and Asia (including Russia). 
 
5.10.2 Bivariate analysis 
 
The first 17 amino acids were excluded from the analysis as they represent the 
signalling sequence. The remaining 549 amino acids of HA segment were analysed 
in R to determine frequency count of amino acids on each site. Each amino acid site 
was tested for association with the susceptibility/resistance in NA using Fisher’s 
exact test and recorded the p-values. Amino acid sites of a p-value of less than 10
-6
 
were considered further resulting in 26 amino acid sites putatively associated with 
susceptibility/resistance data. 
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5.10.3 CART analysis 
 
Decision trees were created by splitting the genotype-phenotype dataset until no 
further splits improved the accuracy. To avoid overfitting, trees were pruned. To 
assess the performance of the models to predict phenotype in unseen genotypes 
standard 10-fold crossvalidation was applied. For the classification models the 
generalization error is measured by the percentage of genotypes misclassified and the 
model’s sensitivity and specificity. To select an optimal model, a ROC curve was 
calculated using 10-fold crossvalidation and the model which produced the best 
trade-off between sensitivity and specificity was chosen (Murray et al., 2008). Trees 
were pruned or extended to test the model fit on the basis of the ROC curve. 
 
5.10.4 Random Forest analysis 
 
This method constructs a number of decision trees where splits are determined on the 
selected subset of amino acid sites at each leaf. To interpret the Random Forest 
model, the importance of each amino acid site selected to predict phenotype was 
determined by the permutation accuracy importance (PAI) measure. PAI permutes 
the amino acid state in each of the sequences randomly which breaks the association 
with the phenotype on that amino acid site and then tests the impact on the accuracy 




10-fold crossvalidation was used to assess the predictive power of the models tested. 
The 542 HA sequences were randomly split into 10 parts (8 parts of 54 sequences 
each and 2 parts of 55 sequences each) with one part used as a test dataset and the 9 
remaining parts of sequences used as a training dataset. This was repeated 10 times. 
True negative, true positive, false negative and false positive values and 
susceptibility and sensitivity were estimated. 
 
 





All models were created in the R environment (version 2.14.1). Decision trees were 
obtained by the tree and predict.tree functions in the tree library (Ripley, 2012). 
Pruned and extended trees were created by the prune.tree and tree.control functions 
respectively in the same library. Random forest trees were created by using 
randomForest and predict functions in the randomForest library (Liaw and Wiener, 
2002). The ROC curves were calculated using prediction, performance and verify 
functions in the ROCR and verification libraries (Sing et al., 2005). 
 
5.10.7 Phylogenetic analysis 
 
Maximum likelihood phylogenetic analysis was conducted on 542 HA nucleotide 
sequences in RAxML v7.2.8 with 1000 bootstraps, the GTR (General Time 
Reversible) model of nucleotide substitution with the gamma rate heterogeneity and 
4 discrete rate categories (Stamatakis et al., 2008). The output tree file was opened in 
FigTree v1.3.1 (Rambaut, 2007). The clade with the majority of resistant sequences 
was then separated from the other HA sequences and analysed in BEAST 
(Drummond and Rambaut, 2007) using the SRD06 nucleotide substitution model, a 
relaxed clock (uncorrelated lognormal) and a constant population size demographic 
model. The NA sequences for the same subset of strains were analysed in BEAST 




Full-length sequences of HA and matching NA sequences of human seasonal 
influenza A/H1N1 virus isolated from October 1
st
 2006 to December 31
st
 2008 were 
downloaded from the GISAID database. After excluding poorly represented regions, 
a dataset of 542 sequences from North, South and Central America and Asia 
(including Russia) was used in the analysis. Table 5.1 shows the geographical and 
temporal distribution of isolated sequences, divided into oseltamivir susceptible or 
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resistant according to mutations encoded in the NA. Resistance-conferring mutations 
in NA were present at only 1 amino acid site (of 2): 275 (N1 numbering). Out of 542 
sequences, 354 were susceptible to oseltamivir and 188 were resistant. Zanamivir-
resistant sequences or sequences resistant to both drugs, oseltamivir and zanamivir, 
were excluded from the study. 
 
Table 5.1 
Temporal and geographical distribution of sequences, divided into oseltamivir-
susceptible (S) or oseltamivir-resistant (R). 
 2006 2007 2008 
continent S R S R S R 
North and Central America 5 / 101 18 66 103 
South America 5 / 2 / 22 18 
Asia (including Russia) 11 / 73 2 69 47 
      S=susceptible, R=resistant 
Decision trees were used in initial analyses of the association between oseltamivir 
resistance and haemagglutinin genotype. Initial Decision Tree analyses resulted in 
relatively simple models with a depth of 4 for the unpruned tree and depth of 3 for 
the pruned one (Figure 5.3). The number of leaves was 4 for the pruned tree. The 














Classification tree from the CART analysis, showing three most important amino 
acid sites in HA and respective amino acids, associated with oseltamivir resistance 
in NA.The tree displayed has been pruned to 4 nodes only. Numbers indicate amino 
acid sites in the HA1 region in H1 numbering. Letters A, N, S, V, K, T indicate the 
amino acid variants observed in branches and leaves below that node. The amino 
acid site in HA that is associated most significantly with the oseltamivir - susceptible 
or –resistant phenotype (as encoded in NA) is 202. The second most significant 
amino acid site is 205 and the third most significant amino acid site is 206.  
 
From the decision tree it can be seen that all mutations at amino acid site 202 in 
haemagglutinin are associated with resistance in NA – 92 strains had a mutation at 
this site (from G to any of A, N, S or V) all of which were resistant. However, 95 
strains that were wild type (G) at 202 were also resistant to oseltamivir. Including 
amino acid sites 205 and 206 in the analysis allowed a further 42 of these to be 
identified. The percentage of samples misclassified using these 3 sites was 10.7% (58 
samples). The percentage of correctly predicted resistant samples (sensitivity) was 
71.3% and specificity (correctly predicting susceptibility in cases labelled as 
susceptible) was 98.6%. The area under the curve (AUC) was 0.882 (Table 5.2). 
CART analysis of susceptible versus resistant phenotype led to a correct 


















Specificity, sensitivity and AUC (area under the ROC curve) for five different models 
tested for determining association of HA genotype and oseltamivir resistance 
encoded in NA. The larger the values, the more significant the model. 
model SPECIFICITY SENSITIVITY AUC 
CART unpruned, 7 leaves 0.986 0.713 0.899 
CART pruned, 4 leaves 0.986 0.713 0.882 
CART extended, 55 leaves 0.972 0.718 0.883 
CART extended, 16 leaves 0.972 0.718 0.882 
Random Forest 0.994 0.734 0.916 
 
Random forest analysis is an extension of the decision tree learning where trees are 
created by growing individual trees on bootstrap samples of the data (Breiman, 
2001). By using 10-fold crossvalidation the number of trees in the forest, the total 
number of amino acid sites randomly selected at each leaf and the maximum tree 
depth are optimized. To identify the key sites in the model, the permutation accuracy 
importance is calculated for each site by randomizing the amino acid allocations at 
the site and calculating the % change in the mean-square error of the model. The 
Random Forest model was a more accurate classifier than the Decision Trees with a 
higher specificity (99.4%), higher sensitivity (73.4%) and higher AUC (0.916) on the 
receiver operator characteristic (ROC) curve (Table 5.2 & Figure 5.4). While both 
models identified the same five amino acid sites: 202, 205, 206, 99, 52 (H1 
numbering) they were not in the same order of importance (Figure 5.5). Other 
mutations are of marginal importance.  





ROC curves for 4 different CART analyses and one Random Forest analysis. Red 
curve: CART model (unpruned, 7 leaves), blue curve: CART model (pruned, 4 
leaves), green curve: CART model (extended, 55 leaves), pink curve: CART model 
(extended, 16 leaves), orange curve: Random Forest model, black curve: unfitted 
data for the CART model (unpruned). The X axis represents the false positive rate 
which equals 1-specificity. The Y axis represents the true positive rate which equals 
sensitivity. The ROC curve defines the area under the ROC curve-AUC-which can 
















Mean increase in mean square error (%) (values on the horizontal axis) for amino 
acid sites in HA (values on the vertical axis) compared to amino acid site 275 in NA 
where susceptibility or resistance to oseltamivir is encoded. The larger the 
%IncMSE value the more significant the association between the amino acid sites 
evaluated. There are 27 amino acid sites in HA, determined as significantly 
associated with NA oseltamivir resistance/susceptibility. Amino acid sites are 
ordered according to their impact on the performance of the Random Forest model. 
The amino acid residue in HA associated most with the residue 275 in NA is at 
position 206 (and has the largest impact on the Random Forest model). HA1 
indicates the codon is in the HA1 region of HA. HA2 indicates the codon is in the 
HA2 region of the HA. Numbers indicate amino acid sites in H1 numbering. 
 
In order to understand better how the association between HA genotype and 
oseltamivir resistance came about the timeline of appearance of the associated 
variants was first examined in the context of the appearance of resistance. Figure 5.6 
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numbering) in HA according to the time the sequences were isolated. Most of the 
resistance-associated HA variants appeared sporadically from January 2007 onwards 
but it was the middle of November 2007 when genotypic resistance in NA took over 
and spread. 
 
The phylogenetic relationships of the HA variants and resistance in the full dataset 
are indicated in Maximum likelihood trees coloured according to oseltamivir 
resistance in NA and different amino acids at positions 202, 205, 206 (H1 
numbering) separately (Figures 5.7A, 5.7B, 5.7C, 5.7D, respectively). A large 
majority of HA sequences, belonging to oseltamivir resistant strains, fall within one 
clade (Figure 5.7A). Four sequences (2 of them found in other two clades) are cases 
of early sporadic appearances of resistance. There are 6 different HA variants at 
amino acid site 202 (H1 numbering; Figure 5.7B) with glycine being most common. 
This corresponds mostly to the susceptible strains but also to many resistant ones 
(95/542; 17.5%). Alanine (A), asparagine (N), serine (S) and valine (V), found in 
resistant strains only (see above), are mostly seen from November and December 
2008 (Figure 5.6). The second most important amino acid site in HA (as recognized 
by CART) is 205 with 5 different amino acid variants, three of which are common 
and each found in the three phylogenetic clades (Figure 5.7C). Figure 5.7D shows 3 
genotypes on amino acid site 206, with amino acids alanine (A) and threonine (T) 
prevailing. Those two amino acids are distributed approximately equally among 













The most frequent amino acids in HA at five amino acid sites most strongly 
associated with oseltamivir susceptibility/resistance as identified with CART and RF 
models: 52, 99, 202, 205, 206 (H1 numbering) according to the isolation date of 
sequences. Red colour indicates resistance to oseltamivir, black colour indicates 
susceptibility to oseltamivir. 






















Maximum likelihood tree of 542 HA sequences, coloured according to: (A) 
oseltamivir resistance in NA, red colour indicates oseltamivir-resistant sequences; 
(B) different amino acids at site 202 (H1 numbering), blue: G, yellow: R, pink: X, red: 
A, turquoise: N, green: S, orange: V; (C) different amino acids at site 205 (H1 
numbering), red: R, blue: K, green: M, orange: S, turquoise: N, yellow: X; (D) 
different amino acids at site 206 (H1 numbering), red: A, blue: T, green: V, orange: 
X. 
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The detailed relationships among these strains are shown in time-resolved trees in 
figures 5.8 (HA) and 5.9 (NA). From both trees it can be seen that sustained 
resistance appeared in a common ancestor in mid-2007. However, from figure 5.6 it 
is obvious that resistance started spreading in the middle of November 2007 as 
mentioned above. This discrepancy probably reflects the lack of influenza 
transmission in the Northern hemisphere summer. While the HA and NA trees are 
similar, particularly in regards to the time estimate of sustained resistance, however, 
they differ in one important detail. The HA tree (Figure 5.8) contains a clade of 
susceptible strains (coloured blue) among two resistant clades (red). In the NA tree 
(Figure 5.9) this susceptible clade (coloured blue) is found earlier and shares a 
common ancestor with the resistant sequences. It can be concluded that a 
reassortment event occurred between HA and NA lineages in association concurrent 
with the spread of oseltamivir resistance.  
 
Figure 5.8 
BEAST tree for a partial dataset of HA sequences forming a clade on the maximum 
likelihood tree with the majority of oseltamivir-resistant strains. This tree shows the 
evolutionary relationship among strains and the amino acid variants in HA at 
position 202 (H1 numbering). Black: susceptible strains, violet: sporadic resistant 














BEAST tree for a partial dataset of NA sequences matching the HA sequences that 
form a clade on the maximum likelihood tree with the majority of oseltamivir-
resistant strains. Black: susceptible strains, violet: sporadic resistant strains, blue: 
susceptible strains, found between two resistant HA clades, red: resistant strains 
 
The amino acids observed at position 202 in HA are plotted as tip labels on Figure 
5.8. This shows that while among the susceptible strains glycine is almost universal, 
within the resistant clade there is substantial variability at this site, with glycine and 3 
alternative amino acids, serine, alanine and valine, appearing in different resistant 
subclades. Each of these changes involved a single nucleotide substitution, with 
asparagines evolving from serine in 2 cases by one further single change. The 
asparagine arises from serine and not directly from glycine, while alanine and valine 
come directly from glycine. So the wild-type codon is GGT as expected but not GGA 
or GGG (Figure 5.8). From the time-resolved tree it can be seen that the wild-type 
glycine at HA 202 persisted at least 6 months after resistance arose in NA and 
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indeed, in a minor subclade continued until the end of 2008. The first variant to 
appear was valine (late 2007), followed in a different subclade by serine (early 2008) 
and alanine in a third subclade in mid-2008. There is therefore no simple 
phylogenetic explanation for the association of HA variation with oseltamivir 




In this study evidence has been found which shows complex pattern of associations 
between genetic variants in HA and the appearance of the NA clade within which 
resistance arose, at sites in HA close to the receptor binding site.  
 
The main mutation responsible for the oseltamivir resistant phenotype is H275Y (N1 
numbering), however it is strongly deleterious to the virus in the absence of the drug 
(Aoki et al., 2007). Evidence that a balance of activity between NA and HA is 
required has been found in studies done by Xu et al (2012), Richard et al (2012), Lu 
et al (2005) and Baigent and McCauley (2001). Epistatic interactions between 
genetic variants at different loci can have a significant effect on fitness. 
Kryazhimskiy et al. (2011) identified 225 epistatic pairs of sites in H1 and 205 of 
them in N1. However, they did not look explicitly at associations between HA and 
NA. In this study a dataset comprising 542 human seasonal A/H1N1 sequences of 
HA and NA was obtained. Sequences were isolated from the end of 2006 and the 
whole of 2007 and 2008 – just before and just after the emergence of oseltamivir 
resistance in this group of influenza virus. 
 
Associations between oseltamivir resistance (determined by the presence of H275Y 
in NA) and genetic variants across HA were analysed using machine learning models 
including Classification and Regression Trees analysis (CART) and Random Forest 
which both permit the identification of contributing amino acid sites (unlike neural 
networks or support vector machines). The results showed that three amino acid sites 
in HA are important for determining drug-resistant phenotype in influenza (202, 205, 
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206; H1 numbering) which were identified by both models used, although not in the 
same order of importance.  
 
Amino acids at sites 205 and 206 are two of the amino acids that form receptor-
binding sites (Sriwilaijaroen and Suzuki, 2012). Amino acid site 206 is also one of 
the antigenic sites. Amino acid site 202 is near the 190-helix, which is a receptor-
binding site and amino acid site 99 is near a conserved glycosylation site 
(Sriwilaijaroen and Suzuki, 2012). Taking that in consideration it is not surprising 
that the mutations at sites 202, 205 and 206 are so diverse and consequently enabling 
the existence of different HA genotypes over a short time period. Looking at the 
frequency of the resistance-conferring mutations at position 202 in HA it can be 
seen, that all except one are found in strains, isolated in 2008. 
 
Rameix-Welti et al. (2008) studied enzymatic properties of the neuraminidase of 
seasonal A/H1N1 and found that resistant viruses that harboured the H275Y 
mutation had a slightly higher activity and affinity for the substrate than sensitive 
viruses. They concluded that these features could contribute to the overall fitness of 
resistant strains, however, they did not exclude the possibility of the contribution 
from other genes. 
 
Co-occurrence of mutations at different amino acid sites is expected, even in 
different genes because of shared phylogenetic history (Poon et al., 2007). However, 
the pattern observed in HA 202 is complex and cannot be explained on that basis. 
First, the wild-type glycine persists into several resistant subclades, then different 
allelic forms arise in 3 different resistant subclades at different times. It can be 
suggested that an optimum configuration was disrupted, which led to a number of 
variants having similar short-term fitness. Secondly, a reassortment event occurred in 
early to mid-2007 which led to a “resistance-adapted” HA clade becoming associated 
with a sensitive NA. This subclade lasted about a year but then failed. However, the 
long-term outcome of this set of alternative configurations cannot now be known as 
seasonal H1N1 was displaced by the appearance of pandemic H1N1 in 2009 and has 
not returned since (WHO, 2013). Nevertheless, the recurrent observation of 
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oseltamivir resistance in pandemic H1N1 (Ghedin et al., 2012; Storms et al., 2012; 
Hurt et al., 2012) show the importance of understanding the fitness interactions that 
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6 Thesis summary and discussion 
 
Influenza infections can be combated by two different strategies: vaccination and 
chemotherapy. The latter has been used for many decades because of the low price of 
anti-influenza drugs and limited vaccination effectiveness due to antigenic drifts and 
shifts that the influenza virus undergoes from year to year. However, viral resistance 
to both classes of anti-influenza drugs has emerged and spread widely (Lackenby et 
al., 2008). 
 
In my PhD thesis I have focused on the origin and mechanisms of amantadine 
resistance in swine influenza A viruses and oseltamivir resistance in human seasonal 
influenza A viruses as well as reassortment in swine influenza A viruses.  
 
My first research chapter focused on the quantification of reassortment in swine 
influenza viruses. Namely, reassortment is not only the mechanism for the 
emergence of novel influenza viruses (such as A/H1N1pan09) but also a mechanism 
for the acquisition and spread of drug resistant mutations in influenza viruses. As 
shown in the study by Simonsen et al (2007) the amantadine resistant A/H3N2 
viruses circulating in 2005-2006 influenza season were generated by reassortment 
and genetic drift. Also, the study by Yang et al (2011) found that the same 
mechanisms are responsible for the emergence of oseltamivir resistant A/H1N1 
viruses. Additionally, the amantadine resistant mutation S31N in M2 of A/H3N2 
viruses and oseltamivir resistant mutation H275Y (N1 numbering) in NA of A/H1N1 
were spread due to a hitch-hiking event (Simonsen et al., 2007; Yang et al, 2011). 
 
Because reassortment is a frequent event appearing in pigs, contributing both to 
novel influenza virus emergence as well as the spread of drug resistant mutations, my 
study focused on determining the extent of this event in pigs. There are some studies 
published that researched the extent of reassortment in swine influenza viruses, 
however, none of them was as extensive as my study. Nelson et al (2012) based their 
paper on coloured phylogenetic trees but did also heat-maps. Khiabanian et al (2009) 
also used heat-maps and Lycett et al (2012) used coloured phylogenetic trees and 
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GARD. My study also used coloured phylogenetic trees and GARD but not heat-
maps. In addition, my study used the distance in topology measure, which has not 
been described in published papers. The limitation of using coloured phylogenetic 
trees is that the trees usually represent only a few viral segments because of the large 
number of all possible trees. That was the case also in my study, where trees were 
coloured only according to one segment (MP). The results of my study support the 
results of previous studies. Namely, the segments most prone to reassortment are HA 
and NA that are reassorting most frequently with the polymerase segments. Pigs are 
considered to be mixing vessels for reassortment, where reassortment of viral 
segments from different hosts (swine, avian, human) can occur and spread to these 
hosts. Therefore, also established swine viral lineages contain segments from not 
only swine influenza viruses but also avian and human influenza viruses. The study 
by Furuse et al (2010) revealed the mutations in six internal segments of different 
hosts that appeared due to reassortment in order to break down the host barrier of the 
virus and enable its spread to new hosts. For swine host, Furuse et al (2010) looked 
for mutations in segments NP, MP and NS as these segments were retained in swine 
classical and swine triple reassortant lineages after reassortment. They found some 
mutations in all three of these segments and these mutations were similar to amino 
acids in avian and human host. These mutations probably appeared in order to 
accommodate avian PB2 and PA segments and human PB1 segment after 
reassortment (Furuse et al., 2010). My study also confirms that it is these three 
polymerase segments that are very prone to reassortment. 
 
My second research chapter focused on the amantadine resistance in swine flu. The 
first thing I noticed was a wide spread of amantadine resistance in pigs and second, 
the appearance of this resistance (in swine H1N1) even before amantadine was 
available and after it was no longer widely used. Third, by far the most prevalent 
mutation in all types and both hosts studied (swine, human) was the mutation S31N 
in M2. It has been mentioned before (Hay et al., 1985) that the site 31 in M2 includes 
only one mutation, while on other resistance-associated sites, the variability of 
mutations is greater. It was also noted that in human influenza A viruses the S31N 
mutation is closely linked to significant outbreaks or epidemics of human influenza 
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or shows the high selective pressure of amantadine because of its high usage 
(Cheung et al., 2006; Lee et al., 2008). In swine, however, I believe that is not the 
case because as mentioned above, resistance to this drug appeared before amantadine 
was available and persisted strongly even after its usage declined. Another set of 
studies propose the appearance of S31N mutation to be linked to the emergence of 
viruses from the same lineage (Simonsen et al., 2007; Krumbholz et al., 2009). 
However, again I do not agree with that because in my study as mentioned above, the 
S31N mutation was the most prevalent in different subtypes and different hosts. 
Some authors (Saito et al., 2003; Abed et al., 2005; Astrahan et al., 2004) try to 
justify the widespread appearance of the S31N mutation in M2 with its high degree 
of resistance to amantadine compared to the V27A mutation which renders the virus 
resistant but impairs the M2’s channel activity by 33% (Pinto et al., 1992). Other 
authors noted that the same mutation can have different impact on different M2 types 
(at different pH) (Balannik et al., 2010; Pinto et al., 1992; Holsinger et al., 1994). It 
is known that the S31N mutation causes impaired growth of the virus (Grambas et 
al., 1992) therefore it has been shown (Grambas et al., 1992) that other mutations in 
M2 (such as I27T and I27S) occur that cause an increase in M2 activity. However, in 
my study, those two mutations appeared rarely and were not always associated with 
the resistant S31N mutation. Taken together, majority of the studies focused only on 
the M2 ion channel but neglected other viral proteins. 
 
However, some studies (Grambas et al., 1992; Steinhauer et al., 1991; Ilyushina et 
al., 2007) noticed that along with mutations in M2, the amantadine also causes 
mutations in haemagglutinin protein. These studies showed that in some cases the 
mutated hæmeagglutinin that arose by the growth in the presence of amantadine, is 
sufficient to provide amantadine tolerance. My study went even further and checked 
the amino acid changes in not only M2 but also M1, HA and NA proteins that are 
associated with the serine to asparagines change at site 31 in M2. I noticed that there 
are several mutations in each of these proteins that coincide with the S31N mutation, 
with one mutation in each protein being strongly associated with the resistance-
conferring mutation in M2. I also show co-evolution of these amino acid sites in four 
different proteins. Considering that these four proteins come in a physical contact 
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inside a virion and that these physical interactions are important for virus’ 
physiology (McCown and Pekosz, 2006; Burleigh et al., 2005; Lakdawala et al., 
2011; Rossman and Lamb, 2011; Bilsel et al., 1993; Mitnaul et al., 1996; Chen et al., 
2005) my results indicate there are epistatic interactions among these four proteins 
which are responsible for their co-evolution. Due to hitch-hiking these mutations 
spread in the population, one of them being the amantadine resistance-conferring 
mutation S31N. So, the reason for the wide spread of this mutation lies in the 
benefits for the virus other than viability in the presence of amantadine (filamentous 
morphology of the virions associated with their capacity for efficient transmissibility, 
evading host’s immune response by changing epitopes in HA and NA). 
 
The third research chapter of my thesis studied the correlation of amino acid variants 
in HA with oseltamivir resistance encoded in NA. Namely, it is known that the 
functions of HA and NA are balanced (Bantia et al., 1998; Blick et al., 1998; 
McKimm-Breschkin et al., 1996) therefore if the function of one of these two 
glycoproteins is decreased the other glycoprotein will also acquire mutations that 
decrease its function to enable the virus to still be infectious. One of the reasons for 
lower activity of NA is chemotherapy with neuraminidase inhibitors such as 
oseltamivir which binds in the active site of NA enzyme and prevents the NA from 
cleaving sialic acid residues (Moscona, 2005). The consequence is the inhibition of 
release of newly formed virions from infected cells (Liu et al., 1995), viral 
aggregation on the cell surface (Liu et al., 1995) and reduced viral infectivity (Suzuki 
et al., 2005; Matrosovich et al., 2004). Oseltamivir was first available in 1999 and 
until 2007-2008 influenza season it was very efficient in combating influenza 
infections. However, in 2007-2008 influenza season the oseltamivir resistance-
conferring mutation H274Y (N2 numbering) appeared worldwide in seasonal H1N1 
(Moscona, 2009) and within a year it was present in most seasonal H1N1 (Moscona, 
2009). The H274Y mutation is found near but not directly in the substrate-binding 
pocket (Russell et al., 2006) and causes structural alterations of the NA that weaken 
oseltamivir binding (Russell et al., 2006; Collins et al., 2008) but has also a negative 
effect on viral growth and is therefore quickly replaced with a wild type NA in the 
absence of the drug. However, the resistant NA from 2007-2008 influenza season 
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showed no obvious attenuation relative to earlier viruses carrying tyrosine at position 
274 (Rameix-Welti et al., 2008). This feature sparkled interest of scientific 
community that tried to find the mechanism(s) responsible for that. For example, 
Bloom et al (2010) hypothesized that the evolution of oseltamivir resistance was 
enabled by permissive mutations that alleviated the deleterious effects of subsequent 
occurrences of H274Y. They also further hypothesized that these permissive 
mutations obliterated previously unobserved deficiencies in NA folding or stability 
caused by H274Y (Bloom et al., 2010). Using a computational method (Bloom and 
Glassman, 2009), Bloom et al (2010) found the mutation R194G to restore the total 
surface-expressed activity of NA with H274Y to approximately wild-type levels. 
They also found two further mutations, R222Q and V234M, to decrease the 
magnitude of the defect caused by H274Y. However, Bloom et al (2010) did not 
elucidate the mechanism(s) responsible for the spread of these mutations in seasonal 
H1N1. They speculated that the permissive mutations could be the result of a drift, 
genetic hitchhiking (Simonsen et al., 2007), selection for antigenic change or 
balancing the NA/HA functions (Wagner et al., 2002). Unlike the study by Bloom et 
al (2010), my study focused on the HA and its mutations that followed the H274Y 
acquisition. Using two machine learning methods, we found several mutations in HA 
that appeared as the consequence of influenza virus acquiring the resistant NA. We 
concluded that these mutations were due to epistatic interactions between NA and 
HA and enhanced viral fitness. However, my study lacked to identify the 
substitutions in NA that might have also been associated with the appearance of 
H274Y and this is something that remains to be done as future work. On the other 
hand, Kryazhimskiy et al (2011) identified 225 pairs of sites in H1 and 205 in N1 of 
seasonal H1N1 that were epistatically linked. For N1 NA, the two leading sites were 
344 and 275 (N1 numbering). Site 275 was associated with six other mutations that 
most likely enhance the fitness of the virus with H274Y mutation and therefore 
enable the virus to survive. So, the appearance of the resistance-conferring mutation 
in N1 is either predating or following other mutations in the same gene as also 
described by Bloom et al (2010). 
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When analysing influenza sequence data, it is imperative to search for sequence data 
from and/or upload sequence data to the appropriate database. One of the most 
important databases for influenza is GenBank, which plays a vital role in sharing and 
archiving influenza virus sequences (Schnirring, 2009). Another pivotal sequence 
repository of genetic data for influenza is GISAID’s EpiFlu database, established in 
2006, which provides a more complete picture of the influenza data because it 
includes some previously unpublished sequences and also because it permits 
scientists to submit extra information, such as clinical features and viral passage 
history. The advantage of using this database is also in the availability of sequences 
immediately after their submission (Schnirring, 2009). 
 
The global spread of some drug resistant influenza strains, such as now extinct 
human seasonal H1N1 resistant to oseltamivir, and swine influenza circulating in 
Eurasia resistant to amantadine, as well as the pandemic H1N1 2009 infecting 
humans, has stressed the importance of fast, inexpensive and accurate sequencing 
methods for creating a broader array of sequences available. Apart from increasing 
the number of influenza strains sequenced it is also important to sequence the whole 
viral genome, not just heamagglutinin and neuraminidase segments as was the case 
years ago. Having whole influenza genomes available facilitates better understanding 
of the evolution of influenza A viruses in humans as well as other hosts, which is 
important for the surveillance of this important pathogen and also for selecting the 
appropriate influenza vaccine strain (Holmes et al., 2005).  
 
Because multiple influenza lineages can co-circulate, persist and reassort to cause 
epidemics and occasional pandemics it is very important to obtain full genomic data 
of this viruses for future influenza surveillance (Holmes et al., 2005). 
 
The influenza surveillance is crucial in order to be able to predict the emergence of 
new circulating influenza strains for developing influenza vaccine on an annual basis 
(Gensheimer et al., 1999). Today, the global influenza surveillance network is 
coordinated by the World Health Organization, which every year selects the 
appropriate strains of influenza A and B viruses for the production of vaccine for the 
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northern and southern hemispheres. For making the best recommendation on 
candidate vaccine strains, antigenic, genetic and epidemiological data are examined 
(Holmes et al., 2005) which again underlies the importance of maintaining sequence 
databases and their extent regarding the amount of information available for each 
strain. 
 
Because the number of influenza virus sequences in the past was small and the 
genetic information usually available just for HA and NA segments, it is unclear how 
the entire genome of influenza A viruses evolves during epidemics. Sequencing of 
influenza A virus genome was in the past limited to HA and NA segments only 
because it was known that antigenic drift of these two proteins is vital for the 
survival of influenza viruses (Colman et al., 1983). Today we know that other factors 
such as binding specificity of HA (Nobusawa et al., 2000), matched activity between 
HA and NA (Kaverin et al., 2000; Mitnaul et al., 2000; Wagner et al., 2002) and the 
interaction of other influenza virus’ proteins with each other and with the proteins of 
their host cells are also affecting viral fitness (Holmes et al., 2005). Because of this 
lack of molecular data for segments other than HA and NA, it is also unclear how 
many lineages of influenza A viruses are circulating between epidemics (Holmes et 
al., 2005). Due to lack of molecular data it was also believed that influenza genetic 
diversity is more restricted and due only to genetic drift. However, with the 
accumulation of whole genome sequences of influenza viruses from different 
geographical locations, it became clear that reassortment is a very important event 
that has the potential to cause sudden and significant changes to viral antigenic 
structure (Holmes et al., 2005). Therefore, collecting whole genome sequences from 
different geographic locations is very important for understanding the mechanisms of 
viral evolution and its rates, for understanding the pathogenesis and transmission 
patterns of influenza viruses between humans and animals and for planning 
surveillance and control measures (Holmes et al., 2005). 
 
For surveillance purposes a list of notifiable diseases of humans and animals, 
separately, has been set at the national level and renewed annually. Notifiable disease 
is considered one which has to be reported in a timely manner in order to prevent and 
                                                                                            6: Thesis summary and discussion 
190 
 
control the disease and therefore protect the public’s health. Influenza infections are 
considered a notifiable disease of both, humans and animals. For humans, deaths due 
to influenza infection and infections with a novel influenza A virus have to be 
reported. For animals, infection of birds with highly pathogenic avian influenza virus 
has to be reported as well as an infection of humans with swine influenza viruses 
(CDC, 2012; Gov.UK, 2014). 
 
Swine influenza A viruses that infect swine do not normally infect humans and 
human influenza A viruses that infect humans do not normally infect pigs. However, 
sporadic infections of humans with swine influenza viruses and infections of pigs 
with human influenza viruses have been reported. Transmission of swine influenza 
viruses from human to human and transmission of human influenza viruses from pig 
to pig are rare but do occur (CDC, 2014). As pigs are considered to be a mixing 
vessel for generating novel influenza strains due to reassortment, these transmissions 
of influenza viruses from pigs to humans and vice versa as well as the capability of 
pigs to be equally susceptible to infection with not only pig and human influenza 
viruses but also avian influenza viruses, open a biosecurity issue for the health of 
humans and animals. Namely, novel influenza strains unseen before can be generated 
and spread in the susceptible hosts but they can also be drug resistant due to 
reassortment which included a resistant virus.  
 
So, my thesis which studied the mechanisms responsible for influenza virus’ drug 
resistance and spread is relevant for understanding how to better protect human 
health in terms of a reasonable drug usage but can also be applied to vaccination of 
both, humans and pigs. It also underlies the importance of influenza surveillance in 
humans, pigs and birds in order to detect early the occurrence of novel influenza 
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8.1 Appendix A 
 
 
Figure A 1 
The MCC tree of NA for swine H1N1, coloured according to two clades in MP. 











Figure A 2 
The MCC tree of NP for swine H1N1, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 
 




Figure A 3 
The MCC tree of NS for swine H1N1, coloured according to two clades in MP. 





Figure A 4 
The MCC tree of PA for swine H1N1, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 





Figure A 5 
The MCC tree of PB2 for swine H1N1, coloured according to two clades in MP. 




Figure A 6 
The MCC tree of NA for swine H1N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 





Figure A 7 
The MCC tree of NP for swine H1N2, coloured according to two clades in MP. 




Figure A 8 
The MCC tree of NS for swine H1N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 




Figure A 9 
The MCC tree of PA for swine H1N2, coloured according to two clades in MP. 





Figure A 10 
The MCC tree of PB2 for swine H1N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 




Figure A 11 
The MCC tree of NA for swine H3N2, coloured according to two clades in MP. 





Figure A 12 
The MCC tree of NP for swine H3N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 





Figure A 13 
The MCC tree of NS for swine H3N2, coloured according to two clades in MP. 




Figure A 14 
The MCC tree of PA for swine H3N2, coloured according to two clades in MP. 
Departures of colour pattern of this tree compared to the MP tree indicate 
reassortment. 





Figure A 15 
The MCC tree of PB2 for swine H3N2, coloured according to two clades in MP. 
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8.2 Appendix B 
 
Table B 1 
Distance in topology scores for swine H1N1 using dist.topo (PH85). 
Segment PB2 PB1 PA HA NP NA MP NS 
PB2 372.9 710.2 689.6 734.1 729.6 760.0 783.8 777.2 
PB1  366.5 728.9 773.3 753.7 780.3 798.3 800.8 
PA   401.5 752.7 733.6 761.1 787.7 789.8 
HA    374.9 757.6 710.8 786.0 783.3 
NP     444.3 767.4 806.2 794.5 
NA      393.0 804.8 787.2 
MP       551.2 824.7 
NS        516.9 
random 1007.6 1007.6 1007.6 1007.6 1007.6 1007.6 1007.6 1007.6 
 
Table B 2 
Distance in topology scores for swine H1N2 using dist.topo (PH85). 
Segment PB2 PB1 PA HA NP NA MP NS 
PB2 54.42 130.85 130.13 183.24 148.17 170.14 157.31 166.13 
PB1  51.88 130.72 174.85 146.49 167.92 158.72 164.66 
PA   51.68 176.43 149.22 164.23 164.66 170.95 
HA    66.46 182.91 157.84 180.62 184.27 
NP     66.60 174.35 168.06 171.64 
NA      69.15 177.01 174.08 
MP       78.61 173.35 
NS        75.67 
random 223.46 223.46 223.46 223.55 223.46 223.46 223.46 223.46 
 
Table B 3 
Distance in topology scores for swine H3N2 using dist.topo (PH85). 
Segment PB2 PB1 PA HA NP NA MP NS 
PB2 174.5 346.8 332.3 359.9 360.5 363.8 376.0 361.4 
PB1  177.0 328.7 358.0 371.1 362.0 384.0 369.3 
PA   176.8 356.4 359.3 360.0 374.2 361.3 
HA    159.3 375.6 326.8 354.9 380.3 
NP     198.6 380.2 389.2 374.3 
NA      194.0 370.0 378.4 
MP       231.3 375.2 
NS        225.4 
random 445.5 445.5 445.5 445.5 445.5 445.5 445.5 445.5 
 




Figure B 1 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. HA 
compared to all other segments. 
 
 
Figure B 2 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. MP 
compared to all other segments. 




Figure B 3 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. NA 
compared to all other segments. 
 
Figure B 4 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. NP 
compared to all other segments. 




Figure B 5 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. NS 
compared to all other segments. 
Figure B 6 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. PA 
compared to all other segments. 
 




Figure B 7 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. PB1 
compared to all other segments. 
 
 
Figure B 8 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. PB2 
compared to all other segments. 




Figure B 9 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. HA 
compared to all other segments. 
 
 
Figure B 10 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. MP 
compared to all other segments. 




Figure B 11 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. NA 
compared to all other segments. 
 
 
Figure B 12 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. NP 
compared to all other segments. 




Figure B 13 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. NS 
compared to all other segments. 
 
Figure B 14 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. PA 
compared to all other segments. 




Figure B 15 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. PB1 
compared to all other segments. 
 
Figure B 16 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. PB2 
compared to all other segments. 




Figure B 17 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. HA 
compared to all other segments. 
 
Figure B 18 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. MP 
compared to all other segments. 




Figure B 19 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. NA 
compared to all other segments. 
 
Figure B 20 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. NP 
compared to all other segments. 




Figure B 21 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. NS 
compared to all other segments. 
 
Figure B 22 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. PA 
compared to all other segments. 




Figure B 23 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. PB1 
compared to all other segments. 
 
Figure B 24 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. PB2 
compared to all other segments. 




Figure B 25 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. HA 
compared to all other segments. The values are normalised to the value of HA. 
 
Figure B 26 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. MP 
compared to all other segments. The values are normalised to the value of MP. 




Figure B 27 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. NA 
compared to all other segments. The values are normalised to the value of NA. 
 
Figure B 28 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. NP 
compared to all other segments. The values are normalised to the value of NP. 




Figure B 29 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. NS 
compared to all other segments. The values are normalised to the value of NS. 
 
Figure B 30 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. PA 
compared to all other segments. The values are normalised to the value of PA. 




Figure B 31 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. PB1 
compared to all other segments. The values are normalised to the value of PB1. 
 
Figure B 32 
Mean distance in topology for 2 sets of swine H1N1 BEAST trees compared. PB2 
compared to all other segments. The values are normalised to the value of PB2. 




Figure B 33 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. HA 
compared to all other segments. The values are normalised to the value of HA. 
 
Figure B 34 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. MP 
compared to all other segments. The values are normalised to the value of MP. 




Figure B 35 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. NA 
compared to all other segments. The values are normalised to the value of NA. 
 
Figure B 36 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. NP 
compared to all other segments. The values are normalised to the value of NP. 




Figure B 37 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. NS 
compared to all other segments. The values are normalised to the value of NS. 
 
Figure B 38 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. PA 
compared to all other segments. The values are normalised to the value of PA. 




Figure B 39 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. PB1 
compared to all other segments. The values are normalised to the value of PB1. 
 
Figure B 40 
Mean distance in topology for 2 sets of swine H1N2 BEAST trees compared. PB2 
compared to all other segments. The values are normalised to the value of PB2. 




Figure B 41 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. HA 
compared to all other segments. The values are normalised to the value of HA. 
 
Figure B 42 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. MP 
compared to all other segments. The values are normalised to the value of MP. 




Figure B 43 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. NA 
compared to all other segments. The values are normalised to the value of NA. 
 
Figure B 44 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. NP 
compared to all other segments. The values are normalised to the value of NP. 




Figure B 45 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. NS 
compared to all other segments. The values are normalised to the value of NS. 
 
Figure B 46 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. PA 
compared to all other segments. The values are normalised to the value of PA. 




Figure B 47 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. PB1 
compared to all other segments. The values are normalised to the value of PB1. 
 
Figure B 48 
Mean distance in topology for 2 sets of swine H3N2 BEAST trees compared. PB2 
compared to all other segments. The values are normalised to the value of PB2. 




Figure B 49 
Distance in topology for swine H1N1 HA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 50 
Distance in topology for swine H1N1 NA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
















Figure B 51 
Distance in topology for swine H1N1 NP if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 52 
Distance in topology for swine H1N1 NS if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 















Figure B 53 
Distance in topology for swine H1N1 PA if tips are randomized. The percentage of 













Figure B 54 
Distance in topology for swine H1N1 PB1 if tips are randomized.  The percentage of 
randomized tips is an approximation for reassortment. 















Figure B 55 
Distance in topology for swine H1N1 PB2 if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 56 
Distance in topology for swine H1N2 HA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 




Figure B 57 
Distance in topology for swine H1N2 NA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 58 
Distance in topology for swine H1N2 NP if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 




Figure B 59 
Distance in topology for swine H1N2 NS if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 60 
Distance in topology for swine H1N2 PA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 




Figure B 61 
Distance in topology for swine H1N2 PB1 if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 62 
Distance in topology for swine H1N2 PB2 if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 




Figure B 63 
Distance in topology for swine H3N2 HA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 64 
Distance in topology for swine H3N2 NA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 




Figure B 65 
Distance in topology for swine H3N2 NP if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 66 
Distance in topology for swine H3N2 NS if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 




Figure B 67 
Distance in topology for swine H3N2 PA if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Figure B 68 
Distance in topology for swine H3N2 PB1 if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 




Figure B 69 
Distance in topology for swine H3N2 PB2 if tips are randomized. The percentage of 
randomized tips is an approximation for reassortment. 
 
Table B 4 
Values from the Wilcoxon test for HA H1N1 pairs. 
W HA-HA HA-MP HA-NA HA-NP HA-NS HA-PA HA-PB1 HA-PB2 
HA-
HA 
405000 0 0 0 0 0 0 0 
HA-
MP 
810000 405000 29189.5 25010.5 167858.5 4378 1135 14036.5 
HA-
NA 
810000 780810.5 405000 419967 699967 135416.5 13012.5 99730 
HA-
NP 
810000 784989.5 390033 405000 699866 120562 14035 91117 
HA-
NS 
810000 642141.5 110033 110134 405000 17918.5 2380.5 28193.5 
HA-
PA 





810000 808865 796987.5 795965 807619.5 759066.5 405000 717426 
HA-
PB2 
810000 795963.5 710270 718883 781806.5 505666.5 92574 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 5 
Values from the Wilcoxon test for MP H1N1 pairs. 
W MP-HA MP-MP MP-NA MP-NP MP-NS MP-PA MP-PB1 MP-PB2 
MP-
HA 
405000 810000 374520 715369.5 800054.5 615784 213516 411706 
MP-
MP 
0 405000 0 0 0 0 0 0 
MP-
NA 





94630.5 810000 67075.5 405000 731708.5 222168 24120.5 99283 
MP-
NS 
9945.5 810000 2912 78291.5 405000 22912.5 277 8681.5 
MP-
PA 
194216 810000 159180.5 587832 787087.5 405000 63217 207179 
MP-
PB1 
596484 810000 574635.5 785879.5 809723 746783 405000 594096 
MP-
PB2 
398294 810000 367814.5 710717 801318.5 602821 215904 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 6 
Values from the Wilcoxon test for NA H1N1 pairs. 
W NA-HA NA-MP NA-NA NA-NP NA-NS NA-PA NA-PB1 NA-PB2 
NA-
HA 
405000 780768 810000 484557.5 751082.5 184474 14071.5 61208 
NA-
MP 
29232 405000 810000 27050.5 283732.5 1157 1 2613.5 
NA-
NA 
0 0 405000 0 0 0 0 0 
NA-
NP 
325442.5 782949.5 810000 405000 742350.5 112924.5 7860 34673 
NA-
NS 
58917.5 526267.5 810000 67649.5 405000 5477 35 4444 
NA-
PA 
625526 808843 810000 697075.5 804523 405000 39507.5 163835 
NA-
PB1 
795928.5 809999 810000 802140 809965 770492.5 405000 634230 
NA-
PB2 
748792 807386.5 810000 775327 805556 646165 175770 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 7 
Values from the Wilcoxon test for NP H1N1 pairs. 
W NP-HA NP-MP NP-NA NP-NP NP-NS NP-PA NP-PB1 NP-PB2 
NP-
HA 
405000 804404.5 472328.5 810000 797992.5 747600 368906 635246.5 
NP-
MP 
5595.5 405000 4123.5 810000 243366.5 36560 3019.5 13572.5 
NP-
NA 
337671.5 805876.5 405000 810000 799397.5 736927.5 295353.5 595637.5 
NP-
NP 
0 0 0 405000 0 0 0 0 
NP-
NS 
12007.5 566633.5 10602.5 810000 405000 101492.5 6441 35800.5 
NP-
PA 
62400 773440 73072.5 810000 708507.5 405000 40728.5 198374.5 
NP-
PB1 
441094 806980.5 514646.5 810000 803559 769271.5 405000 672882 
NP-
PB2 
174753.5 796427.5 214362.5 810000 774199.5 611625.5 137118 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 8 
Values from the Wilcoxon test for NS H1N1 pairs. 
W NS-HA NS-MP NS-NA NS-NP NS-NS NS-PA NS-PB1 NS-PB2 
NS-
HA 
405000 806872 519656.5 738592.5 810000 559944.5 186958.5 443634.5 
NS-
MP 
3128 405000 1295 34118.5 810000 1548 4 2438 
NS-
NA 
290343.5 808705 405000 702774 810000 451155.5 101967 329276.5 
NS-
NP 
71407.5 775881.5 107226 405000 810000 135144.5 13777.5 84565 
NS-
NS 
0 0 0 0 405000 0 0 0 
NS-
PA 
250055.5 808452 358844.5 674855.5 810000 405000 78680 287444.5 
NS-
PB1 
623041.5 809996 708033 796222.5 810000 731320 405000 652273.5 
NS-
PB2 
366365.5 807562 480723.5 725435 810000 522555.5 157726.5 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 9 
Values from the Wilcoxon test for PA H1N1 pairs. 
W PA-HA PA-MP PA-NA PA-NP PA-NS PA-PA PA-PB1 PA-PB2 
PA-
HA 
405000 809543.5 491001 796919.5 805355 810000 564271 781449 
PA-
MP 
456.5 405000 104 89114.5 124054 810000 278 28503.5 
PA-
NA 
318999 809896 405000 797143 806632 810000 480844 772871 
PA-
NP 










0 0 0 0 0 405000 0 0 
PA-
PB1 





28551 781496.5 37129 600286.5 639689.5 810000 54452.5 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 10 
Values from the Wilcoxon test for PB1 H1N1 pairs. 






405000 809780 519265 796765 807379.5 790507 810000 773969.5 
PB1-
MP 
220 405000 192.5 37701.5 113215.5 10664 810000 12675.5 
PB1-
NA 
290735 809807.5 405000 797193.5 808550.5 785489.5 810000 758131 
PB1-
NP 
13235 772298.5 12806.5 405000 585896 235471.5 810000 171169 
PB1-
NS 
2620.5 696784.5 1449.5 224104 405000 101617 810000 72959.5 
PB1-
PA 
19493 799336 24510.5 574528.5 708383 405000 810000 311334 
PB1-
PB1 
0 0 0 0 0 0 405000 0 
PB1-
PB2 
36030.5 797324.5 51869 638831 737040.5 498666 810000 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 11 
Values from the Wilcoxon test for PB2 H1N1 pairs. 





405000 797148.5 339177.5 768698.5 786636.5 775099.5 566041 810000 
PB2-
MP 
12851.5 405000 3115.5 100718 202488.5 108383.5 5429 810000 
PB2-
NA 
470822.5 806884.5 405000 790670 803196.5 796939.5 626451.5 810000 
PB2-
NP 
41301.5 709282 19330 405000 545306 414784 49257 810000 
PB2-
NS 
23363.5 607511.5 6803.5 264694 405000 275589 19019 810000 
PB2-
PA 
34900.5 701616.5 13060.5 395216 534411 405000 42948.5 810000 
PB2-
PB1 
243959 804571 183548.5 760743 790981 767051.5 405000 810000 
PB2-
PB2 
0 0 0 0 0 0 0 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 12 
Values from the Wilcoxon test for HA H1N2 pairs. 
W HA-HA HA-MP HA-NA HA-NP HA-NS HA-PA HA-PB1 HA-PB2 
HA-
HA 
405000 0 0 0 0 0 0 0 
HA-
MP 
810000 405000 608813.5 114538.5 262773.5 24809 36152 19359 
HA-
NA 
810000 201186.5 405000 35890.5 108092 5730 9433 4354.5 
HA-
NP 
810000 695461.5 774109.5 405000 600058.5 161251 193211.5 130605 
HA-
NS 
810000 547226.5 701908 209941.5 405000 55036.5 75251.5 43806.5 
HA-
PA 
810000 785191 804270 648749 754963.5 405000 435521 354484 
HA-
PB1 
810000 773848 800567 616788.5 734748.5 374479 405000 327217 
HA-
PB2 
810000 790641 805645.5 679395 766193.5 455516 482783 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 13 
Values from the Wilcoxon test for MP H1N2 pairs. 
W MP-HA MP-MP MP-NA MP-NP MP-NS MP-PA MP-PB1 MP-PB2 
MP-
HA 
405000 810000 530751 631942 706201 352604 477231.5 564131 
MP-
MP 
0 405000 0 0 0 0 0 0 
MP-
NA 
279249 810000 405000 520487.5 612364 238922.5 356652 448516 
MP-
NP 
178058 810000 289512.5 405000 506448.5 151165 251731 338020.5 
MP-
NS 
103799 810000 197636 303551.5 405000 87929.5 169404.5 245989.5 
MP-
PA 
457396 810000 571077.5 658835 722070.5 405000 520632 598159 
MP-
PB1 
332768.5 810000 453348 558269 640595.5 289368 405000 490862 
MP-
PB2 
245869 810000 361484 471979.5 564010.5 211841 319138 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 14 
Values from the Wilcoxon test for NA H1N2 pairs. 
W NA-HA NA-MP NA-NA NA-NP NA-NS NA-PA NA-PB1 NA-PB2 
NA-
HA 
405000 314011.5 810000 137194.5 306723.5 57651 40826.5 46692.5 
NA-
MP 
495988.5 405000 810000 196662.5 397253.5 88188.5 63651 73332.5 
NA-
NA 
0 0 405000 0 0 0 0 0 
NA-
NP 
672805.5 613337.5 810000 405000 605778 240263 192882 211710 
NA-
NS 
503276.5 412746.5 810000 204222 405000 95092 69784 79352.5 
NA-
PA 
752349 721811.5 810000 569737 714908 405000 345658 369469 
NA-
PB1 
769173.5 746349 810000 617118 740216 464342 405000 427877 
NA-
PB2 
763307.5 736667.5 810000 598290 730647.5 440531 382123 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 15 
Values from the Wilcoxon test for NP H1N2 pairs. 
W NP-HA NP-MP NP-NA NP-NP NP-NS NP-PA NP-PB1 NP-PB2 
NP-
HA 
405000 780973 613237.5 810000 744064 651213.5 684687 708358 
NP-
MP 
29027 405000 119654 810000 270118.5 161704 214693.5 236191.5 
NP-
NA 
196762.5 690346 405000 810000 599248 461351 516450 547918 
NP-
NP 
0 0 0 405000 0 0 0 0 
NP-
NS 
65936 539881.5 210752 810000 405000 265921.5 328041 356785.5 
NP-
PA 
158786.5 648296 348649 810000 544078.5 405000 462215 493231.5 
NP-
PB1 
125313 595306.5 293550 810000 481959 347785 405000 434482.5 
NP-
PB2 
101642 573808.5 262082 810000 453214.5 316768.5 375517.5 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 16 
Values from the Wilcoxon test for NS H1N2 pairs. 
W NS-HA NS-MP NS-NA NS-NP NS-NS NS-PA NS-PB1 NS-PB2 
NS-
HA 
405000 764627.5 640819 636385.5 810000 290162 417945 460257 
NS-
MP 
45372.5 405000 190408 176664 810000 22749.5 61378 72418 
NS-
NA 
169181 619592 405000 392348 810000 104056 192340.5 220492.5 
NS-
NP 
173614.5 633336 417652 405000 810000 106110.5 197578 227063.5 
NS-
NS 
0 0 0 0 405000 0 0 0 
NS-
PA 
519838 787250.5 705944 703889.5 810000 405000 524924.5 561665.5 
NS-
PB1 
392055 748622 617659.5 612422 810000 285075.5 405000 443936 
NS-
PB2 
349743 737582 589507.5 582936.5 810000 248334.5 366064 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
                                                                                                                          8.2: Appendix B 
302 
 
Table B 17 
Values from the Wilcoxon test for PA H1N2 pairs. 
W PA-HA PA-MP PA-NA PA-NP PA-NS PA-PA PA-PB1 PA-PB2 
PA-
HA 
405000 770536.5 657342.5 765965.5 694328 810000 751668.5 774678.5 
PA-
MP 
39463.5 405000 198640 413679.5 220998 810000 410090.5 495057.5 
PA-
NA 
152657.5 611360 405000 610986.5 444882.5 810000 598036 658938 
PA-
NP 
44034.5 396320.5 199013.5 405000 220459 810000 402155.5 486065 
PA-
NS 
115672 589002 365117.5 589541 405000 810000 575988.5 643336 
PA-
PA 
0 0 0 0 0 405000 0 0 
PA-
PB1 
58331.5 399909.5 211964 407844.5 234011.5 810000 405000 483117.5 
PA-
PB2 
35321.5 314942.5 151062 323935 166664 810000 326882.5 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 18 
Values from the Wilcoxon test for PB1 H1N2 pairs. 






405000 782380 577643 763947 728154 736567.5 810000 758407 
PB1-
MP 
27620 405000 92872.5 359238 231240.5 303847.5 810000 372895 
PB1-
NA 
232357 717127.5 405000 683601.5 603780.5 638391 810000 680460.5 
PB1-
NP 
46053 450762 126398.5 405000 278441 348660.5 810000 416191 
PB1-
NS 
81846 578759.5 206219.5 531559 405000 470953 810000 534966 
PB1-
PA 
73432.5 506152.5 171609 461339.5 339047 405000 810000 469208.5 
PB1-
PB1 
0 0 0 0 0 0 405000 0 
PB1-
PB2 
51593 437105 129539.5 393809 275034 340791.5 810000 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 19 
Values from the Wilcoxon test for PB2 H1N2 pairs. 





405000 801383.5 655709.5 790615.5 767339 781361 777314.5 810000 
PB2-
MP 
8616.5 405000 67675 303040 188558 305548.5 295664 810000 
PB2-
NA 
154290.5 742325 405000 693656 612661 678569.5 667171 810000 
PB2-
NP 
19384.5 506960 116344 405000 279098 402660.5 388745 810000 
PB2-
NS 
42661 621442 197339 530902 405000 521028.5 504236 810000 
PB2-
PA 
28639 504451.5 131430.5 407339.5 288971.5 405000 392644.5 810000 
PB2-
PB1 
32685.5 514336 142829 421255 305764 417355.5 405000 810000 
PB2-
PB2 
0 0 0 0 0 0 0 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 20 
Values from the Wilcoxon test for HA H3N2 pairs. 
W HA-HA HA-MP HA-NA HA-NP HA-NS HA-PA HA-PB1 HA-PB2 
HA-
HA 
405000 0 0 0 0 0 0 0 
HA-
MP 
810000 405000 310591 2817 46173 2542 1413.5 1004 
HA-
NA 
810000 499409 405000 13555 101772 10913.5 7870 5859.5 
HA-
NP 
810000 807183 796445 405000 706183 344237.5 319336.5 260590 
HA-
NS 
810000 763827 708228 103817 405000 84676.5 69049.5 51773.5 
HA-
PA 
810000 807458 799086.5 465762.5 725323.5 405000 384362.5 321752 
HA-
PB1 
810000 808586.5 802130 490663.5 740950.5 425637.5 405000 338847 
HA-
PB2 
810000 808996 804140.5 549410 758226.5 488248 471153 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 21 
Values from the Wilcoxon test for MP H3N2 pairs. 
W MP-HA MP-MP MP-NA MP-NP MP-NS MP-PA MP-PB1 MP-PB2 
MP-
HA 
405000 810000 645103.5 424210 790235 343707.5 206090 286545 
MP-
MP 
0 405000 0 0 0 0 0 0 
MP-
NA 
164896.5 810000 405000 168493 708743.5 118496.5 50684 87587 
MP-
NP 
385790 810000 641507 405000 791639 318526.5 179926 260314 
MP-
NS 
19765 810000 101256.5 18361 405000 11863 2110.5 6323.5 
MP-
PA 
466292.5 810000 691503.5 491473.5 798137 405000 247009.5 341619.5 
MP-
PB1 
603910 810000 759316 630074 807889.5 562990.5 405000 502635 
MP-
PB2 
523455 810000 722413 549686 803676.5 468380.5 307365 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 22 
Values from the Wilcoxon test for NA H3N2 pairs. 
W NA-HA NA-MP NA-NA NA-NP NA-NS NA-PA NA-PB1 NA-PB2 
NA-
HA 
405000 696871.5 810000 170563.5 540447.5 170915 144969.5 113089 
NA-
MP 
113128.5 405000 810000 15577 196412.5 21117 12545.5 9376.5 
NA-
NA 
0 0 405000 0 0 0 0 0 
NA-
NP 
639436.5 794423 810000 405000 738205.5 385921 361565 296038 
NA-
NS 
269552.5 613587.5 810000 71794.5 405000 78865.5 57888 43743.5 
NA-
PA 
639085 788883 810000 424079 731134.5 405000 380684.5 317000 
NA-
PB1 
665030.5 797454.5 810000 448435 752112 429315.5 405000 336961.5 
NA-
PB2 
696911 800623.5 810000 513962 766256.5 493000 473038.5 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 23 
Values from the Wilcoxon test for NP H3N2 pairs. 
W NP-HA NP-MP NP-NA NP-NP NP-NS NP-PA NP-PB1 NP-PB2 
NP-
HA 
405000 808960 757470.5 810000 809574.5 768756.5 707629.5 755651.5 
NP-
MP 
1040 405000 70736.5 810000 564784 118575.5 29306.5 84217 
NP-
NA 
52529.5 739263.5 405000 810000 781081.5 471111.5 283034.5 418447.5 
NP-
NP 
0 0 0 405000 0 0 0 0 
NP-
NS 
425.5 245216 28918.5 810000 405000 57244.5 11754 38376.5 
NP-
PA 
41243.5 691424.5 338888.5 810000 752755.5 405000 221446.5 352670 
NP-
PB1 
102370.5 780693.5 526965.5 810000 798246 588553.5 405000 543010.5 
NP-
PB2 
54348.5 725783 391552.5 810000 771623.5 457330 266989.5 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 24 
Values from the Wilcoxon test for NS H3N2 pairs. 
W NS-HA NS-MP NS-NA NS-NP NS-NS NS-PA NS-PB1 NS-PB2 
NS-
HA 
405000 809895.5 773793.5 797313.5 810000 780434 751906.5 770093.5 
NS-
MP 
104.5 405000 24572 61318 810000 31154 10939 28809 
NS-
NA 
36206.5 785428 405000 533696 810000 429716 296704 391008.5 
NS-
NP 
12686.5 748682 276304 405000 810000 299120.5 181923 266007.5 
NS-
NS 
0 0 0 0 405000 0 0 0 
NS-
PA 
29566 778846 380284 510879.5 810000 405000 270837.5 366295.5 
NS-
PB1 
58093.5 799061 513296 628077 810000 539162.5 405000 500294 
NS-
PB2 
39906.5 781191 418991.5 543992.5 810000 443704.5 309706 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 25 
Values from the Wilcoxon test for PA H3N2 pairs. 
W PA-HA PA-MP PA-NA PA-NP PA-NS PA-PA PA-PB1 PA-PB2 
PA-
HA 
405000 807484 757793 775772 808603.5 810000 802296 788763.5 
PA-
MP 
2516 405000 121374 166376.5 539463 810000 328170.5 232396.5 
PA-
NA 
52207 688626 405000 474484 738728 810000 631373.5 541146 
PA-
NP 
34228 643623.5 335516 405000 710458 810000 576455 476024 
PA-
NS 
1396.5 270537 71272 99542 405000 810000 213038 145253 
PA-
PA 
0 0 0 0 0 405000 0 0 
PA-
PB1 
7704 481829.5 178626.5 233545 596962 810000 405000 302633 
PA-
PB2 
21236.5 577603.5 268854 333976 664747 810000 507367 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 26 
Values from the Wilcoxon test for PB1 H3N2 pairs. 






405000 808693 766160.5 746432.5 808751 805033 810000 740142 
PB1-
MP 
1307 405000 93568 54453.5 403970 328170.5 810000 66275 
PB1-
NA 
43839.5 716432 405000 318963 709850 660397.5 810000 338057.5 
PB1-
NP 
63567.5 755546.5 491037 405000 752324 713084 810000 413745 
PB1-
NS 
1249 406030 100150 57676 405000 332490 810000 70353 
PB1-
PA 
4967 481829.5 149602.5 96916 477510 405000 810000 109873 
PB1-
PB1 
0 0 0 0 0 0 405000 0 
PB1-
PB2 
69858 743725 471942.5 396255 739647 700127 810000 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 27 









405000 807678 755427 784131 809129.5 798920 757066 810000 
PB2-
MP 
2322 405000 101211 171127.5 563667 286461 96901 810000 
PB2-
NA 
54573 708789 405000 516677.5 762288.5 617867.5 404896 810000 
PB2-
NP 
25869 638872.5 293322.5 405000 723322 525189.5 292902.5 810000 
PB2-
NS 
870.5 246333 47711.5 86678 405000 165573.5 45982 810000 
PB2-
PA 
11080 523539 192132.5 284810.5 644426.5 405000 186327 810000 
PB2-
PB1 
52934 713099 405104 517097.5 764018 623673 405000 810000 
PB2-
PB2 
0 0 0 0 0 0 0 405000 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 28 
Normalised values from the Wilcoxon test for HA H1N1 pairs. 
p-
value 
HA-HA HA-MP HA-NA HA-NP HA-NS HA-PA HA-PB1 HA-PB2 
HA-
HA 
0.5 0 0 0 0 0 0 0 
HA-
MP 
1 0.5 0.036 0.031 0.207 0.005 0.001 0.017 
HA-
NA 
1 0.964 0.5 0.518 0.864 0.167 0.016 0.123 
HA-
NP 
1 0.969 0.482 0.5 0.864 0.149 0.017 0.112 
HA-
NS 
1 0.793 0.136 0.136 0.5 0.022 0.003 0.035 
HA-
PA 
1 0.995 0.833 0.851 0.978 0.5 0.063 0.376 
HA-
PB1 
1 0.999 0.984 0.983 0.997 0.937 0.5 0.886 
HA-
PB2 
1 0.983 0.877 0.888 0.965 0.624 0.114 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 29 
Normalised values from the Wilcoxon test for NA H1N1 pairs. 
p-
value 
NA-HA NA-MP NA-NA NA-NP NA-NS NA-PA NA-PB1 NA-PB2 
NA-
HA 
0.5 0.964 1 0.598 0.927 0.228 0.017 0.076 
NA-
MP 
0.036 0.5 1 0.033 0.350 0.001 1 0.003 
NA-
NA 
0 0 0.5 0 0 0 0 0 
NA-
NP 
0.402 0.967 1 0.5 0.916 0.139 0.010 0.043 
NA-
NS 
0.073 0.649 1 0.084 0.5 0.007 0 0.005 
NA-
PA 
0.772 0.999 1 0.861 0.993 0.5 0.049 0.202 
NA-
PB1 
0.983 0.999 1 0.990 0.999 0.951 0.5 0.783 
NA-
PB2 
0.924 0.997 1 0.957 0.995 0.798 0.217 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 30 
Normalised values from the Wilcoxon test for NP H1N1 pairs. 
p-
value 
NP-HA NP-MP NP-NA NP-NP NP-NS NP-PA NP-PB1 NP-PB2 
NP-
HA 
0.5 0.993 0.583 1 0.985 0.923 0.455 0.784 
NP-
MP 
0.007 0.5 0.005 1 0.300 0.045 0.004 0.017 
NP-
NA 
0.417 0.995 0.5 1 0.987 0.910 0.365 0.735 
NP-
NP 
0 0 0 0.5 0 0 0 0 
NP-
NS 
0.015 0.700 0.013 1 0.5 0.125 0.008 0.044 
NP-
PA 
0.077 0.955 0.090 1 0.875 0.5 0.050 0.245 
NP-
PB1 
0.545 0.996 0.635 1 0.992 0.950 0.5 0.831 
NP-
PB2 
0.216 0.983 0.265 1 0.956 0.755 0.169 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 31 
Normalised values from the Wilcoxon test for NS H1N1 pairs. 
p-
value 
NS-HA NS-MP NS-NA NS-NP NS-NS NS-PA NS-PB1 NS-PB2 
NS-
HA 
0.5 0.996 0.642 0.912 1 0.691 0.231 0.548 
NS-
MP 
0.004 0.5 0.002 0.042 1 0.002 0 0.003 
NS-
NA 
0.358 0.998 0.5 0.868 1 0.056 0.126 0.407 
NS-
NP 
0.088 0.958 0.132 0.5 1 0.167 0.017 0.104 
NS-
NS 
0 0 0 0 0.5 0 0 0 
NS-
PA 
0.309 0.998 0.443 0.833 1 0.5 0.097 0.355 
NS-
PB1 
0.769 1 0.874 0.983 1 0.903 0.5 0.805 
NS-
PB2 
0.452 0.997 0.593 0.896 1 0.645 0.195 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 32 
Normalised values from the Wilcoxon test for PA H1N1 pairs. 
p-
value 
PA-HA PA-MP PA-NA PA-NP PA-NS PA-PA PA-PB1 PA-PB2 
PA-
HA 
0.5 0.999 0.606 0.984 0.994 1 0.700 0.965 
PA-
MP 
0 0.5 0 0.110 0.153 1 0 0.035 
PA-
NA 
0.394 1 0.5 0.984 0.996 1 0.594 0.954 
PA-
NP 
0.016 0.890 0.016 0.5 0.567 1 0.021 0.259 
PA-
NS 
0.006 0.847 0.004 0.433 0.5 1 0.007 0.210 
PA-
PA 
0 0 0 0 0 0.5 0 0 
PA-
PB1 
0.303 1 0.406 0.979 0.993 1 0.5 0.933 
PA-
PB2 
0.035 0.965 0.046 0.741 0.790 1 0.067 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 33 
Normalised values from the Wilcoxon test for PB1 H1N1 pairs. 
p-
value 







0.5 1 0.641 0.984 0.997 0.976 1 0.956 
PB1-
MP 
0 0.5 0 0.047 0.140 0.013 1 0.016 
PB1-
NA 
0.359 1 0.5 0.984 0.998 0.970 1 0.936 
PB1-
NP 
0.016 0.953 0.016 0.5 0.723 0.291 1 0.211 
PB1-
NS 
0.003 0.860 0.002 0.277 0.5 0.125 1 0.090 
PB1-
PA 
0.024 0.987 0.030 0.709 0.875 0.5 1 0.384 
PB1-
PB1 
0 0 0 0 0 0 0.5 0 
PB1-
PB2 
0.044 0.984 0.064 0.789 0.910 0.616 1 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 34 
Normalised values from the Wilcoxon test for PB2 H1N1 pairs. 
p-
value 







0.5 0.984 0.419 0.949 0.971 0.957 0.700 1 
PB2-
MP 
0.016 0.5 0.004 0.124 0.250 0.134 0.007 1 
PB2-
NA 
0.581 0.996 0.5 0.976 0.992 0.984 0.773 1 
PB2-
NP 
0.051 0.876 0.024 0.5 0.673 0.512 0.061 1 
PB2-
NS 
0.029 0.750 0.008 0.327 0.5 0.340 0.023 1 
PB2-
PA 
0.043 0.866 0.016 0.488 0.660 0.5 0.053 1 
PB2-
PB1 
0.301 0.993 0.227 0.939 0.977 0.947 0.5 1 
PB2-
PB2 
0 0 0 0 0 0 0 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 35 
Normalised values from the Wilcoxon test for HA H1N2 pairs. 
p-
value 
HA-HA HA-MP HA-NA HA-NP HA-NS HA-PA HA-PB1 HA-PB2 
HA-
HA 
0.5 0 0 0 0 0 0 0 
HA-
MP 
1 0.5 0.752 0.141 0.324 0.031 0.044 0.024 
HA-
NA 
1 0.248 0.5 0.044 0.133 0.007 0.012 0.005 
HA-
NP 
1 0.859 0.956 0.5 0.741 0.199 0.239 0.161 
HA-
NS 
1 0.676 0.867 0.259 0.5 0.068 0.093 0.054 
HA-
PA 
1 0.969 0.993 0.801 0.932 0.5 0.538 0.438 
HA-
PB1 
1 0.955 0.988 0.761 0.907 0.462 0.5 0.404 
HA-
PB2 
1 0.976 0.995 0.839 0.946 0.562 0.596 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 36 
Normalised values from the Wilcoxon test for NA H1N2 pairs. 
p-
value 
NA-HA NA-MP NA-NA NA-NP NA-NS NA-PA NA-PB1 NA-PB2 
NA-
HA 
0.5 0.388 1 0.169 0.379 0.071 0.050 0.058 
NA-
MP 
0.612 0.5 1 0.243 0.490 0.109 0.079 0.091 
NA-
NA 
0 0 0.5 0 0 0 0 0 
NA-
NP 
0.831 0.757 1 0.5 0.748 0.297 0.238 0.261 
NA-
NS 
0.621 0.510 1 0.252 0.5 0.117 0.086 0.098 
NA-
PA 
0.929 0.891 1 0.703 0.883 0.5 0.427 0.456 
NA-
PB1 
0.946 0.921 1 0.762 0.914 0.573 0.5 0.528 
NA-
PB2 
0.942 0.909 1 0.739 0.902 0.544 0.472 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 37 
Normalised values from the Wilcoxon test for NP H1N2 pairs. 
p-
value 
NP-HA NP-MP NP-NA NP-NP NP-NS NP-PA NP-PB1 NP-PB2 
NP-
HA 
0.5 0.964 0.757 1 0.919 0.804 0.845 0.875 
NP-
MP 
0.036 0.5 0.148 1 0.333 0.200 0.265 0.292 
NP-
NA 
0.243 0.852 0.5 1 0.740 0.570 0.638 0.676 
NP-
NP 
0 0 0 0.5 0 0 0 0 
NP-
NS 
0.081 0.667 0.260 1 0.5 0.328 0.405 0.440 
NP-
PA 
0.196 0.800 0.430 1 0.672 0.5 0.571 0.609 
NP-
PB1 
0.155 0.735 0.362 1 0.595 0.429 0.5 0.536 
NP-
PB2 
0.125 0.708 0.324 1 0.560 0.391 0.464 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 38 
Normalised values from the Wilcoxon test for NS H1N2 pairs. 
p-
value 
NS-HA NS-MP NS-NA NS-NP NS-NS NS-PA NS-PB1 NS-PB2 
NS-
HA 
0.5 0.944 0.791 0.786 1 0.358 0.516 0.568 
NS-
MP 
0.056 0.5 0.235 0.218 1 0.028 0.076 0.089 
NS-
NA 
0.209 0.765 0.5 0.484 1 0.128 0.237 0.272 
NS-
NP 
0.214 0.782 0.516 0.5 1 0.131 0.244 0.280 
NS-
NS 
0 0 0 0 0.5 0 0 0 
NS-
PA 
0.642 0.972 0.872 0.869 1 0.5 0.648 0.693 
NS-
PB1 
0.484 0.924 0.763 0.756 1 0.352 0.5 0.548 
NS-
PB2 
0.432 0.911 0.728 0.720 1 0.307 0.452 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 39 
Normalised values from the Wilcoxon test for PA H1N2 pairs. 
p-
value 
PA-HA PA-MP PA-NA PA-NP PA-NS PA-PA PA-PB1 PA-PB2 
PA-
HA 
0.5 0.951 0.812 0.946 0.857 1 0.928 0.956 
PA-
MP 
0.049 0.5 0.245 0.511 0.273 1 0.506 0.611 
PA-
NA 
0.188 0.755 0.5 0.754 0.549 1 0.738 0.814 
PA-
NP 
0.054 0.489 0.246 0.5 0.272 1 0.496 0.600 
PA-
NS 
0.143 0.727 0.451 0.728 0.5 1 0.711 0.794 
PA-
PA 
0 0 0 0 0 0.5 0 0 
PA-
PB1 
0.072 0.494 0.262 0.504 0.289 1 0.5 0.596 
PA-
PB2 
0.044 0.389 0.186 0.400 0.206 1 0.404 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 40 
Normalised values from the Wilcoxon test for PB1 H1N2 pairs. 
p-
value 







0.5 0.966 0.713 0.943 0.899 0.909 1 0.936 
PB1-
MP 
0.034 0.5 0.115 0.444 0.285 0.375 1 0.460 
PB1-
NA 
0.287 0.885 0.5 0.844 0.745 0.788 1 0.840 
PB1-
NP 
0.057 0.556 0.156 0.5 0.344 0.430 1 0.514 
PB1-
NS 
0.101 0.714 0.255 0.656 0.5 0.581 1 0.660 
PB1-
PA 
0.091 0.625 0.212 0.570 0.419 0.5 1 0.579 
PB1-
PB1 
0 0 0 0 0 0 0.5 0 
PB1-
PB2 
0.064 0.540 0.160 0.486 0.340 0.421 1 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 41 
Normalised values from the Wilcoxon test for PB2 H1N2 pairs. 
p-
value 







0.5 0.989 0.810 0.976 0.947 0.965 0.960 1 
PB2-
MP 
0.011 0.5 0.084 0.374 0.233 0.377 0.365 1 
PB2-
NA 
0.190 0.916 0.5 0.856 0.756 0.838 0.824 1 
PB2-
NP 
0.024 0.626 0.144 0.5 0.345 0.497 0.480 1 
PB2-
NS 
0.053 0.767 0.244 0.655 0.5 0.643 0.623 1 
PB2-
PA 
0.035 0.623 0.162 0.503 0.357 0.5 0.485 1 
PB2-
PB1 
0.040 0.635 0.176 0.520 0.377 0.515 0.5 1 
PB2-
PB2 
0 0 0 0 0 0 0 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 42 
Normalised values from the Wilcoxon test for HA H3N2 pairs. 
p-
value 
HA-HA HA-MP HA-NA HA-NP HA-NS HA-PA HA-PB1 HA-PB2 
HA-
HA 
0.5 0 0 0 0 0 0 0 
HA-
MP 
1 0.5 0.383 0.003 0.057 0.003 0.002 0.001 
HA-
NA 
1 0.617 0.5 0.017 0.126 0.013 0.010 0.007 
HA-
NP 
1 0.997 0.983 0.5 0.872 0.425 0.394 0.322 
HA-
NS 
1 0.943 0.874 0.128 0.5 0.105 0.085 0.064 
HA-
PA 
1 0.997 0.987 0.575 0.895 0.5 0.475 0.397 
HA-
PB1 
1 0.998 0.990 0.606 0.915 0.525 0.5 0.418 
HA-
PB2 
1 0.999 0.993 0.678 0.936 0.603 0.582 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 43 
Normalised values from the Wilcoxon test for NA H3N2 pairs. 
p-
value 
NA-HA NA-MP NA-NA NA-NP NA-NS NA-PA NA-PB1 NA-PB2 
NA-
HA 
0.5 0.860 1 0.211 0.667 0.211 0.179 0.140 
NA-
MP 
0.140 0.5 1 0.019 0.242 0.026 0.015 0.012 
NA-
NA 
0 0 0.5 0 0 0 0 0 
NA-
NP 
0.789 0.981 1 0.5 0.911 0.476 0.446 0.365 
NA-
NS 
0.333 0.758 1 0.089 0.5 0.097 0.071 0.054 
NA-
PA 
0.789 0.974 1 0.524 0.903 0.5 0.470 0.391 
NA-
PB1 
0.821 0.985 1 0.554 0.929 0.530 0.5 0.416 
NA-
PB2 
0.860 0.988 1 0.635 0.946 0.609 0.584 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 44 
Normalised values from the Wilcoxon test for NP H3N2 pairs. 
p-
value 
NP-HA NP-MP NP-NA NP-NP NP-NS NP-PA NP-PB1 NP-PB2 
NP-
HA 
0.5 0.999 0.935 1 0.999 0.949 0.874 0.933 
NP-
MP 
0.001 0.5 0.087 1 0.697 0.146 0.036 0.104 
NP-
NA 
0.065 0.913 0.5 1 0.964 0.582 0.349 0.517 
NP-
NP 
0 0 0 0.5 0 0 0 0 
NP-
NS 
0 0.303 0.036 1 0.5 0.071 0.015 0.047 
NP-
PA 
0.051 0.854 0.418 1 0.929 0.5 0.273 0.435 
NP-
PB1 
0.126 0.964 0.651 1 0.985 0.727 0.5 0.670 
NP-
PB2 





The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 45 
Normalised values from the Wilcoxon test for NS H3N2 pairs. 
p-
value 
NS-HA NS-MP NS-NA NS-NP NS-NS NS-PA NS-PB1 NS-PB2 
NS-
HA 
0.5 1 0.955 0.984 1 0.963 0.928 0.951 
NS-
MP 
0 0.5 0.030 0.076 1 0.038 0.014 0.036 
NS-
NA 
0.045 0.970 0.5 0.659 1 0.531 0.366 0.483 
NS-
NP 
0.016 0.924 0.341 0.5 1 0.369 0.225 0.328 
NS-
NS 
0 0 0 0 0.5 0 0 0 
NS-
PA 
0.037 0.962 0.469 0.631 1 0.5 0.334 0.452 
NS-
PB1 
0.072 0.986 0.634 0.775 1 0.666 0.5 0.618 
NS-
PB2 
0.049 0.964 0.517 0.672 1 0.548 0.382 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 46 
Normalised values from the Wilcoxon test for PA H3N2 pairs. 
p-
value 
PA-HA PA-MP PA-NA PA-NP PA-NS PA-PA PA-PB1 PA-PB2 
PA-
HA 
0.5 0.997 0.936 0.958 0.998 1 0.990 0.974 
PA-
MP 
0.003 0.5 0.150 0.205 0.666 1 0.405 0.287 
PA-
NA 
0.064 0.850 0.5 0.586 0.912 1 0.779 0.668 
PA-
NP 
0.042 0.795 0.414 0.5 0.877 1 0.712 0.588 
PA-
NS 
0.002 0.334 0.088 0.123 0.5 1 0.263 0.179 
PA-
PA 
0 0 0 0 0 0.5 0 0 
PA-
PB1 
0.010 0.595 0.221 0.288 0.737 1 0.5 0.374 
PA-
PB2 
0.026 0.713 0.332 0.412 0.821 1 0.626 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
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Table B 47 
Normalised values from the Wilcoxon test for PB1 H3N2 pairs. 
p-
value 







0.5 0.998 0.946 0.922 0.998 0.994 1 0.914 
PB1-
MP 
0.002 0.5 0.116 0.067 0.499 0.405 1 0.082 
PB1-
NA 
0.054 0.884 0.5 0.394 0.876 0.815 1 0.417 
PB1-
NP 
0.078 0.933 0.606 0.5 0.929 0.880 1 0.511 
PB1-
NS 
0.002 0.501 0.124 0.071 0.5 0.410 1 0.087 
PB1-
PA 
0.006 0.595 0.185 0.120 0.590 0.5 1 0.136 
PB1-
PB1 
0 0 0 0 0 0 0.5 0 
PB1-
PB2 
0.086 0.918 0.583 0.489 0.913 0.864 1 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 
Table B 48 
Normalised values from the Wilcoxon test for PB2 H3N2 pairs. 
p-
value 







0.5 0.997 0.933 0.968 0.999 0.986 0.935 1 
PB2-
MP 
0.003 0.5 0.125 0.211 0.696 0.354 0.120 1 
PB2-
NA 
0.067 0.875 0.5 0.638 0.941 0.763 0.500 1 
PB2-
NP 
0.032 0.789 0.362 0.5 0.893 0.648 0.362 1 
PB2-
NS 
0.001 0.304 0.059 0.107 0.5 0.204 0.057 1 
PB2-
PA 
0.014 0.646 0.237 0.352 0.796 0.5 0.230 1 
PB2-
PB1 
0.065 0.880 0.500 0.638 0.943 0.770 0.5 1 
PB2-
PB2 
0 0 0 0 0 0 0 0.5 
 
The segment pair comparisons in the table are to be read as a row against a column. 
 




Figure B 70 
Distance in topology for segment pairs of real and simulated sequences for H1N1. 
 
 
Figure B 71 
Distance in topology for segment pairs of real and simulated sequences for H1N2. 




Figure B 72 
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8.3 Appendix C 
 
 
Figure C 1 
NJ tree for H1 (H1N1 and H1N2 subtypes sequences). Green colour is for H1N1 
subtype, orange colour is for H1N2 subtype. 
 
 
Figure C 2 
NJ tree for H3 (H3N2 subtypes sequences). Violet colour is for H3N2 subtype. 





Figure C 3 
NJ tree for N1 (H1N1 subtypes sequences). Green colour is for H1N1 subtype. 
 
 
Figure C 4 
NJ tree for N2 (H1N2 and H3N2 subtypes’ sequences). Orange colour is for H1N2 
subtype, violet colour is for H3N2 subtype. 
 
